

1 DNA repair and anti-cancer mechanisms in the long-lived bowhead whale

2

3 Denis Firsanov^{1*}, Max Zacher^{1*}, Xiao Tian¹, Todd L. Sformo², Yang Zhao¹, Greg Tomblin¹, J.
4 Yuyang Lu¹, Zhizhong Zheng¹, Luigi Perelli³, Enrico Gurreri³, Li Zhang³, Jing Guo¹, Anatoly
5 Korotkov¹, Valentin Volobaev¹, Seyed Ali Biashad¹, Zihui Zhang¹, Johanna Heid⁴, Alex Maslov⁴,
6 Shixiang Sun⁴, Zhuoer Wu¹, Jonathan Gigas¹, Eric Hillpot¹, John Martinez¹, Minseon Lee¹, Alyssa
7 Williams¹, Abbey Gilman¹, Nicholas Hamilton¹, Ena Haseljic¹, Avnee Patel¹, Maggie Straight¹,
8 Nalani Miller¹, Julia Ablaeva¹, Lok Ming Tam¹, Chloé Couderc¹, Michael Hoopman⁵, Robert Moritz⁵,
9 Shingo Fujii⁶, Dan J. Hayman⁷, Hongrui Liu^{8,9}, Yuxuan Cai⁸, Anthony K. L. Leung^{8,10,11,12}, Mirre J. P.
10 Simons⁷, Zhengdong Zhang⁴, C. Bradley Nelson¹³, Lisa M. Abegglen^{14,15}, Joshua D. Schiffman^{14,15},
11 Vadim N. Gladyshev¹⁶, , Mauro Modesti⁶, Giannicola Genovese³, Jan Vijg^{4, #}, Andrei Seluanov^{1,17, #},
12 Vera Gorbunova^{1,17, #}

13

14 ¹Department of Biology, University of Rochester, Rochester, NY, USA.

15 ²Department of Wildlife Management, North Slope Borough, Utqiagvik (Barrow), AK 99723, USA

16 ³Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center,
17 Houston, TX, USA

18 ⁴Department of Genetics, Albert Einstein College of Medicine, Bronx, NY 10461, USA

19 ⁵Institute for Systems Biology, Seattle, WA USA

20 ⁶Cancer Research Center of Marseille, Department of Genome Integrity, CNRS UMR7258, Inserm
21 U1068, Institut Paoli-Calmettes, Aix Marseille Univ, Marseille, France

22 ⁷School of Biosciences, University of Sheffield, UK

23 ⁸Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins
24 University, Baltimore, MD 21205, USA

25 ⁹Cross-Disciplinary Graduate Program in Biomedical Sciences, School of Medicine, Johns Hopkins
26 University, Baltimore, MD 21205, USA

27 ¹⁰McKusick-Nathans Institute of the Department of Genetic Medicine, Johns Hopkins University School of
28 Medicine, Baltimore, MD 21205, USA

29 ¹¹Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine,
30 Baltimore, MD 21205, USA

31 ¹²Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
32 School of Medicine, Baltimore, MD 21205, USA

33 ¹³Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA

34 ¹⁴Department of Pediatrics & Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA

35 ¹⁵Peel Therapeutics, Inc., Salt Lake City, UT, USA

36 ¹⁶Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School,
37 Boston, MA 02115, USA

38 ¹⁷Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA

39

40 *These authors contributed equally to this work.

41

42 #Corresponding authors:

43 **Vera Gorbunova**

44 **University of Rochester**

45 Email:

46 vera.gorbunova@rochester.edu

47 **Andrei Seluanov**

48 **University of Rochester**

49 Email:

50 andrei.seluanov@rochester.edu

51 **Jan Vijg**

52 **Albert Einstein College of**

53 **Medicine**

54 Email: jan.vijg@einsteinmed.edu

55

56

57 **Abstract**

58

59 At over 200 years, the maximum lifespan of the bowhead whale exceeds that of all
60 other mammals. The bowhead is also the second-largest animal on Earth, reaching
61 over 80,000 kg¹. Despite its very large number of cells and long lifespan, the bowhead
62 is not highly cancer-prone, an incongruity termed Peto's Paradox². This phenomenon
63 has been explained by the evolution of additional tumor suppressor genes in other
64 larger animals, supported by research on elephants demonstrating expansion of the p53
65 gene³⁻⁵. Here we show that bowhead whale fibroblasts undergo oncogenic
66 transformation after disruption of fewer tumor suppressors than required for human
67 fibroblasts. However, analysis of DNA repair revealed that bowhead cells repair double
68 strand breaks (DSBs) and mismatches with uniquely high efficiency and accuracy
69 compared to other mammals. The protein CIRBP, implicated in protection from
70 genotoxic stress, was present in very high abundance in the bowhead whale relative to
71 other mammals. We show that CIRBP and its downstream protein RPA2, also present
72 at high levels in bowhead cells, increase the efficiency and fidelity of DNA repair in
73 human cells. These results indicate that rather than possessing additional tumor
74 suppressor genes as barriers to oncogenesis, the bowhead whale relies on more
75 accurate and efficient DNA repair to preserve genome integrity. This strategy which
76 does not eliminate damaged cells but repairs them may be critical for the long and
77 cancer-free lifespan of the bowhead whale.

78 **Introduction**

79 The Alaskan Iñupiat Inuit, who carry on a long tradition of subsistence hunting of the
80 bowhead whale (*Balaena mysticetus*), maintain that these animals “live two human
81 lifetimes”⁶. A series of bowhead whales captured in the late-twentieth and early-twenty-
82 first centuries lent new credence to these claims, as embedded in their bodies were
83 traditional stone harpoon points and bomb lance fragments dating to the Victorian era⁷.

84 Subsequent scientific study and age estimation through quantification of ovarian
85 corpora, baleen dating, and eye lens aspartic acid racemization analysis supported a
86 maximum lifespan exceeding 200 years in the bowhead whale^{7–12}. Thus, the range of
87 mammalian lifespans covers roughly 2 orders of magnitude, with the model organism
88 *Mus musculus* living for 2-3 years while the bowhead whale lives 100 times as long.

89 The increased number of cells and cell divisions in larger organisms does not lead to
90 increased cancer incidence and shorter lifespans¹³. The apparent contradiction between
91 expected and observed cancer rates in relation to species body mass has been noted
92 for decades and is known as Peto’s Paradox^{2,14–16}. Cancer resistance and longer
93 lifespans in larger species are theorized to result from compensatory evolutionary
94 adaptations driven by reduced extrinsic mortality². The bowhead whale exceeds 80,000
95 kg in mass and 200 years in lifespan. Both factors predispose it to accumulating large
96 numbers of DNA mutations throughout life. To remain alive for so long it must possess
97 uniquely potent genetic mechanisms to prevent cancer and other age-related diseases.
98 However, primary research publications on genetic and molecular mechanisms of aging
99 in the bowhead whale are scarce, consisting primarily of genome and transcriptome
100 analysis^{17–19}.

101 The multi-stage model of carcinogenesis posits that the transition from a normal cell to a
102 cancer cell involves multiple distinct genetic “hits,” or mutations²⁰. Larger and longer-
103 living species might require greater numbers of “hits” for oncogenic transformation,
104 given their greater cell number and increased lifespan. Indeed, there is experimental
105 evidence to support this hypothesis. Rangarajan et al. found that while mouse
106 fibroblasts require perturbation of 2 pathways for tumorigenic transformation (p53 and
107 Ras), human fibroblasts require 5 hits (p53, pRb, PP2A, telomerase and Ras)²¹. A
108 human should thus have a dramatically lower per-cell incidence of malignant
109 transformation than a mouse, and as a result can maintain a larger number of cells for a
110 longer period of time.

111 Species that are large-bodied and long-lived may be expected to have even more layers
112 of protection against oncogenic transformation than humans. In support of this
113 hypothesis, recent studies have identified copy number expansion and functional
114 diversification of multiple tumor suppressor genes, such as *TP53* and *LIF*, in elephants
115 and other taxa^{3,5,22–24}. These studies identified multiple copies of *TP53* in the elephant
116 genome, several of which were confirmed to be transcribed and translated in elephant
117 fibroblasts and contributed to an enhanced apoptotic response to genotoxic stress²⁵.
118 However, additional copies of p53 genes are unlikely to slow down aging^{26,27}. One
119 promising mechanism that could explain both cancer resistance and slower aging in
120 long-lived mammals is more accurate or efficient DNA repair. Genetic mutations have
121 been identified as causal factors in carcinogenesis for over a century²⁸. Perhaps one of
122 the most compelling lines of evidence supporting the role of DNA repair in the
123 pathogenesis of aging and cancer comes from studies of mutants with accelerated

124 aging phenotypes. Remarkably, most such mutants have defects in DNA repair
125 enzymes^{29–33}. Across species, several studies have also pointed toward improved DNA
126 repair capacity and reduced mutation accumulation as characteristics associated with
127 species longevity^{34–38}. Here, we identify specific cellular and molecular traits
128 characterizing bowhead whale cancer resistance and longevity that distinguish it from
129 shorter-lived mammals including humans. We show that bowhead whale cells are not
130 more prone to apoptosis and do not require additional genetic hits for malignant
131 transformation relative to human cells. Instead, the bowhead whale relies on more
132 accurate and efficient DNA double strand break (DSB) repair promoted by CIRBP and
133 RPA2, as well as more efficient mismatch repair. This more “conservative” strategy that
134 does not needlessly eliminate cells but repairs them may be critical for the long and
135 cancer-free lifespan of the bowhead whale.

136

137 **Results**

138 **Growth characteristics, cellular senescence, and cell death in the bowhead whale**

139 Most human somatic cells lack telomerase activity and as a result undergo replicative
140 senescence with serial passaging in culture³⁹. Replicative and stress-induced
141 senescence are important mechanisms for preventing cancer. Using TRF and TRAP
142 assays to measure telomere length and telomerase activity, we found that bowhead
143 whale skin fibroblasts, like human fibroblasts, lack telomerase activity and experience
144 telomere shortening followed by replicative senescence with serial passaging in culture
145 (Figure 1a, b). In both species, nearly all cells stained positive for senescence-
146 associated β -galactosidase upon terminal growth arrest (Figure 1c, d). As in human

147 fibroblasts, stable overexpression of human telomerase reverse transcriptase (*hTERT*)
148 to maintain telomere length prevented replicative senescence in bowhead cells (Figure
149 1a). Senescence can also be induced by DNA damage. Like human cells, bowhead
150 whale skin fibroblasts readily entered senescence but did not significantly induce cell
151 death in response to 10 or 20 Gy of γ -irradiation (Figure 1c-e).

152 Interestingly, transcriptome analysis of human and bowhead whale senescent
153 fibroblasts showed reduced induction of senescence-associated secretory phenotype
154 (SASP) factors in bowhead whale fibroblasts (Figure 1f) relative to human cells.
155 Paracrine effects of SASP on surrounding cells are thought to contribute to age-related
156 diseases and carcinogenesis. These transcriptomic differences may indicate that
157 senescence is able to preserve its anti-cancer function in the bowhead with reduced
158 harmful paracrine signaling.

159 To test whether increased p53 activity could contribute to cancer resistance in the
160 bowhead whale, we transiently transfected primary mouse, cow, human and bowhead
161 whale skin fibroblasts with a luciferase reporter vector containing a p53-response
162 element. The bowhead whale cells had the lowest basal p53 activity of the species
163 tested (Figure 1g). Additionally, we did not observe any differences in the induction of
164 apoptosis in response to UVC between species (Figure 1h). Together, our results argue
165 against the idea that increased clearance of damaged cells through apoptosis
166 contributes to cancer resistance in the bowhead whale.

167 **Requirements for oncogenic transformation of bowhead whale cells**

168 We initially identified a minimal combination of oncogene and tumor suppressor hits
169 required for *in vitro* malignant transformation of bowhead whale skin fibroblasts using
170 the soft agar assay, which measures anchorage-independent growth, a hallmark of
171 cancer. While normal cells undergo growth arrest or programmed cell death (anoikis) in
172 soft agar, malignant cells continue to grow without substrate adhesion and form visible
173 colonies⁴⁰. We introduced constructs targeting oncogene and tumor suppressor
174 pathways into primary skin fibroblasts with PiggyBac (PB) transposon vectors, which
175 integrate into the genome and drive stable expression. Since bowhead whale primary
176 fibroblasts, like human fibroblasts, exhibit progressive telomere shortening and lack
177 telomerase activity (Figure 1b), we used cell lines expressing (*hTERT*) to bypass
178 replicative senescence.

179 In agreement with published findings, malignant transformation of human *hTERT*+
180 fibroblasts required combined expression of H-Ras^{G12V}, SV40 Large T (LT) antigen
181 (which binds and inactivates p53 and the Rb family of tumor suppressors), and SV40
182 Small T (ST) antigen (which binds and inactivates PP2A) (Figure 2a)²¹. Rather than
183 requiring hits to additional pathways, however, bowhead whale *hTERT*+ fibroblasts
184 were transformed by H-Ras^{G12V} and SV40 LT alone, suggesting that bowhead cells may
185 require fewer genetic mutations to become cancerous compared to human cells (Figure
186 2a). These findings were supported by mouse xenograft assays, in which the number of
187 hits needed for tumor growth matched findings from soft agar (Figure 2b).

188 We next sought to confirm these findings at the genetic level, through CRISPR editing
189 of individual tumor suppressor genes in bowhead fibroblasts. While the sequenced
190 bowhead genome has not revealed copy number expansion of canonical tumor

191 suppressor genes^{17,18}, CRISPR knockout allows for more precise quantification of the
192 number of genetic mutations required for oncogenesis. While the most important target
193 of SV40 LT is thought to be Rb (*RB1* gene), it is also known to inactivate p130 and
194 p107, two additional members of the Rb-family, providing some level of functional
195 redundancy. Using CRISPR, we introduced targeted mutations into the bowhead *RB1*
196 gene, along with *TP53* (the other target of LT), and *PTEN* (an upstream inhibitor of Akt
197 signaling commonly mutated in human cancers and operating in the same pathway as
198 PP2A). Following transfection of *hTERT*+ bowhead fibroblasts with Cas9-guide RNA
199 ribonucleoprotein complexes targeting each of the aforementioned genes, we screened
200 clonally isolated colonies for loss of the targeted protein by Western blot (Figure 2c, d,
201 Extended Data Figure 1a, b). We additionally screened the colonies with luciferase
202 reporter assays to confirm loss of protein function and activity (Extended Data Figure
203 1c, d). For each selected clone, we sequenced the CRISPR-targeted genes to confirm
204 homozygous knockout at the genetic level and determine the causal mutations
205 (Supplementary Figures 1, 2). Through this strategy, we generated single and
206 compound homozygous knockout bowhead whale fibroblasts for *TP53*, *RB1*, and
207 *PTEN*. In agreement with our initial findings, genetic inactivation of *TP53* and *RB1* in
208 bowhead whale fibroblasts expressing *hTERT* and H-Ras^{G12V} was sufficient for
209 malignant transformation in both soft agar and mouse xenograft assays (Figure 2).
210 These findings suggest that despite its larger size and longer lifespan, the cells of the
211 bowhead whale unexpectedly require fewer mutational hits for malignant transformation
212 than human cells.

213 **Mismatch repair, excision repair and mutagenesis in the bowhead whale**

214 As defects in mismatch repair genes are well-characterized drivers of oncogenesis, we
215 assessed the efficiency of mismatch repair (MMR) in bowhead whale cells using a
216 reporter assay that measures cellular correction of a targeted G/T mismatch introduced
217 to a plasmid *in vitro*⁴¹. We found that correction of the mismatch was significantly more
218 efficient in whale cells than in mouse, cow, and human cells (Extended Data Figure 2a).

219 We next assessed the efficiency of nucleotide excision repair (NER) and base excision
220 repair (BER) repair in bowhead whale cells. NER is primarily responsible for removing
221 helix-distorting DNA lesions. To quantify NER activity, we utilized a host cell plasmid
222 reactivation assay³³ and quantified clearance of cyclobutane pyrimidine dimers (CPDs)
223 by ELISA to measure repair of UVC-induced DNA damage. NER efficiency by plasmid
224 reactivation was similar between bowhead and human cells (Extended Data Figure 2b),
225 but the kinetics of CPD removal tended to be slower in whale cells (Extended Data
226 Figure 2c). BER is responsible for ameliorating many types of spontaneous DNA base
227 damage, such as oxidation and deamination. The efficiency of BER, as measured by
228 the plasmid reactivation assay, trended toward higher BER activity in bowhead whales
229 compared to human cells, but this difference was not statistically significant (Extended
230 Data Figure 2d).

231 We found that PARP activity in bowhead fibroblasts exposed to H₂O₂, and γ -irradiation
232 was dramatically higher than in human cells (Extended Data Figure 3a, b). Basal PARP
233 activity was also much higher in untreated bowhead whale nuclear extracts (Extended
234 Data Figure 3c). PARP proteins are recruited to sites of DNA damage, where they
235 participate in the DNA damage response and repair. Bowhead whale cells also
236 displayed higher survival rates after H₂O₂ treatment in comparison to human cells

237 (Extended Data Figure 3d). When we measured the kinetics of damage repair after
238 H₂O₂ treatment by alkaline comet assay, repair was slightly accelerated in bowhead
239 whale relative to human cells, which may relate to its increased PARP activity
240 (Extended Data Figure 3e).

241 To determine whether whale cells might accumulate fewer mutations after DNA
242 damage, we measured mutation frequency following treatment with the potent mutagen
243 and alkylating agent N-ethyl-N-nitrosourea (ENU) using single-molecule, quantitative
244 detection of low-abundance somatic mutations by high-throughput sequencing (SMM-
245 seq)⁴². ENU treatment resulted in a statistically significant increase in somatic mutation
246 frequency in fibroblasts from all tested species (Extended data Figure 2e). Specifically,
247 we found that mouse cells showed the greatest increase in ENU-induced single
248 nucleotide variants, while bowhead whale cells experienced the lowest mutation
249 induction. The levels of induced mutational load in cow and human cells were
250 intermediate, in line with their relative lifespans. This suggests a correlation between the
251 rate of mutation induction and maximum lifespan among the included species
252 (Extended Data Figure 2e), confirming previous findings by us and others^{43,44}.
253 Importantly, the excessive mutational burden observed in ENU-treated cells
254 predominantly comprised an increased fraction of A to T transversions (Extended Data
255 Figure 2f), the type of mutation preferentially induced by ENU⁴².

256 We additionally compared mutation induction in response to chemical mutagen
257 treatment in the bowhead whale and human using the HPRT mutagenesis assay, which
258 relies on loss of HPRT activity after mutagen treatment⁴⁵. The *HPRT* gene exists as a
259 single copy on the X chromosome in male mammalian cells, a feature we found to be

260 true for the bowhead (see Methods). We treated primary fibroblast lines from male
261 bowhead whale and human with ENU and then plated cells in selective media
262 containing 6-thioguanine, which kills cells with functional HPRT. Despite a slightly
263 higher sensitivity to ENU in bowhead whale cells as indicated by colony-forming
264 efficiency in non-selective media, the rate of HPRT mutant colony formation was
265 markedly lower in bowhead whale than human fibroblasts, an effect which remained
266 significant after adjusting for plating efficiency (Extended Data Figure 2g, h). This result
267 supports the above SMM-seq data that bowhead whale cells may possess more
268 accurate DNA repair than humans. There was no difference in the rate of apoptosis in
269 response to ENU treatment in human and bowhead whale fibroblasts, suggesting that
270 apoptosis is not responsible for the observed differences in ENU sensitivity (Extended
271 Data Figure 2i). To further validate these findings, we also measured HPRT mutant
272 colony formation after γ -irradiation. As with ENU, we observed markedly lower HPRT
273 mutant colony formation in bowhead whale cells (Extended Data Figure 2j, k).

274 **Double-strand break repair and chromosomal stability in the bowhead whale**

275 DNA DSBs are toxic if not repaired and may lead to mutations through inaccurate
276 repair. DSBs are repaired through two major pathways: non-homologous end joining
277 (NHEJ) and homologous recombination (HR). To assess relative NHEJ and HR
278 efficiencies, we integrated fluorescent GFP-based reporter cassettes⁴⁶ (Extended Data
279 Figure 5a) into fibroblasts from mouse, cow, human and bowhead whale. Following DSB
280 induction with I-SceI, we observed markedly elevated NHEJ efficiency in bowhead
281 whales relative to other species (Figure 3a, Extended Data Figure 4a). We also found
282 that HR efficiency is significantly higher in whale cells than in human cells (Figure 3b).

283 To examine whether this more efficient DSB repair could promote chromosomal
284 stability, we measured formation of micronuclei induced by γ -irradiation and by I-SceI
285 cleavage. One potential outcome resulting from an unrepaired DSB in mitotic cells is the
286 loss of an acentric chromosome fragment, which can be measured as the formation of a
287 micronucleus. We found that bowhead whale fibroblasts accumulated fewer micronuclei
288 than human fibroblasts after 2 Gy γ -irradiation (Figure 3c, Extended Data Figure 4b).
289 We also observed that DSB induction with I-SceI increased the rate of micronucleus
290 formation, likely reflecting acentric fragment loss, and that this rate was reduced in the
291 bowhead whale compared to human (Extended Data Figure 4c). Thus, the more
292 efficient rejoining of DSB ends observed in bowhead whale cells appears to guard
293 against chromosomal instability.

294 We also measured resolution of γ H2AX and 53BP1 foci, which mark cellular DSBs. We
295 found that endogenous levels of these foci are significantly lower in whale cells,
296 suggesting reduced baseline burden of DSBs (Figure 3d). We observed that the kinetics
297 of DSB repair after γ -irradiation are not faster in the bowhead whale than in human cells
298 (Extended Data Figure 4d, e)³³. We further tested the ability of bowhead whale cells to
299 resolve DSBs after treatment with the DSB-inducing drug bleomycin. We observed
300 similar induction of foci one hour after bleomycin treatment in human and whale cells;
301 however, fewer foci remained in cells from the bowhead whales than in those from
302 humans after 24 hours (Figure 3e, f), indicating a reduced burden of residual unrepaired
303 damage in the bowhead whale.

304 **Fidelity of DSB repair in the bowhead whale**

305 As mutations resulting from inaccurate DSB repair can promote cancer development,
306 we next sought to assess the fidelity of DSB repair in the bowhead whale. Sequencing
307 and analysis of repair junctions from integrated NHEJ reporter (Extended Data Figure
308 5a, b) and extra-chromosomal NHEJ reporter (Extended Data Figure 5a, c) assays
309 suggested higher fidelity of NHEJ in bowhead whale cells: compared to human, the
310 bowhead whale is less prone to producing deletions during the repair of incompatible
311 DNA termini and far more frequently joins ends without deleting any bases beyond the
312 small overhang region.

313 We also measured the fidelity of repair at an endogenous genomic locus. To
314 systematically compare mutational outcomes of CRISPR break repair in the bowhead
315 whale to those of humans and shorter-living mammals, we performed CRISPR
316 transfections in primary fibroblast lines, 2-3 individual animals per species, from
317 bowhead whale, human, cow, and mouse, and used deep amplicon sequencing of the
318 targeted locus to generate detailed profiles of repair outcomes. We took advantage of
319 the fact that exon 1 of the *PTEN* tumor suppressor gene is highly conserved across
320 mammals, with 100% sequence identity across included species (Supplementary Figure
321 3). We were therefore able to examine species-specific DSB repair outcomes at an
322 endogenous genomic locus while minimizing intra-species variation in the break-
323 proximal sequence context.

324 Analysis of sequencing data revealed species-specific repair outcomes, which were
325 consistent across cell lines derived from multiple individual animals of each species
326 (Figure 3g-i). In human, cow, and mouse, the most common mutational outcomes were
327 deletions. In contrast, the bowhead was the only species for which a single-base

328 insertion was the most common mutational event. The frequency of unmodified alleles,
329 which are known to occur after error-free repair of CRISPR DSBs^{47,48}, was the highest
330 in bowhead whale (Figure 3h). Sequencing of untreated control samples confirmed that
331 the detected insertions and deletions were CRISPR-induced (Supplementary Table 1).
332 As analysis of CRISPR RNP transfection efficiency by flow cytometry and cleavage
333 efficiency by digital droplet PCR showed similar CRISPR efficiencies across species
334 (Extended Data Figure 5d, Supplementary Figure 4a, b), differences observed in the
335 unmodified allele fraction most likely result from differences in repair fidelity. While small
336 indels predominated in all species, we observed a marked inverse correlation between
337 the frequency of large deletions and species lifespan, with the bowhead producing
338 fewer large deletions than human, cow, and mouse (Figure 3g-i). Intriguingly, this
339 reduction in large deletions was not accompanied by reduced microhomology usage
340 (Extended Data Figure 5f, g). When we assigned frequency-based percentile ranks from
341 most negative to most positive indel size (largest deletions to largest insertions), we
342 observed a strong correlation between species lifespan and 5th percentile indel size,
343 corresponding to large deletions (Pearson's $r=0.85$, $p=0.0009$) (Extended Data Figure
344 5e, Supplementary Table 2). The results of these experiments suggest a greater fidelity
345 of DSB repair in the bowhead whale relative to humans and other mammals.

346 To determine whether these differences in repair outcomes of targeted DSBs might
347 predict the types of genomic changes accumulated through spontaneous cellular DNA
348 damage, we performed whole genome sequencing (WGS)⁴⁹ of bowhead whale, human
349 and mouse fibroblast-derived tumor xenografts and assessed somatic mutations
350 through comparison to parental non-transformed primary fibroblast cultures sequenced

351 in tandem (Extended Data Figure 1e). The frequency of spontaneous de novo somatic
352 single nucleotide variants (SNVs) was significantly lower in bowhead whale tumor
353 xenografts than in human and mouse (Extended Data Figure 1g). Intriguingly, we
354 observed no differences in the relative proportions of each type of SNV across species,
355 suggesting shared underlying mutational drivers during tumor evolution despite
356 differences in overall mutation rate (Extended Data Figure 1f). We further assessed
357 WGS data for small indels (Extended Data Figure 1h, i) and large structural variants
358 (SVs) (Extended Data Figure 1j-l) across species; strikingly, whale tumors were
359 characterized by a significant reduction in both small and large deletions, as well as
360 small insertions, large duplications and inversions (Extended Data Figures 1g-l,
361 Supplementary Table 3). SV size distributions were remarkably different in bowhead
362 whale tumors in comparison to human and mouse tumors: whale tumors showed a
363 significant reduction in the proportion of large SVs (>500Kb, $p < 0.0001$, Extended Data
364 Figure 1m, n). Altogether, these data demonstrate consistent reductions in both the
365 frequency and size of inserted and deleted bases in bowhead whale cells relative to
366 those of shorter-lived mammals in response to both nuclease-induced and endogenous
367 DNA breaks. These differences are likely to reduce the accumulation of deleterious
368 genomic instability over time.

369 **CIRBP contributes to high DSB repair efficiency and chromosomal stability in the** 370 **bowhead whale**

371 To identify mechanisms contributing to the efficiency and accuracy of DSB repair in the
372 bowhead whale, we compared expression of DNA repair proteins in the bowhead whale
373 to other mammalian species by Western blot, quantitative mass spectrometry, and

374 transcriptome sequencing (Figure 4a, Extended Data Figures 6-7). Unexpectedly, we
375 found that levels of three canonical NHEJ proteins- Ku70, Ku80, and DNA-PKcs- are
376 substantially higher in human cells than any other species tested (Figure 4a, Extended
377 Data Figure 6f), while their abundance in the bowhead whale appears to be at more
378 typical mammalian levels. We speculate that the unusually high levels of Ku/DNA-PKcs
379 in humans may be a human-specific adaptation to promote DSB repair and genome
380 stability.

381 However, we consistently observed a strikingly higher abundance of cold-inducible
382 RNA-binding protein (CIRBP) in cells and tissues of the bowhead whale than in other
383 mammalian species (Figure 4a, Extended Data Figure 6a, b, d, f). Levels of PARP1, a
384 functional partner of CIRBP during DNA repair⁵⁰, were also increased relative to human
385 and showed even greater enrichment at an *in vitro* DSB substrate (Extended Data
386 Figure 6g). Interestingly, we also found that the CtIP protein, which is required for
387 efficient HR⁵¹, is more abundant in whale cells compared to humans. It is possible that
388 CtIP upregulation in the whale contributes to better HR compared to humans.

389 CIRBP is an RNA- and PAR-binding protein whose expression is induced by a variety of
390 cellular stressors including cold shock, hypoxia, and UV irradiation^{50,52-54}. CIRBP has
391 been shown to bind the 3' UTR of mRNAs that encode proteins involved in cellular
392 stress and DNA damage responses and promote their stability and translation⁵⁵⁻⁵⁸.
393 There is also evidence for a more direct role of CIRBP in DNA repair: PARP-1-
394 dependent localization of CIRBP to sites of DNA damage promotes DSB repair and
395 antagonizes micronucleus formation⁵⁰.

396 To test whether CIRBP contributes to efficient NHEJ and HR in bowhead whale cells,
397 we overexpressed human (hCIRBP) and bowhead whale (bwCIRBP) in human reporter
398 cells. Overexpression of bwCIRBP, but not hCIRBP, enhanced NHEJ and HR
399 efficiencies in human cells (Figure 4b, c, f). Conversely, CIRBP depletion in bowhead
400 whale cells by siRNA significantly reduced NHEJ and HR efficiency (Figure 4d, e, g).
401 Consistent with published observations, overexpression of bwCIRBP with nine arginines
402 in the repeated RGG motif mutated to alanine (9R/A), which impairs CIRBP's ability to
403 bind to PAR-polymers⁵⁰, failed to stimulate HR and reduced stimulation of NHEJ (Figure
404 4b, c, f).

405 To test the effects of CIRBP overexpression on chromosomal stability, we quantified the
406 formation of micronuclei in human cells after γ -irradiation. In cells overexpressing wild-
407 type hCIRBP, a codon-optimized hCIRBP, and bwCIRBP, we observed a significant
408 decrease in both basal and γ -irradiation-induced micronuclei in all CIRBP-
409 overexpressing cells relative to control vector (Figure 4h). Micronucleus formation
410 appeared to decrease as CIRBP protein expression increased. To probe the
411 relationship between high NHEJ efficiency, high CIRBP expression, and genome
412 stability, we also overexpressed human and bowhead whale CIRBP in human NHEJ
413 reporter cells and observed a reduction in I-SceI-induced micronuclei in cells
414 overexpressing CIRBP (Extended Data Figure 8f).

415 We next examined the effect of CIRBP overexpression on formation of gross
416 chromosomal aberrations in human cells exposed to γ -irradiation. We observed a
417 markedly decreased frequency of chromosomal aberrations after irradiation in cells
418 overexpressing hCIRBP and bwCIRBP (Extended Data Figure 8g). This further

419 suggests a protective effect of high CIRBP expression on genomic stability. Basal
420 γ H2AX/53BP1 foci were reduced by bwCIRBP overexpression, consistent with
421 improved genome stability (Figure 4i).

422 The human and bowhead CIRBP proteins differ by only 5 C-terminal amino acids, which
423 do not overlap with any residues of known functional significance (Extended Data
424 Figure 9a). Substitution of these 5 codons in hCIRBP with bowhead codons increased
425 protein expression, while substitution of bwCIRBP with the 5 hCIRBP codons decreased
426 it (Extended Data Figure 9d). Interestingly, although CIRBP abundance increased
427 following introduction of the 5 bowhead substitutions, it did not achieve the expression
428 levels of bwCIRBP, suggesting that synonymous changes to the mRNA coding
429 sequence contribute to higher translation efficiency of bwCIRBP. Consistent with this
430 notion, bwCIRBP has a higher codon adaptation index (CAI)⁵⁹ than hCIRBP (Extended
431 Data Figure 9e). We also conducted a phylogenetic analysis of the CIRBP variant
432 present in the bowhead whale. Serine 126 appears to be ancient, already present in
433 bovids and bats. The unique cluster of 4 amino acids starting at position 147 is more
434 recent, only appearing in *Balaenopteridae*, the baleen whales (Extended Data Figure
435 9b). All baleen whales are very large and long-lived. Interestingly, analysis of primary
436 fibroblasts from other marine mammals and hippopotamus (who share a common
437 ancestor with whales), showed that CIRBP is similarly abundant in the humpback whale
438 but not in sea lions or hippos, while dolphins showed a very mild increase in CIRBP
439 compared to other mammals (Extended Data Figure 7e).

440 We did not observe significant upregulation of canonical CIRBP targets in the bowhead
441 whale following DNA damage. However, CIRBP knockdown showed a trend towards

442 reducing RPA2 levels (Extended Data Figure 8b). Conversely, bwCIRBP
443 overexpression in human cells showed a trend towards upregulation of RPA2 levels
444 (Extended Data Figure 8c).

445 When we compared the PAR-binding affinity of bwCIRBP to that of hCIRBP through
446 fluorescence polarization (FP) measurements of labeled PAR, we observed similar K_D
447 values for both proteins, indicating similar affinity for PAR. K_D values were lower for
448 longer PAR polymers (PAR₂₈ or PAR₁₆) than shorter PAR chains (PAR₈), indicating
449 higher-affinity binding of CIRBP to the longer polymers (Extended Data Figure 8j). As
450 CIRBP is present in over 10-fold excess in the whale, there is likely to be greater overall
451 PAR-binding capacity in whale cells. Intriguingly, despite similar affinity for PAR,
452 bwCIRBP produced a greater increase in FP of labeled PAR than did hCIRBP,
453 indicating a stronger effect on PAR hydrodynamics. This raises the possibility that
454 amino acid differences between the two proteins might lead to differences in binding
455 conformation or stoichiometry of the CIRBP-PAR complex.

456 We next investigated the direct involvement of CIRBP in the DSB repair process. We
457 observed that in bowhead whale cells, the majority of CIRBP is in the nuclear soluble
458 fraction, but some is always associated with chromatin. This association with chromatin
459 appeared to be in large part RNA-dependent (Extended Data Figure 8a).

460 Chen et al ⁵⁰ demonstrated CIRBP recruitment to laser induced DSBs. To confirm this
461 result using a different method, we treated whale cells with the DSB-inducing agent
462 neocarzinostatin (NCS) and tested CIRBP enrichment in the chromatin fraction. Within
463 minutes after the addition of NCS, CIRBP became transiently enriched in the chromatin
464 fraction (Extended Data Figure 8d). Damage-induced CIRBP enrichment was sensitive

465 to RNase A treatment, suggesting that local RNA binding contributes to the association
466 of CIRBP with chromatin upon DNA damage (Extended Data Figure 8e).

467 Upon *in vitro* incubation with various nucleic acid substrates, recombinant human
468 CIRBP produced a concentration-dependent electrophoretic mobility decrease for both
469 RNA and DNA (Extended Data Figure 8k, l), lending support to prior findings of DNA
470 binding by CIRBP^{60,61}. With sufficient CIRBP, nearly all sheared RNA and DNA
471 fragments were retained in the well, suggesting an ability of CIRBP to physically tether
472 or aggregate nucleic acid fragments.

473 We next investigated whether CIRBP directly facilitates *in vitro* end joining of linearized
474 plasmid incubated *in vitro* with human XRCC4-Ligase IV complex. We observed that the
475 ligation of cohesive DNA ends was markedly enhanced by CIRBP in a concentration-
476 dependent manner (Figure 4j). In contrast, the addition of the accessory protein PAXX⁶²
477 failed to stimulate ligation. Interestingly, without addition of Ku70/Ku80, ligation
478 stimulation by CIRBP was more pronounced and almost comparable to stimulation by
479 XLF, which directly interacts with the XRCC4-Ligase IV complex and is considered a
480 core component of the NHEJ machinery⁶³. This result suggests that CIRBP directly
481 stimulates NHEJ and can promote NHEJ in the absence of Ku70/Ku80. In the whale,
482 abundant CIRBP may compensate for lower levels of Ku70/Ku80 relative to human.

483 We additionally tested the effect of bwCIRBP overexpression on repair fidelity in human
484 cells and observed a reduction in indel rates (Figure 5c, Extended Data Figure 8h). We
485 also knocked down CIRBP in whale cells harboring an integrated NHEJ reporter and
486 assessed the mutation spectrum after I-SceI-induced DSBs by sequencing. We

487 observed an increase in deletions, upon CIRBP knockdown (Extended Data Figure 8i),
488 suggesting that CIRBP also contributes to repair fidelity.

489 We additionally observed that human fibroblasts with integrated NHEJ reporters
490 displayed an increase in NHEJ efficiency when cultured at 33°C rather than 37°C. This
491 increase in NHEJ efficiency was accompanied by an increase in CIRBP protein
492 abundance in the cells cultured at 33°C (Extended Data Figure 8m).

493 **Effect of bowhead whale CIRBP on anchorage-independent cell growth**

494 We investigated whether CIRBP overexpression affects the anchorage-independent
495 growth of transformed cells. bwCIRBP was overexpressed in human fibroblasts
496 containing SV40 LT, SV40 ST, H-Ras^{G12V}, and hTERT. These cells showed delayed
497 formation of colonies in soft agar compared to control cells (Extended Data Figure 11a,
498 b). Importantly, there was no difference in the proliferation rate and cell viability between
499 CIRBP-expressing and control cells in 2D culture, as assessed by MTT and trypan blue
500 exclusion assays (Extended Data Figure 11c, d). Furthermore, there was no significant
501 change in the expression of SV40 LT, H-Ras^{G12V}, and cyclin-dependent kinase
502 inhibitors (p16INK4a and p21) (Extended Data Figure 11e). Strikingly, we also observed
503 a lower frequency of chromosomal aberrations in human transformed cells
504 overexpressing bwCIRBP (Extended Data Figure 11f), suggesting that a possible
505 explanation for the delay in colony formation is a reduction in chromosomal instability.⁶⁵

506 **Role of RPA2 in bowhead whale DNA repair fidelity**

507 LC-MS proteomics data, Western blots, and transcriptome analysis suggested
508 increased abundance of the single-stranded DNA binding protein RPA2 in bowhead

509 whale cells and tissues relative to other mammals (Figure 4a, Extended Data Figure 6c,
510 e-g, Extended Data Figure 7a-d). RPA is a conserved heterotrimeric ssDNA-binding
511 protein complex required for eukaryotic DNA replication, which plays a critical role in
512 DNA repair and DNA damage signaling^{64,65}. RPA deficiency increases the frequency of
513 DSBs in human cells under both basal⁶⁶ and stressed⁶⁷ conditions. Conversely, RPA
514 overexpression increases resistance to genotoxic insults⁶⁷⁻⁷⁰. RPA promotes NHEJ *in*
515 *vitro*⁷¹ and protects ssDNA overhangs at DSBs^{72,73}.

516 Treatment of cells transfected with CRISPR to induce DSBs with the small-molecule
517 RPA DNA-binding inhibitor TDRL-505⁷⁴ significantly increased indel rates in both
518 bowhead and human fibroblasts (Figure 5a, b; Supplementary Table 5, 6). In bowhead,
519 RPA inhibition also increased the frequency of larger deletions, although this difference
520 did not reach significance (Figure 5b; Supplementary Table 6). Conversely, co-
521 transfection of trimeric recombinant human RPA protein during CRISPR significantly
522 decreased the frequency of mutated alleles in human cells without affecting CRISPR
523 RNP transfection efficiency (Figure 5a, Supplementary Figure 4c).

524 In summary, these results suggest that increased abundance of CIRBP and RPA2
525 positively affects the fidelity of DSB repair, promoting genomic stability in the bowhead
526 whale.

527 **Discussion**

528 By studying a mammal capable of maintaining its health and avoiding death from cancer
529 for over two centuries, we are offered a unique glimpse behind the curtain of a global
530 evolutionary experiment that tested more mechanisms affecting cancer and aging than

531 humans could hope to approach. Through experiments using primary fibroblasts from
532 the bowhead whale, we experimentally determined genetic requirements for oncogenic
533 transformation in the world's longest living mammal and provide evidence that additional
534 tumor suppressors are not the only solutions to Peto's Paradox. Instead, we find that
535 the bowhead whale solution lies upstream of tumor suppressor loss and is defined by a
536 capacity for highly accurate and efficient DNA DSB repair, as well as improved
537 mismatch repair. We also present evidence that two proteins highly expressed in the
538 bowhead relative to other mammals, RPA2 and CIRBP, contribute to more efficient and
539 accurate DSB repair.

540 CIRBP is highly abundant in the bowhead whale compared to most other mammals. We
541 speculate that baleen whales evolved this high abundance of CIRBP as an adaptation
542 to life in cold water and CIRBP was subsequently co-opted to facilitate genome
543 maintenance. We show that CIRBP directly stimulates NHEJ, and in a purified system
544 can promote NHEJ in the absence of Ku70/80. A potential mechanism by which CIRBP
545 could promote end joining *in vivo* is through recruitment to damaged DNA in a manner
546 enhanced by PAR and RNA, and by promoting the ligation of DNA ends either through
547 direct interaction with DNA and/or through interaction with DNA repair proteins within a
548 synaptic complex, tethering broken ends. Another potential mechanism by which CIRBP
549 could promote ligation of DNA ends might involve liquid-liquid phase separation (LLPS).
550 Recent evidence suggests that RNA-binding proteins can promote phase separation
551 around DSB sites. For example, the FUS RNA-binding protein was found to maintain
552 genomic stability and promote formation of droplet-like compartments in response to
553 DNA damage⁷⁵. Furthermore, it has been shown that long non-coding RNAs

554 synthesized at DSBs are necessary to drive molecular crowding of 53BP1 into foci that
555 exhibit LLPS condensate properties⁷⁶. CIRBP has also been shown to undergo LLPS *in*
556 *vitro*⁷⁷. CIRBP may attract DNA into condensates through its affinity for nucleic acids,
557 increasing rates of intermolecular interaction and ligation kinetics.

558 Cytosine deamination is an important endogenous source of age-related point
559 mutations. Our mismatch repair assay measured repair of a G-T mismatch, one
560 possible intermediate during cytosine deamination. The markedly improved efficiency of
561 repair of this type of mismatch which we observed in the bowhead whale may hint at
562 improved repair of this important source of age-related mutation.

563 While the source of the single-base insertion preference in the bowhead whale remains
564 an open question, we speculate that this may be related to differential employment of
565 bypass polymerases during repair synthesis. While mammals have over a dozen
566 different DNA polymerases, many being specialized error-prone enzymes involved in
567 lesion bypass, polymerase mu (Pol μ) was specifically found to be lost in the cetacean
568 lineage⁷⁸. Pol μ is one of the primary error-prone polymerases involved in NHEJ, along
569 with polymerase lambda (Pol λ) and in some cases terminal deoxynucleotidyl
570 transferase (TdT)⁷⁹. Pol μ , in comparison with other repair polymerases such as Pol λ ,
571 has a unique propensity to “skip” ahead of 3’ unpaired bases, generating deletions^{79,80}.
572 The absence of Pol μ may lead to increased reliance on other repair polymerases,
573 many of which are able to add a single terminal templated or untemplated nucleotide to
574 a 3’ end and could explain the 1-bp insertion bias observed in the bowhead whale.

575 While we did not identify a signature of positive selection on amino acids in bowhead
576 whale RPA2, we did identify a difference of possible functional significance in an N-

577 terminal phosphorylation domain. Previous research has shown that
578 hyperphosphorylation of multiple S/T residues within this domain drives important
579 alterations in RPA2's function. Bowhead whale RPA2 has more N-terminal S/T residues
580 (13) than human RPA2 (9). It has been shown that RPA2 N-terminal
581 hyperphosphorylation inhibits DNA end resection⁸¹, prevents localization to replication
582 centers but not to damage sites⁸², and is specifically required for the maintenance of
583 genome stability during replication stress⁸³.

584 Prior work has identified positive selection in cancer-related genes such as *CXRC2*,
585 *ADAMTS8*, and *ANXA1* in cetaceans, as well as cetacean-specific evolutionary
586 changes to multiple FGF genes^{84,85}. Expansion of the eukaryotic initiation factor 2,
587 polyadenylate binding protein, and 60S ribosomal L10 gene families have also been
588 identified in the genome of the bowhead whale, potentially implying substantial
589 alterations to translational regulation⁸⁶. An additional anti-cancer mechanism was
590 recently reported for the bowhead whale in the form of a *CDKN2C* checkpoint gene
591 duplication⁸⁷. It has further been suggested that the low body temperature and low
592 metabolic rate of the bowhead whale may also contribute in part to its extended
593 lifespan⁸⁸. Indeed, it is likely that numerous individual factors combine to modify cancer
594 risk and produce the longest mammalian lifespan.

595 Improvements in DNA repair pathways have also been previously implicated in the
596 evolution of mammalian longevity. Expression of DNA repair genes was found to be
597 positively correlated with longevity in a transcriptomic study of 26 mammalian species.⁸⁹
598 Interestingly, a prior study found higher levels of PAR synthesis and higher PARP1
599 recruitment to a DNA probe in vitro in the long-lived naked mole rat relative to the

600 mouse⁹⁰, which mirror cellular phenotypes we observed in the bowhead whale relative
601 to human. While this study also noted higher NER activity in the naked mole rat relative
602 to mouse, a subsequent study using additional rodent species found that the efficiency
603 of DSB repair correlates more strongly with longevity across rodent species⁹¹.

604 One potential drawback of a very accurate DNA repair system could be a reduction in
605 standing genetic variation and thus a slower rate of evolution of new traits. However,
606 species living in safe and stable environments have less evolutionary pressure to
607 rapidly evolve new adaptations. A genome analysis of long-lived rockfishes living in
608 deep ocean revealed positive selection in DNA repair pathways⁹². Interestingly, a recent
609 analysis of germline mutations in baleen whales based on analysis of pedigrees
610 concluded that germline mutation frequencies are similar to those in primates, in
611 contrast to prior studies finding reduced germline mutation rates in whales⁹³. Thus, it
612 appears that germline and somatic mutation rates are not inherently linked and could
613 respond to selection independently.

614 Why would improved DNA repair have evolved in the bowhead whale, as opposed to
615 the increased tumor suppressor copy number and elevated apoptotic response found in
616 the elephant and often proposed as a solution to Peto's Paradox? One possible
617 explanation is that tumor suppressors, apoptosis, and senescence all appear to pose
618 costs to the organism and force tradeoffs between cancer and cell depletion leading to
619 age-related degeneration. Simply shifting the balance from apoptosis/senescence to
620 survival and repair could be detrimental if not also coupled with increased fidelity, as
621 evidenced by the frequent upregulation of DNA repair pathways in cancer cells⁹⁴.
622 However, evolutionary improvements that couple high efficiency with high fidelity, as

623 found in the bowhead whale, would promote long-term tissue function and maintenance
624 at both the cellular and genomic levels. Maintenance of genome stability would reduce
625 cancer risk and, as suggested by a rapidly growing body of evidence implicating age-
626 related somatic mosaicism as a ubiquitous feature and functional driver of aging^{95–99},
627 likely protect against numerous other aspects of age-related decline. Thus, the lower
628 accuracy and efficiency of DNA repair observed in mammals with shorter lifespans may
629 simply reflect the absence of sufficient selective pressure⁸⁸. Indeed, there is little
630 selective advantage of DNA repair capacity to last far beyond the age of first
631 reproduction.

632 There are currently no approved therapeutics which aim to bolster DNA repair for the
633 prevention of cancer or age-related decline, and it has been suggested that DNA repair
634 would be difficult or impossible to improve¹⁰⁰. However, the bowhead whale provides
635 evidence that this notion is incorrect. Expression of bwCIRBP in human cells improves
636 the efficiency and accuracy of DSB repair. Therapeutics based on the evolutionary
637 strategy of the bowhead whale, including trying to increase activity or abundance of
638 proteins like CIRBP or RPA2, could one day enable the treatment of genome instability
639 as a modifiable disease risk factor (for discussion of therapeutic hypothermia see
640 Supplementary Note). Improving DNA repair could be especially important for patients
641 with increased genetic predisposition for cancer, or more generally, for aging
642 populations at increased risk for cancer development.

643

644

645 **Acknowledgements**

646 We would like to thank the researchers at the North Slope Borough Department of
647 Wildlife Management, the Alaska Eskimo Whaling Commission, and the Iñupiaq
648 community of Barrow for generously sharing bowhead whale samples, time, resources,
649 skill, and knowledge, and without whom the above work would not have been possible.
650 We would like to give a special thanks to John Craighead “Craig” George, whose
651 pioneering field work established the remarkable longevity of the bowhead whale, and
652 whose kind collaboration and insights helped initiate this project, but who sadly was
653 unable to see its completion. We would like to thank Carlo Maley for suggesting
654 collaboration between Schiffman and Gorbunova groups during a memorable meeting
655 in Arcachon. We would like to thank Aaron Rogers, Mallory Wilmot, and Ryan
656 Kennington for technical support. We would like to thank Tara Harrison, Leigh Duke, the
657 Exotic Species Research Alliance, and Georgia Aquarium for facilitating the collection of
658 the bottlenose dolphin sample. We thank the Marine Mammal Care Center Los Angeles
659 for collecting samples from California sea lions. We would like to thank San Diego Zoo
660 Wildlife Alliance for providing cells from hippopotamus, common dolphin, and humpback
661 whale. Experiments on in vitro ligation were supported by the French National Research
662 Agency. Experiments on PAR-binding were supported by National Institutes of Health
663 R01GM104135 to A.K.L.L. We thank V.K. Thomas in the URM Center for Advanced
664 Light Microscopy and Nanoscopy (RRID:SCR_023177) for images acquired on the
665 Abberior 3D STED instrument (S10 OD023440). This work was supported by grants
666 from US National Institutes on Aging to VNG, ZZ, JV, AS and VG, and by an award from
667 The Milky Way Research Foundation to VG.

668

669 **Author contributions**

670 VG, AS, DF, MZ designed research; DF conducted molecular cloning, lentivirus
671 production, immunofluorescence experiments, PFGE, senescence experiments, cell
672 survival experiments, DNA repair assays, micronuclei assays, PARP experiments,
673 CIRBP experiments, and assessed DNA repair fidelity using NHEJ reporter with help
674 from SAB, AP, EH, AW, NM, ML; MZ conducted tumor suppressor CRISPR
675 experiments, RPA experiments, HPRT assays, comet assays, micronuclei analysis,
676 EMSA, and assessed DNA repair fidelity using CRISPR with help from SAB, MS, NH;
677 XT analyzed tumorigenicity; DF and XT conducted cell growth curves and telomere
678 experiments; VV analyzed chromosomal aberrations; AK conducted MMR assay; YZ,
679 CC, Zhihui Zhang and AG assisted with mouse tumor studies; MM and SF conducted
680 NHEJ ligation assay; JCG, TLS, MZ, DF collected bowhead specimens; LP, EG, LZ,
681 and GG performed tumor xenograft sequencing and analysis with help from MZ; JH,
682 AM, SS, and JV performed SMM-Seq of ENU-treated cells with help from JA; ZW
683 assisted with LC-MS and micronuclei; JG assisted with micronuclei and the alkaline
684 comet assay; JM assisted with the HPRT assay; JG performed STED imaging; MH, RM,
685 and GT did LC-MS of liver tissue; LMT did nuclear extractions from liver; MZ, GT
686 performed cell proteomics; JYL and Zhizhong Zheng analyzed RNAseq with help from
687 DF; HL, YC, AKLL performed PAR-binding assays; VG, Zhengdong Zhang, JV
688 contributed data analysis and conceptualization; VG and AS obtained funding and
689 supervised the study; MZ, DF, AS and VG wrote the manuscript with input from all
690 authors.

691

692 **Competing interests**

693 The authors declare no competing interests.

694

695 **Methods**

696 **Reagents**

697 Detailed information on reagents, such as antibodies and sequences of primers, probes,
698 CRISPR guides, and siRNAs, is provided in Supplementary Methods.

699 **Animal experiments**

700 All animal experiments were approved and performed under pre-approved protocols
701 and in accordance with guidelines set by the University of Rochester Committee on
702 Animal Resources (UCAR).

703 **Whale sample collection**

704 Bowhead whale tissues were obtained from adult bowhead whales (*Balaena*
705 *mysticetus*) captured during 2014 and 2018 Iñupiaq subsistence harvests in Barrow
706 (Utqiagvik), AK, in collaboration with the North Slope Borough Department of Wildlife
707 Management (NSB DWM) and Alaska Eskimo Whaling Commission after signing a
708 Memorandum of Understanding (September 2014 and March 2021). Tissues were
709 sampled immediately after bowhead whales were brought ashore, after permission to
710 sample was given by the whaling captain, and explants kept in culture medium on ice or
711 at 4°C through initial processing and shipping until arrival at the University of Rochester
712 (UR) for primary fibroblast isolation from skin and lung. Transfer of bowhead whale
713 samples from NSB DWM to UR was under NOAA/NMFS permit 21386.

714 **Primary cell cultures**

715 Primary skin fibroblasts were isolated from skin (dermal) tissues as previously
716 described.¹⁰¹ Briefly, skin tissues were shaved and cleaned with 70% ethanol. Tissues
717 were minced with a scalpel and incubated in DMEM/F-12 medium (ThermoFisher) with
718 Liberase™ (Sigma) at 37°C on a stirrer for 15-90 min. Tissues were then washed and
719 plated in DMEM/F-12 medium containing 12% fetal bovine serum (GIBCO) and
720 Antibiotic-Antimycotic (GIBCO). All subsequent maintenance culture for fibroblasts from
721 bowhead and other species was in EMEM (ATCC) supplemented with 12% fetal bovine
722 serum (GIBCO), 100 units/mL penicillin, and 100 mg/mL streptomycin (GIBCO). All
723 primary cells were cultured at 37°C with 5% CO₂ and 3% O₂ except bowhead whale
724 cells, which were cultured at 33°C with 5% CO₂ and 3% O₂ based on published field
725 measurements of bowhead body temperature, which measured a core temperature of
726 33.8 °C and a range of lower temperatures in muscle and peripheral tissue.^{102,103} Prior
727 to beginning experiments with bowhead whale fibroblasts, optimal growth and viability
728 conditions were empirically determined through testing of alternative temperatures,
729 serum concentrations, and cell culture additives, with optimal culture medium found to
730 be the same for bowhead and other species. Following isolation, low population-
731 doubling (PD) primary cultures were preserved in liquid nitrogen, and PD was
732 continually tracked and recorded during subsequent use for experiments.

733 Established, primary fibroblasts from mammals were obtained from San Diego Zoo
734 Wildlife Alliance (hippopotamus, common dolphin, and humpback whale) or generated
735 at Huntsman Cancer Institute from bottlenose dolphin tissues collected by Georgia
736 Aquarium through Tara Harrison (Exotic Species Cancer Research Alliance) and
737 California sea lion tissues collected by the Marine Mammal Care Center Los Angeles

738 under Institutional Animal Care and Use Committee oversight and National Marine
739 Fisheries Service permit number 21636.

740 **Soft agar assay**

741 Fibroblast culture medium as described above was prepared at 2X concentration using
742 2X EMEM (Lonza). To prepare the bottom layer of agar plates, 2X medium was mixed
743 with a sterile autoclaved solution of 1.2% Noble Agar (Difco) at a 1:1 volumetric ratio,
744 and 3 mL of 1X medium/0.6% agar was pipetted into each 6-cm cell culture dish and
745 allowed to solidify at room temperature in a tissue culture hood. To plate cells into the
746 upper layer of soft agar, cells were harvested and washed, and immediately prior to
747 plating were resuspended in 2X medium at 20,000 cells/1.5 mL and diluted twofold in
748 0.8% Noble Agar pre-equilibrated to 37°C. The cells in 0.4% agar/1X medium were
749 pipetted gently to ensure a homogeneous single cell suspension, and 3 mL (20,000
750 cells) per 6 cm dish were layered on top of the solidified lower layer. After solidifying in
751 tissue culture hoods for 20-30 min, additional medium was added to ensure the agar
752 layers were submerged, and dishes were moved into cell culture incubators. Fresh
753 medium was added onto the agar every 3 days. 4 weeks after plating, viable colonies
754 were stained overnight with nitro blue tetrazolium chloride (Thermo Fisher) as
755 previously described.⁴⁰ All cell lines were plated in triplicate.

756 Images of colonies in soft agar were captured using the ChemiDoc MP Imaging System
757 (Bio-Rad). Colony quantification was performed using ImageJ software (NIH). Initially,
758 images were converted to 8-bit format. Subsequently, the threshold function was
759 adjusted to eliminate any red pixels highlighting non-colony objects. Following threshold
760 adjustment, images were converted to binary. Colony counting was executed using the

761 'Analyze Particles' function with the following parameters: Size (pixel²) = 1 to infinity;
762 Circularity = 0.5 to 1.

763 **Mouse xenograft assay**

764 NIH-III nude mice (Crl:NIH-LyStbg-J Foxn1nuBtkxid) were purchased from Charles
765 River Laboratories Inc. (Wilmington, MA, USA). Seven-week-old female mice were used
766 to establish xenografts. For each injection, 2×10^6 cells were harvested and
767 resuspended in 100 μ l of ice-cold 20% matrigel (BD Bioscience, Franklin Lakes, NJ) in
768 PBS (Gibco). Mice were anesthetized with isoflurane gas, and 100 μ l solution per
769 injection was injected subcutaneously into the right and left flanks of each mouse with a
770 22 gauge needle. 3 mice were injected bilaterally, for a total of 6 injections, per cell line
771 tested. Tumor length and width were measured and recorded every 3-4 days. Mice
772 were euthanized after reaching a predetermined humane tumor burden endpoint of a
773 maximum tumor dimension of 20mm in diameter, determined by the longest dimension
774 of the mouse's largest tumor. For mice that did not reach tumor burden endpoints,
775 experiments were terminated, and mice euthanized after a maximum of 60 days.
776 Euthanized mice were photographed, and tumors were excised, photographed, and
777 weighed to determine the mass of each tumor. Sections of each tumor were frozen at -
778 80°C and preserved in formalin.

779 **MTT Assay**

780 Cell metabolic activity was determined using Thiazolyl Blue Tetrazolium Bromide (MTT)
781 (Sigma). Cells were seeded in 24-well plates at a density of 20,000 cells per well one
782 day before the assay. An MTT solution in PBS was added to the growth medium to

783 achieve a final concentration of 0.5 mg/mL, and cells were then incubated for 4 hours in
784 a CO₂ incubator. Following incubation, the growth medium was discarded, and 0.5 mL
785 of DMSO was added to each well to solubilize the purple formazan crystals completely.
786 The plate was further incubated until the crystals were fully dissolved.
787 Spectrophotometric absorbance of the samples was measured at a wavelength of 570
788 nm using a Tecan Spark 20M plate reader.

789 **Telomere lengths**

790 Telomere length was analyzed by Southern blot using the TRF method. Genomic DNA
791 was extracted from cultured fibroblasts at different population doublings, digested with a
792 mixture of AluI, HaeIII, RsaI, and HinfI restriction enzymes that do not cut within
793 telomeric repeat sequences, separated using pulsed-field gel electrophoresis, and
794 hybridized with a radiolabeled oligonucleotide containing telomeric sequence
795 (TTAGGG)₄. Pulsed field gels were run using a CHEF-DR II apparatus (Bio-Rad) for
796 22h at a constant 45 V, using ramped pulse times from 1 to 10 s.

797 **Telomeric repeat amplification protocol**

798 Telomeric repeat amplification protocol assay was performed using the TRAPeze kit
799 (Chemicon, Temecula, CA, USA) according to manufacturer instructions. Briefly, in the
800 first step of the TRAP assay, radiolabeled substrate oligonucleotide is added to 0.5 µg
801 of protein extract. If telomerase is present and active, telomeric repeats (GGTTAG) are
802 added to the 3' end of the oligonucleotide. In the second step, extended products are
803 amplified by PCR. Telomerase extends the oligonucleotide by multiples of 6 bp,

804 generating a ladder of products of increasing length. A human cancer cell line
805 overexpressing telomerase as well as rodent cells were used as a positive control.

806 **CRISPR ribonucleoprotein transfection**

807 CRISPR RNP complexes were formed in vitro by incubating Alt-R™ S.p.Cas9 Nuclease
808 V3 (Integrated DNA technologies) with tracrRNA annealed to target-specific crRNA
809 (Integrated DNA Technologies) according to manufacturer instructions. For generation
810 of tumor suppressor knockouts, 3 RNP complexes with crRNAs targeting different sites
811 in a single target gene were combined and Alt-R Cas9 Electroporation Enhancer
812 (Integrated DNA Technologies) was added to transfection mixes prior to electroporation.
813 For comparative analysis of repair fidelity, 3 µg of pmaxGFP plasmid (Lonza) was
814 added to transfection mixes to monitor transfection efficiency. Cells were trypsinized
815 and washed with PBS, and 1×10^6 cells were resuspended in 100 µL of NHDF
816 Nucleofector Solution (Lonza). The cell suspension was then combined with the
817 CRISPR transfection solution and gently mixed prior to electroporation on an Amaxa
818 Nucleofector 2b (Lonza) using program U-23. For RPA inhibition, human and bowhead
819 fibroblasts were treated with 50 µM TDRL-505 (Sigma) (diluted 1000x into culture
820 medium from 50mM stock solution in DMSO) for 3 hours prior to CRISPR transfection
821 and kept in medium with 50 µM TDRL-505 for 18 hours after transfection. For RPA co-
822 transfection, 1 µg of recombinant human RPA heterotrimer (Enzymax) was added to
823 CRISPR transfection solution immediately prior to electroporation.

824 **Isolation of clonal cell colonies and screening for tumor suppressor knockout**

825 Following CRISPR transfection, cells were plated at low density in 15 cm dishes to allow
826 for the formation of isolated colonies. Once clonal colonies of sufficient size had formed,
827 positions of well-isolated colonies were visually marked on the bottom of the cell culture
828 dish while under a microscope using a marker. Dishes were aspirated and washed with
829 PBS. Forceps were used to dip PYREX® 8x8 mm glass cloning cylinders in adhesive
830 Dow Corning® high-vacuum silicone grease (Millipore Sigma) and one glass cylinder
831 was secured to the dish over each marked colony. 150 µL of trypsin was added to each
832 cylinder and returned to the incubator. When cells had rounded up from the plate, the
833 trypsin in each cylinder was pipetted to detach cells and each colony was added to a
834 separate well in a 6-cm culture dish containing culture medium. After colonies were
835 expanded and split into 2 wells per colony, one well was harvested for Western blot
836 screening for absence of target proteins, while the remaining well was kept for further
837 experiments.

838 **Luciferase reporter assays for knockout verification**

839 For p53 activity measurement, 1×10^6 cells of control (WT) and clonally isolated p53 KO
840 cell lines were electroporated with 3 µg p53 firefly luciferase reporter plasmid pp53-TA-
841 Luc (Clontech/Takara) and 0.3 µg renilla luciferase control plasmid pRL-CMV
842 (Promega) on an Amaxa Nucleofector 2b (Lonza). 24h later, cells were treated with 200
843 µM etoposide (Sigma) to induce p53 activity. 24h following etoposide treatment, cells
844 were harvested, and luciferase activity of cell lysates was measured using the Dual-
845 Luciferase Reporter Assay System (Promega) in a GloMax 20/20 Luminometer
846 (Promega) according to manufacturer instructions.

847 For Rb activity measurement, 2 different reporters were tested in parallel: pE2F-TA-Luc
848 (Clontech/Takara) to measure E2F transcriptional activity (repressed by Rb), and pRb-
849 TA-Luc (Clontech/Takara) (promoter element directly suppressed by Rb). 1×10^6 cells
850 of control (WT) and clonally isolated Rb KO cell lines were electroporated with 3 μ g of
851 either pE2F-TA-luc or pRb-TA-luc and 0.3 μ g renilla luciferase plasmid on an Amaxa
852 Nucleofector 2b (Lonza). Following transfection, cells were grown in complete medium
853 for 24h followed by serum-free medium for 24h. Cells were then harvested, and
854 luciferase activity measured as described above.

855 **Error-corrected sequencing by SMM-seq of ENU-mutated cells**

856 Skin fibroblasts from mouse, cow, human and whale were isolated and cultured as
857 described before. Confluent cells were treated with 20mg/ml ENU overnight. Then cells
858 were split 1:4 and grown until confluence for harvest.

859 Genomic DNA (gDNA) was isolated from frozen cell pellets using the Quick DNA/RNA
860 Microprep Plus Kit (Zymo D7005). Three hundred ng were used for library preparation
861 as described before¹⁰⁴: in brief, DNA was enzymatically fragmented, treated for end
862 repair before adapter ligation and exonuclease treatment. A size selection step was
863 performed using a 1.5% cassette on a PippinHT machine prior pulse rolling circle
864 amplification (RCA) and indexing PCR. Library quality was determined with a Tape
865 Station (Agilent) and quantified with Qubit (Thermo Fisher). All libraries were sequenced
866 by Novogene Corp. Inc (CA) on an Illumina platform.

867 Sequencing analysis and mutation calling was performed as described¹⁰⁴ . After
868 trimming and alignment to the corresponding reference genome, additional filtering was
869 performed to distinguish germline mutations from somatic mutations.

870 Graphs were generated and statistical testing was performed using GraphPad Prism.

871 **Next-generation sequencing of CRISPR repair products**

872 72h after transfection, cells were harvested, and genomic DNA was isolated with the
873 Wizard Genomic DNA Purification Kit (Promega). DNA concentration was measured on
874 a Nanodrop spectrophotometer and 100 ng of DNA per sample was PCR-amplified with
875 KAPA2G Robust HotStart ReadyMix (Roche) based on findings of low PCR bias for
876 KAPA polymerase^{105,106}. Primers targeted a conserved region surrounding *PTEN* exon 1
877 (Extended Data Figure 4a). PCR was performed according to manufacturer instructions,
878 with an annealing temperature of 66°C for 30 cycles. To purify samples for next-
879 generation sequencing, PCR products were electrophoresed on a 0.8% agarose gel
880 and post-stained with SYBR Gold Nucleic Acid Gel Stain (Thermo Fisher). Gels were
881 visualized on a blue light tray (BioRad) to minimize damage to DNA. A gel slice for each
882 lane was excised using a scalpel, and each slice was cut to include the region ranging
883 from just above the prominent *PTEN* PCR band down to and including the “primer
884 dimer” region to ensure inclusion of any deletion alleles. DNA was extracted from gel
885 slices using the QiaQuick Gel Extraction Kit (Qiagen), and triplicate PCR reaction
886 eluates per sample were pooled for sequencing. Sample concentrations were measured
887 by Nanodrop and adjusted as necessary prior to submission for 2x250 bp paired-end
888 Illumina MiSeq sequencing with target depth of >40,000 reads/sample (Genewiz).

889 **Analysis of CRISPR NGS data**

890 FASTQ files from each sequenced sample were analyzed with both CRISPResso2,¹⁰⁷
891 which uses an alignment-based algorithm, and CRISPRPic,¹⁰⁸ which uses a kmer-based
892 algorithm. CRISPResso2 was run using the following parameters: window size = 30,
893 maximum paired-end overlap = 500, bp excluded from left and right ends = 15,
894 minimum alignment score = 50, minimum identity score = 50, plot window size = 20. For
895 CRISPRPic analysis, SeqPrep¹⁰⁹ was used to merge overlapping read pairs and trim
896 adapter sequences. CRISPRPic was run on merged FASTQ sequences for each
897 sample with the following parameters: index size = 8, window size = 30.

898 **HPRT mutation assay**

899 For the HPRT mutation assay, cells used were low-passage primary dermal fibroblasts
900 from multiple species that were known to originate from male animals, to ensure single
901 copy-number of the X-linked *HPRT* gene. Each species was tested with 3 different cell
902 lines from 3 individual animals. The bowhead *HPRT* coding sequence was BLASTed
903 against bowhead genome scaffolds¹⁷ and neighboring gene sequences were analyzed
904 to confirm mammal-typical localization of *HPRT* on the bowhead X-chromosome. Cells
905 were cultured in standard fibroblast growth medium, but with FBS being replaced with
906 dialyzed FBS (Omega Scientific, Inc.) and supplemented with Fibroblast Growth Kit
907 Serum-Free (Lonza) to improve growth and viability in dialyzed FBS. Dialyzed FBS was
908 found in optimization experiments to be necessary for efficient 6-thioguanine selection.
909 Prior to mutagenesis, cells were cultured for 7 days in medium containing HAT
910 Supplement (Gibco) followed by 4 days in HT Supplement (Gibco) to eliminate any pre-
911 existing HPRT mutants. To induce mutation, cells were incubated for 3 hours in serum-

912 free MEM containing 150 µg/mL N-ethyl-N-nitrosourea (ENU) (Sigma), or exposed to 2
913 Gy γ -irradiation. Cells were then maintained in ENU-free medium for 9 days to allow
914 mutations to establish and existing HPRT to degrade. 1×10^6 cells from each cell line
915 were harvested and plated in dialyzed FBS medium containing 5 µg/mL 6-thioguanine
916 (Chem-Impex), in parallel with 1×10^6 untreated control cells for each cell line. Cells
917 were plated at a density of 1×10^5 cells per 15-cm dish to allow for efficient selection
918 and colony separation, and to prevent potential "metabolic cooperation"⁴⁵. In tandem, for
919 each cell line 200 cells from untreated and control conditions were plated in triplicate
920 10-cm dishes in non-selective medium to calculate plating efficiency. After 3 weeks of
921 growth, surviving colonies were fixed and stained with a crystal violet/glutaraldehyde
922 solution as previously described¹¹⁰. Colonies were counted, and HPRT mutation rate
923 was calculated as plating-efficiency adjusted number of HPRT-negative colonies
924 containing >50 cells. Appropriate concentrations of ENU and 6-TG, as well as optimal
925 plating densities and growth conditions, were determined prior to the experiment
926 described above through optimization and dose titration experiments.

927 **Digital droplet PCR measurement of CRISPR cleavage rate**

928 A ddPCR assay similar to a previously published method¹¹¹ was used for time-course
929 quantification of CRISPR DSB induction across species. qPCR primers at conserved
930 sites flanking the guide RNA target site in the *PTEN* gene were designed such that
931 cleavage would prevent PCR amplification. As an internal copy number reference
932 control, a second set of previously validated qPCR primers targeting an ultraconserved
933 element present in all mammals as a single copy per genome (UCE.359) was designed
934 based on published sequences¹¹². To allow for multiplexing and copy number

935 normalization of *PTEN* within each ddPCR reaction, 5' fluorescent hydrolysis probes
936 (FAM for *PTEN* and HEX for UCE.359) targeting conserved sequences were designed,
937 with 3' Iowa Black® and internal ZEN™ quenchers (Integrated DNA Technologies). All
938 primers and probes were checked for specificity by BLAST against each species'
939 genome¹¹². Fibroblasts were transfected with *PTEN* CRISPR RNP as described in
940 "Next-generation sequencing of CRISPR repair products" and returned to cell culture
941 incubators. At the indicated times post-transfection, cells were harvested, flash frozen,
942 and genomic DNA was isolated with the Wizard Genomic DNA Purification Kit
943 (Promega). During isolation, newly lysed cells were treated with Proteinase K and
944 RNase A for 30 minutes each at 37°C to minimize the possibility of residual CRISPR
945 RNP activity. DNA concentration was measured on a Nanodrop spectrophotometer, and
946 genomic DNA was pre-digested with BamHI-HF (NEB) and XhoI (NEB), which do not
947 cut within target amplicons, to maximize PCR efficiency and distribution across droplets.
948 15 ng of genomic DNA per sample was added to duplicate PCR reactions using the
949 ddPCR™ Supermix for Probes (No dUTP) master mix (Bio-Rad). Droplets were
950 prepared and measured according to manufacturer instructions. Briefly, each 20 µL
951 reaction was mixed with 70 µL Droplet Generation Oil for Probes (Bio-Rad) and droplets
952 were formed in a QX100 Droplet Generator (Bio-Rad). 40 µL of droplets per reaction
953 were transferred to 96-well PCR plates and sealed with a PX1 PCR Plate Sealer (Bio-
954 Rad). The sealed plates were then subjected to PCR using a pre-optimized cycling
955 protocol. Following PCR, the plates were loaded into a QX100™ Droplet Reader (Bio-
956 Rad) and each droplet measured on both FAM and HEX channels. *PTEN* copy number
957 normalized to UCE.359 reference copy number within each well was determined with

958 QuantaSoft™ software (Bio-Rad). For each species, positive/negative gates in mock-
959 transfected control samples were adjusted as necessary to compensate for differences
960 in multiplex PCR efficiency/specificity and “rain” droplets between species and bring
961 normalized *PTEN* copy number closer to 1. The control gates were then applied across
962 all samples/time points within the same species and used for *PTEN* copy number
963 calculation.

964 **Flow cytometric measurement of CRISPR RNP transfection efficiency**

965 CRISPR RNP transfections were performed as described above, but with ATTO-550
966 fluorescently labeled tracrRNA (Integrated DNA Technologies). At 0h and 24h post-
967 transfection, cells were harvested, pelleted, and analyzed by flow cytometry on a
968 CytoFlex S Flow Cytometer (Beckman Coulter). Gain and ATTO-550 positive gates
969 were set based on mock-transfected control cells included in each experiment.

970 **Senescence-associated β -galactosidase (SA- β -gal) staining**

971 SA- β -gal staining was performed as previously described^{113,114}. Cells were washed
972 twice with PBS and fixed in a solution containing 2% formaldehyde and 0.2%
973 glutaraldehyde in PBS for 5 min at room temperature. After fixation, cells were
974 immediately washed twice with PBS and stained in a solution containing 1 mg/mL 5-
975 bromo-4-chloro-3-indolyl P3-D-galactoside (X-Gal), 40 mM citric acid/sodium phosphate
976 buffer, pH 6.0, 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 150 mM
977 NaCl, and 2 mM MgCl₂. Plates were incubated at 37°C for 16 h without CO₂.
978 Colorimetric images were taken from different areas of each plate and quantified.

979 **Cell survival assay**

980 Percentage of live cells was quantified using the Annexin-V FLUOS Staining Kit (Roche)
981 and Annexin V Apoptosis Kit [FITC] (Novus Biologicals) following the manufacturer's
982 instructions. After staining, cells were analyzed on a CytoFlex S flow cytometer
983 (Beckman Coulter).

984 Where indicated cell viability was assessed using a trypan blue exclusion assay. All
985 cells (both floated and attached to the culture dish) were collected into the same tube,
986 centrifuged, and resuspended in PBS. The cells were then mixed in a 1:1 ratio with
987 0.4% trypan blue solution, and approximately 3 minutes later, the percentage of dead
988 cells was assessed using the Countess 3FL instrument (ThermoFisher) according to the
989 manufacturer's instructions.

990 **p53 activity**

991 To test p53 activity in cultured primary fibroblasts, 150,000 cells were seeded in 6-well
992 plates 1 day before transfection with 1 µg pp53-TA-Luc vector (Clontech) and 0.015 µg
993 pRL-CMV-Renilla (Promega) to normalize for transfection efficiency. Transfections were
994 performed using PEI MAX Transfection Grade Linear Polyethylenimine Hydrochloride
995 (MW 40,000) (Polysciences) according to manufacturer instructions. 24h after
996 transfections cells were lysed using 50µl passive lysis buffer (Promega) per 10⁵ cells
997 and flash frozen/thawed two times in liquid nitrogen and a 37°C water bath. Luciferase
998 assays were performed using the Dual-Luciferase Reporter Assay System (Promega)
999 and program DLR-2-INJ on a Glomax 20/20 Luminometer (Promega) with 20µl cell
1000 extract as the input.

1001 **Generation of NHEJ and HR reporter cell lines**

1002 NHEJ and HR reporter constructs⁴⁶ were digested with NheI restriction enzyme and
1003 purified with the QIAEX II gel extraction kit (QIAGEN). The same plasmid DNA
1004 preparation was used for generating all reporter cell lines of the studied species. Cells
1005 PD < 15 were recovered from liquid nitrogen and passaged once before the integration
1006 of the constructs. 0.25 µg of linearized NHEJ and HR constructs were electroporated
1007 into one million cells for each cell line. Two days after transfection, media was
1008 refreshed, and G418 was applied to select stable integrant clones. Triplicates of each
1009 reporter in each cell line were prepared to obtain an adequate number of stable clones.
1010 Clones from triplicate plates were pooled to get at least 50 clones per reporter per cell
1011 line.

1012 **DSB repair assays and flow cytometry analysis**

1013 DSB repair assays were performed as previously described¹¹⁵. Briefly, growing cells
1014 were co-transfected with 3 µg of plasmid encoding I-SceI endonuclease and 0.03 µg of
1015 plasmid encoding DsRed. The same batch of I-SceI and DsRed mixture was used
1016 throughout all species to avoid batch-to-batch variation. To test the effect of CIRBP on
1017 DSB repair, 3 µg of CIRBP plasmids were co-transfected with I-SceI and DsRed
1018 plasmids. Three days after transfection, the numbers of GFP+ and DsRed+ cells were
1019 determined by flow cytometry on a CytoFlex S Flow Cytometer (Beckman Coulter). For
1020 gating strategy see Supplementary Figure 5 in Supplementary Information. For each
1021 sample, a minimum of 50,000 cells was analyzed. DSB repair efficiency was calculated
1022 by dividing the number of GFP+ cells by the number of DsRed+ cells.

1023 For NHEJ knockdown experiments, bowhead whale cells containing the NHEJ reporter
1024 were transfected with 120 pmol of anti-bwCIRBP or control siRNAs (Dharmacon) three

1025 days before I-SceI/DsRed transfections using an Amaxa Nucleofector (U-023 program).
1026 For HR knockdown experiments, bowhead whale cells containing the HR reporter were
1027 transfected twice every three days with a final concentration of 10 nM anti-bwCIRBP or
1028 negative control siRNAs (Silencer Select, Thermo Fisher) using Lipofectamine
1029 RNAiMAX transfection reagent (Thermo Fisher) following the manufacturer's
1030 instructions. Cells were further transfected with I-SceI/DsRed plasmids using a 4D-
1031 Nucleofector (P2 solution, DS150 program). The efficiency of knockdown was
1032 determined by Western blot.

1033 For the extrachromosomal assay and fidelity analysis, NHEJ reporter plasmid was
1034 digested with I-SceI for 6h and purified using a QIAEX II Gel Extraction Kit (QIAGEN).
1035 Exponentially growing cells were transfected using an Amaxa nucleofector with the U-
1036 023 program. In a typical reaction, 10^6 cells were transfected with 0.25 μ g of
1037 predigested NHEJ reporter substrate along with 0.025 μ g of DsRed to serve as a
1038 transfection control. 72h after transfection, cells were harvested and analyzed by flow
1039 cytometry on a BD LSR II instrument. At least 20,000 cells were collected for each
1040 sample. Immediately after FACS, genomic DNA was isolated from cells using the
1041 QIAGEN Blood & Tissue kit. DSB repair sites in the NHEJ construct were amplified by
1042 PCR using Phusion polymerase (NEB), cloned using the TOPO Blunt cloning kit (NEB),
1043 and sent for Sanger sequencing. At least 100 sequenced clones were aligned and
1044 analyzed using the ApE software.

1045 **Western blotting**

1046 All antibodies were checked for conservation of the target epitope in the protein
1047 sequence of each included species, and only those targeting regions conserved across

1048 these species were used. For a limited number of proteins where the available
1049 antibodies with specific epitope information disclosed did not target conserved regions,
1050 we selected antibodies based on demonstrated reactivity across a broad range of
1051 mammal species and always confirmed these results with multiple antibodies.

1052 Information on antibodies is provided in Supplementary Methods.

1053 Exponentially growing cells were harvested with trypsin and counted, and 10^6 cells were
1054 resuspended in 100 μ L of PBS containing protease inhibitors. 100 μ L of 2x Laemmli
1055 buffer (Bio-Rad) was added, and samples were boiled at 95°C for 10 minutes. Samples
1056 were separated with 4-20% gradient SDS-PAGE, transferred to a PVDF membrane,
1057 and blocked in 5% milk-TBS-T for 2 hours at room temperature. Membranes were
1058 incubated overnight at +4°C with primary antibodies in 5% milk-TBS-T. After 3 washes
1059 for 10 minutes with TBS-T, membranes were incubated for 1 hour at room temperature
1060 with secondary antibodies conjugated with HRP or a fluorophore. After 3 washes with
1061 TBS-T signal was developed for HRP secondaries with Clarity Western ECL Substrate
1062 (Bio-Rad). CIRBP and RPA2 expression were each measured with 3 different
1063 antibodies targeting conserved epitopes (Extended Data Figure 7b, c).

1064 For detecting chromatin-bound proteins, cells were lysed in 1 mL of CSK buffer (10 mM
1065 Pipes pH 6.8, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl₂, 1 mM EGTA, 0.2% Triton
1066 X-100) or CSK+R buffer (10 mM Pipes pH 6.8, 100 mM NaCl, 300 mM sucrose, 3 mM
1067 MgCl₂, 1 mM EGTA, 0.2% Triton X-100, and 0.3 mg/mL RNase A) at +4°C for 30 min
1068 with gentle rotation. Samples were centrifuged for 10 min at 10,000 \times g at 4°C, and the
1069 supernatant was discarded. Pellets were washed twice with 1 mL of CSK/CSK+R buffer,
1070 resuspended in PBS, and an equal volume of 2x Laemmli buffer (Bio-Rad) was added.

1071 Samples were boiled at 95°C for 10 minutes and subjected to Western blotting as
1072 described above.

1073 For analyzing CIRBP expression in mice and bowhead whale tissues, tissues were
1074 pulverized using the cell crusher. For each 5 mg of tissue, 300 μ L of 4x Laemmli buffer
1075 (Bio-Rad) was added, samples were extensively vortexed, and boiled at 95°C with 1000
1076 rpm for 10 minutes.

1077 **Expression and purification of human and bowhead whale CIRBP protein**

1078 N-terminal histidine-tagged (6xHis) CIRBP was cloned into a pET11a expression vector.
1079 The plasmid was transformed into Rosetta gami B (DE3) pLysS competent E. coli for
1080 protein expression. Bacteria were grown at 37°C to an optical density (OD₆₀₀) of 2.0
1081 and protein expression was induced by adding 0.4mM isopropyl β -d-1-
1082 thiogalactopyranoside (IPTG) for 20 h at 23°C. Bacteria were collected by centrifugation
1083 and pellets were flash frozen on liquid nitrogen and stored at -80°C. In Bacteria were
1084 resuspended in lysis buffer consisting of 50mM Tris pH 7.5, 2.0M NaCl, 50mM
1085 imidazole, 10mg lysozyme, 0.1% Triton X-100, 1mM DTT and protease inhibitors. The
1086 bacterial pellets were sonicated, rotated for 1 h at 4°C, and sonicated again. The
1087 bacterial lysate was clarified by centrifugation at 22,000g for 20 min at 4°C and the
1088 supernatant passed through a 0.45 μ m filter. The clarified lysate was purified using Ni-
1089 NTA agarose beads (Qiagen) washed with 20 column volumes of water and 20 column
1090 volumes of buffer containing 50mM Tris pH 7.5, 2.0M NaCl, 1mM DTT, and 50mM
1091 imidazole (Wash buffer 1). The lysate was placed onto the washed beads and
1092 transferred to a 50mL conical tube and rotated 3 hr at 4°C. The suspended beads were
1093 pelleted by centrifugation and washed with 40 column volumes wash buffer 1 and 10

1094 column volumes with buffer containing 50mM Tris pH 7.5, 150mM NaCl, 1mM DTT, and
1095 50mM imidazole. CIRBP was eluted by adding 5 column volumes of buffer containing
1096 50mM Tris pH 7.5, 150mM NaCl, 1mM DTT, and 500mM imidazole and rotated the
1097 conical tube for 15 minutes at 4oC. The supernatant was collected by centrifugation and
1098 filtered before adding 5% glycerol. The protein was aliquoted, and flash frozen on liquid
1099 nitrogen and stored at -80oC.

1100 **NHEJ ligation in vitro assay**

1101 The assay was performed essentially as described^{116,117}. Reaction mixtures (10 µl)
1102 contained 20 mM Tris-HCl (pH 7.5), 8 mM MgCl₂, 0.1 mM ATP, 2 mM DTT, 0.1 M KCl,
1103 2% Glycerol, 4% PEG 8000, 1 nM linearized pUC19 (with cohesive ends via XbaI; 17.3
1104 ng), 10 nM XRCC4/Ligase IV complex, and 0.5 or 1 µM human CIRBP. When indicated,
1105 reaction mixtures also contained 10 nM Ku70/80 heterodimer, 1 µM XLF dimer, or 1 µM
1106 PAXX dimer. The reaction mixtures were incubated for 1 hr at 30°C, followed by the
1107 addition of 2 µl of Gel Loading Dye, Purple (6X) (NEB), and incubation for 5 min at
1108 65°C. Subsequently, 4 µl of each sample was loaded onto a 0.7% agarose gel and
1109 subjected to gel electrophoresis (50 V, 50 min). The gel was stained with ethidium
1110 bromide, and DNA bands were visualized using a ChemiDoc MP (Bio-Rad).

1111 **PARP activity**

1112 PARP activity was measured in cell nuclear extracts with the PARP Universal
1113 Colorimetric Assay Kit (Trevigen) according to the manufacturer's instructions. Nuclear
1114 extracts were prepared using EpiQuik Nuclear Extraction Kit (EpigenTek) following

1115 manufacturer protocol. 2.5µg of total nuclear extract was added to measure PARP
1116 activity.

1117 For measurement of PARylation efficiency, cells were treated with 400µM H₂O₂ for 15
1118 and 30 min or subjected to 20 Gy γ -radiation. At the end of incubation, cells were placed
1119 on ice, washed once with PBS, and lysed directly on a plate with 2x Laemmli buffer.
1120 Samples were boiled for 10min at 95°C and processed by Western Blot.

1121 **Preparation of fluorescent ligands, binding assays and fluorescence polarization** 1122 **measurements**

1123 Poly(ADP-ribose) (PAR) oligomers of different lengths (PAR₈, PAR₁₆, and PAR₂₈) were
1124 synthesized, purified, fractionated, and labeled with Alexa Fluor 488 (AF488) dye at the
1125 1'' end, following as described previously^{118,119}.

1126 To investigate the binding of human and bowhead whale CIRBPs to the fluorescently
1127 labeled PAR and RNA oligomers, titration experiments were conducted. CIRBP proteins
1128 were 4:3 serially diluted and titrated into solutions containing a fixed concentration (3
1129 nM) of the fluorescently labeled PAR. The binding reactions were performed in triplicate
1130 in a buffer comprising 50 mM Tris-HCl pH 7.5, 100 mM KCl, 2 mM MgCl₂, 10 mM β -
1131 mercaptoethanol, and 0.1 mg/mL BSA. The reactions were incubated in dark at room
1132 temperature for 30 minutes in a Corning 384-well Low Flange Black Flat Bottom
1133 Polystyrene NBS Microplate (3575).

1134 After incubation, fluorescence polarization (FP) measurements were performed on a
1135 CLARIOstar Plus Microplate Reader from BMG LABTECH equipped with polarizers and
1136 Longpass Dichroic Mirror 504 nm. The excitation wavelength was set at 482 nm with 16

1137 nm bandwidth, and emission was monitored at 530 nm with 40 nm bandwidth. The FP
1138 values were measured three times, the means of which were analyzed to determine
1139 binding affinities. The binding curves were fitted using a nonlinear regression model to
1140 determine dissociation constants (K_D). The FP increase was quantified to indicate the
1141 hydrodynamic differences upon proteins binding to ligands. Data analysis and curve
1142 fitting were performed using GraphPad Prism.

1143 **Pulsed-field gel electrophoresis and analysis of DSBs**

1144 After irradiation and repair incubation, confluent human and bowhead whale skin
1145 fibroblasts were harvested, ~400,000 cells were resuspended in PBS, mixed with an
1146 equal volume of 1.4% low gelling temperature agarose and embedded into agarose
1147 plugs. Plugs were kept for 1h at +4°C and incubated in lysis solution 1 (0.5M EDTA, 2%
1148 sodium sarcosine, 0.5 mg/ml Proteinase K) for 24h at +4°C. Subsequently plugs were
1149 placed into lysis solution 2 (1.85M NaCl, 0.15M KCl, 5mM MgCl₂, 2mM EDTA, 4mM Tris
1150 pH 7.5, 0.5% TritonX100) for 40h at +4°C. Plugs were then washed two times for 1h in
1151 TE buffer and stored in TE buffer at +4°C. PFGE was carried out with a CHEF DRII
1152 system (Bio-Rad) in 0.8% agarose gels. The gels were run at 14°C with linearly
1153 increasing pulse times from 50 to 5,000 s for 66 h at a field strength of 1.5 V/cm. Gels
1154 were stained with 0.5 mg/ml ethidium bromide for 4h, washed with TBE buffer and
1155 imaged. Quantitative analysis was performed with Image Lab software (Bio-Rad). The
1156 fraction of DNA entering the gel was quantified. Samples irradiated with various doses
1157 and not incubated for repair served as a calibration to determine the percentage of
1158 remaining DSBs in the repair samples from the fraction of DNA entering the gel.

1159 **Immunofluorescence**

1160 Exponentially growing cells from humans and bowhead whales were cultured on Lab-
1161 Tek II Chamber Slides (ThermoFisher Scientific), followed by treatment with bleomycin
1162 (BLM) at a final concentration of 5 $\mu\text{g}/\text{mL}$ for 1 hour. DNA damage foci were stained
1163 with γH2AX and 53BP1 antibodies and quantified at 1 hour and 24 hours. Considering
1164 the potential non-specificity of γH2AX and 53BP1 antibodies across species, we used
1165 co-localized foci as a more reliable indication of DNA damage.

1166 After BLM treatment, cells were washed twice in PBS, fixed with 2% formaldehyde for
1167 20 minutes at room temperature (RT), washed three times in PBS, and incubated in
1168 chilled 70% ethanol for 5 minutes. After three additional washes in PBS, fixed cells were
1169 permeabilized with 0.2% Triton X-100 for 15 minutes at RT, washed twice for 15
1170 minutes in PBS, and blocked in 8% BSA diluted in PBS supplemented with 0.1%
1171 Tween20 (PBST) for 2 hours at RT. Cells were then incubated with mouse monoclonal
1172 anti- γH2AX (Millipore, 05-636, 1:1000) and rabbit polyclonal anti-53BP1 antibodies
1173 (Abcam, ab172580, 1:1000) diluted in 1% BSA-PBST at +4°C overnight. After
1174 incubation with primary antibodies, cells were washed in PBST three times for 10
1175 minutes and incubated with goat anti-rabbit (Alexa Fluor 488) (Abcam, 1:1500) and goat
1176 anti-mouse antibodies (Alexa Fluor 568) (Thermo Fisher Scientific, 1:1000) for 1 hour at
1177 room temperature. After four washes for 15 minutes in PBST, slides were mounted in
1178 VECTASHIELD Antifade Mounting Medium with DAPI.

1179 For chromatin CIRBP association, cells were pre-incubated with CSK/CSK+R buffer for
1180 3 minutes at RT, washed once in PBS, and subjected to the procedure described above
1181 using rabbit monoclonal anti-CIRBP antibodies (Abcam, 1:1000).

1182 Images were captured using the Nikon Confocal system. Confocal images were
1183 collected with a step size of 0.5 μm covering the depth of the nuclei. Foci were counted
1184 manually under 60x magnification.

1185 **Construction of lentiviral overexpression vectors and lentivirus production**

1186 The coding sequences of hCIRBP and bwCIRBP were amplified by PCR using Phusion
1187 polymerase (NEB), digested with EcoRI and NotI, and cloned between the EcoRI and
1188 NotI sites of the Lego-iC2 plasmid. The sequence was verified by Sanger sequencing.
1189 Lentiviral particles were produced in Lenti-X 293T cells (Takara). Approximately 10×10^6
1190 cells were transfected with a mixture of pVSV-G (1.7 μg), psPAX2 (3.4 μg), and Lego-
1191 iC2-bwCIRBP (6.8 μg) using PEI MAX (Polysciences). The day after transfection, the
1192 DMEM culture medium (ThermoFisher) was replaced with fresh medium, and lentiviral
1193 particles were harvested from the supernatant for the next 3 days.

1194 **Quantification of micronuclei**

1195 To analyze binucleated cells containing micronuclei (MN), 10,000-20,000 cells were
1196 plated per chamber slide before irradiation or I-SceI transfection. Immediately after
1197 treatment, cytochalasin B was added to the cell culture media at a final concentration of
1198 0.5-1 $\mu\text{g}/\text{ml}$, and cells were incubated for an additional 72-120 hours. At the end of the
1199 incubation period, cells were washed with PBS, incubated in 75 mM KCl for 10 minutes
1200 at RT, fixed with ice-cold methanol for 1.5-3 minutes, air-dried, and stored. Immediately
1201 before analysis, cells were stained with 100 $\mu\text{g}/\text{ml}$ acridine orange for 2 minutes,
1202 washed with PBS, mounted in PBS, and analyzed by fluorescence microscopy.

1203 Alternatively, cells were mounted in VECTASHIELD Antifade Mounting Medium with
1204 DAPI. At least 100 binucleated cells were analyzed per sample.

1205 **Chromosomal aberration analysis**

1206 Metaphase spreads were prepared according to a standard protocol. Briefly, 0.06 µg/ml
1207 colchicine (Sigma) was added to the growth medium for 4 hours, and cells were
1208 harvested with a 0.25% solution of trypsin/EDTA, treated for 10 minutes with a
1209 hypotonic solution (0.075 M KCl/1% sodium citrate) at 37°C, and fixed with three
1210 changes of pre-cooled (-20°C) methanol/acetic acid mixture (3:1) at -20°C. Cells were
1211 dropped onto pre-cleaned microscope glass slides and air-dried. Metaphase spreads
1212 were stained with Giemsa Stain (Sigma) solution in PBS. For each variant, 100
1213 metaphases were analyzed.

1214 **Mismatch repair assay**

1215 pGEM5Z(+)-EGFP was a gift from LuZhe Sun (Addgene plasmid #65206;
1216 <http://n2t.net/addgene:65206>; RRID:Addgene_65206). p189 was a gift from LuZhe Sun
1217 (Addgene plasmid #65207; <http://n2t.net/addgene:65207>; RRID:Addgene_65207).
1218 Preparation of the heteroduplex EGFP plasmid was following a published method ⁴¹
1219 Briefly, pGEM5Z(+)-EGFP plasmid was nicked with Nb.Bpu10I (Thermo Scientific). After
1220 phenol/chloroform extraction and ethanol precipitation, the nicked plasmid was digested
1221 with Exonuclease III (Thermo Scientific) for 10 minutes at 30°C. p189 was linearized
1222 with restriction enzyme BstXI (NEB) and mixed with the purified circular ssDNA at a
1223 ratio of 1.0:1.5 to generate a heteroduplex EGFP plasmid containing a G/T mismatch

1224 and a nick. The heteroduplex EGFP plasmid with high purity was recovered using a
1225 DNA cleanup kit.

1226 Exponentially growing cells were transfected using a 4D-nucleofector (Lonza) with the
1227 P1 solution using the DS120 program. In a typical reaction, 2×10^5 cells were transfected
1228 with 50 ng of heteroduplex EGFP plasmid along with 50 ng of DsRed2 to serve as a
1229 transfection control. After transfection (48 hours), cells were harvested and analyzed by
1230 flow cytometry on a CytoFlex S flow cytometer (Beckman Coulter).

1231 **Host cell reactivation assay**

1232 A host cell reactivation assay was employed to assess the repair of UV-induced DNA
1233 damage via nucleotide excision repair, following previously described methods¹²⁰.

1234 To evaluate the repair of oxidative DNA damage (base excision repair), a mixture of 20
1235 μ g of firefly luciferase (FFL) plasmid and 20-200 μ M methylene blue (MB) was
1236 prepared, with water added to reach a final volume of 0.4 ml. The DNA-MB mixture was
1237 dropped onto a petri dish and placed on ice, with another petri dish containing water
1238 positioned on top. Subsequently, the DNA-MB mixture was exposed to visible light for
1239 15 minutes using a 100W lamp positioned at an 11 cm distance. Damaged DNA was
1240 then purified, and the host cell reactivation assay was performed as described for UV-
1241 induced DNA damage³³.

1242 **Cyclobutane pyrimidine dimer (CPD) ELISA**

1243 Human and bowhead whale skin fibroblasts were cultured until they reached confluency
1244 before UVC radiation. Cells were irradiated in PBS at doses of 0, 5, 10, 20, and 30 J/m²
1245 and immediately harvested to construct an induction curve. To assess DNA repair, cells

1246 were irradiated at 30 J/m² and then incubated for 6, 24, and 48 hours before harvesting.
1247 Genomic DNA was isolated using the QIAamp Blood Kit (Qiagen). DNA samples were
1248 diluted in PBS to a final concentration of 2 µg/ml, denatured at 100°C for 10 minutes,
1249 and then incubated in an ice bath for 15 minutes. Next, 100 ng of denatured DNA
1250 solution was applied to ELISA plate wells precoated with protamine sulfate (Cosmo Bio)
1251 and dried overnight at 37°C. Plates were washed five times with PBS supplemented
1252 with 0.05% Tween-20 (PBS-T) and then blocked in 2% FBS in PBS-T for 30 minutes at
1253 37°C. After five washes with PBS-T, plates were incubated with mouse monoclonal anti-
1254 CPD antibodies (Clone TDM-2, 1:1000) in PBS for 30 minutes at 37°C. Subsequently,
1255 plates were sequentially incubated with goat-anti-mouse biotin IgG (Invitrogen, 1:1000)
1256 and streptavidin-HRP (Invitrogen, 1:5000) in PBS for 30 minutes at 37°C each, with five
1257 washes with PBS-T before and after each incubation. Plates were then washed with
1258 citrate buffer and incubated with a substrate solution (citrate buffer/o-
1259 phenylenediamine/hydrogen peroxide) for 30 minutes at 37°C. Finally, the reaction was
1260 stopped with 2M H₂SO₄, and the absorbance was measured at 492 nm using a plate
1261 reader.

1262 **CIRBP variant sequence analysis**

1263 Identification of rare codons (<10% usage for the corresponding amino acid in human
1264 CDS sequences) was performed on CIRBP coding sequences using the Benchling
1265 Codon Optimization Tool¹²¹. Codon adaptation index (CAI) was calculated with human
1266 codon frequencies using the E-CAI web server⁵⁹.

1267 **RNA isolation and RNA-seq analysis**

1268 RNA from exponentially growing or senescent mouse, cow, human and bowhead whale
1269 primary skin fibroblasts was isolated using the RNeasy Plus Mini Kit (Qiagen) according
1270 to manufacturer instructions.

1271 Raw reads were demultiplexed using `configurebcl2fastq.pl` (v1.8.4). Adapter sequences
1272 and low-quality base calls (threshold: Phred quality score <20) in the RNA-seq reads
1273 were first trimmed using `Fastp` (0.23.4)¹²². For all species, the clean reads were aligned
1274 using `Salmon` (v1.5.1)¹²³ to longest coding sequence (CDS) of each gene extracted
1275 from corresponding genome assembly based on human-referenced TOGA annotations.

1276 The values of read count and effective gene lengths for each gene were collected and
1277 integrated into gene-sample table according to their orthologous relationship. `Salmon`
1278 transcript counts were used to perform differential expression analysis. Only human
1279 genes with orthologs in all species were kept for the downstream species. To filter out
1280 low expressed genes, only gene with all sample read counts sum >10 were retained.

1281 The filtered count matrix was normalized using median of ratios method¹²⁴ implemented
1282 in `DESeq2` package¹²⁵. The matrix of effective lengths for each gene in each sample
1283 was delivered to the `DESeq2` 'DESeqDataSet' object to avoid biased comparative
1284 quantifications resulting from species-specific transcript length variation. Differential
1285 expression analysis was performed using `DESeq2` and log transformed fold changes
1286 were used for gene set enrichment analysis to assess the differential expression of DNA
1287 repair pathways in bowhead whale, cow, and mouse compared to human. Genes of
1288 DNA repair pathways were compiled from 3 resources: `MsigDB` database, GO ontology,
1289 and a curated gene list ([www.mdanderson.org/documents/Labs/Wood-](http://www.mdanderson.org/documents/Labs/Wood-Laboratory/human-dna-repair-genes.html)
1290 [Laboratory/human-dna-repair-genes.html](http://www.mdanderson.org/documents/Labs/Wood-Laboratory/human-dna-repair-genes.html))^{126,127}.

1291 **Nanopore sequencing**

1292 72h after transfection, cells were harvested and genomic DNA was isolated with the
1293 Wizard Genomic DNA Purification Kit (Promega). DNA concentration was measured on
1294 a Nanodrop spectrophotometer and 100 ng of DNA per sample was PCR-amplified with
1295 Q5 High-Fidelity 2x Master Mix (NEB). PCR products were prepared for multiplexed
1296 Nanopore sequencing using the Native Barcoding Kit 96 V14 SQK-NBD114.96 (Oxford
1297 Nanopore Technologies). Following end prep, barcoding, and adapter ligation, samples
1298 were cleaned up using AMPure XP Beads and loaded onto a R10.4.1 flow cell on a
1299 MinION Mk1C (Oxford Nanopore Technologies) for sequencing. Raw data was
1300 basecalled in Super-High accuracy mode with barcode and adapter trimming enabled,
1301 demultiplexed, and aligned to the NHEJ reporter construct reference sequence FASTA
1302 in Dorado. A custom Python script was used to parse CIGAR strings from the resulting
1303 BAM files and quantify indels.

1304 **In vitro Cas9 pulldown**

1305 The conserved *PTEN* target amplicon used for assessing DSB repair fidelity was PCR-
1306 amplified from untreated control human fibroblasts as described in "Next-generation
1307 sequencing of CRISPR repair products." The *PTEN* target site was cloned into a
1308 plasmid using the TOPO TA Cloning Kit (Thermo Fisher Scientific). CRISPR RNP
1309 complexes with guide RNAs specific to the target were prepared as follows: 7.2 μ L of
1310 200 μ M Alt-R™ tracrRNA was combined with 7.2 μ L of 200 μ M Alt-R™ crRNA specific to
1311 the *PTEN* genomic target. The tracrRNA/crRNA mixture was heated to 95°C and then
1312 cooled to room temperature. To the guide duplex were added 25.2 μ L of PBS and 20.4
1313 μ L of either Alt-R™ S.p. Cas9 Nuclease V3 (Integrated DNA technologies) or Alt-R™

1314 S.p. dCas9 Nuclease V3 (Integrated DNA technologies). RNPs were incubated at room
1315 temperature for 20 minutes. Next, 10 μ L of Cas9 and dCas9 RNP were combined with
1316 75 μ g of *PTEN* TOPO plasmid and incubated at 37°C for 1 hour in EMEM (ATCC).
1317 Following incubation, 100 ng of soluble nuclear protein extract from either human or
1318 bowhead whale primary fibroblasts, which had been extracted using the NE-PER
1319 Nuclear and Cytoplasmic Extraction Kit (Thermo Fisher Scientific), was added to the
1320 RNP-plasmid complexes to produce cleavage reactions with Cas9 and control reactions
1321 with dCas9 for each species. Nuclear protein extracts were incubated with RNP-plasmid
1322 complexes at 37°C for 45 min. To pull down nuclear proteins associated with
1323 Cas9/dCas9-plasmid complexes (by the His-tag on Cas9/dCas9), 100 μ L Ni-NTA
1324 Agarose (Qiagen) was added to each reaction and incubated at 4°C with rotation for 30
1325 min. Ni-NTA Agarose was washed 3x with EMEM + pMaxGFP plasmid to remove
1326 proteins with non-specific plasmid binding, and washed 2x with EMEM + 40 mM
1327 imidazole + pMaxGFP. To aid elution of bound proteins, the *PTEN* plasmid bound by
1328 Cas9/dCas9 was digested by adding 1 μ L Benzonase for 5 min. Elution was completed
1329 by adding 1x SDS lysis buffer for S-trap with 250 mM imidazole and eluted proteins
1330 were analyzed by LC-MS as described in "LC-MS proteomic analysis of fibroblasts." To
1331 distinguish between non-quantifiable and non-detected proteins for figure displays,
1332 proteins detected but below the limit of quantification were imputed to an abundance of
1333 10^4 , and proteins not detected were imputed to an abundance of 0. For the figure
1334 display, the absolute abundance for each protein was normalized to a value of 1 for the
1335 maximum abundance detected for that protein in any of the Cas9 pulldowns.

1336 **Genomic DNA extraction and whole genome sequencing of tumor xenografts**

1337 Matching primary cell lines, transformed cell lines, and tumor xenograft samples were
1338 prepared as described above. Samples included 1 mouse cell line, 2 human cell lines,
1339 and 2 bowhead whale cell lines. 1 fresh cell pellet was prepared for each primary and
1340 transformed cell line. For frozen tumor samples, 1 tumor for mouse, 1 tumor for each
1341 human cell line (2 tumors total), 4 tumors for whale cell line 14B11SF, and 5 tumors for
1342 whale cell line 18B2SF were included in the analysis. Genomic DNA extraction and
1343 whole genome sequencing were performed as previously described with minor
1344 modifications^{49,128}. Briefly, DNA was extracted from samples using the QIamp DNA Mini
1345 Kit, per manufacturer's recommendations. Isolated genomic DNA was quantified with
1346 Qubit 2.0 DNA HS Assay (ThermoFisher, Massachusetts, USA) and quality assessed
1347 by agarose gel. Library preparation was performed using KAPA Hyper Prep kit (Roche,
1348 Basel, Switzerland) per manufacturer's recommendations. gDNA was sheared to
1349 approximately 400bp using Covaris LE220-plus, adapters were ligated, and DNA
1350 fragments were amplified with minimal PCR cycles. Library quantity and quality were
1351 assessed with Qubit 2.0 DNA HS Assay (ThermoFisher, Massachusetts, USA),
1352 TapeStation High Sensitivity D1000 Assay (Agilent Technologies, California, USA), and
1353 QuantStudio® 5 System (Applied Biosystems, California, USA). Illumina® 8-nt dual-
1354 indices were used. Equimolar pooling of libraries was performed based on QC values
1355 and sequenced on an Illumina® NovaSeq X Plus (Illumina, California, USA) with a read
1356 length configuration of 150 PE for 60M PE reads (30M in each direction) per sample.

1357 **Bioinformatic analysis of tumor xenograft whole genome sequencing**

1358 The bioinformatic processing pipeline of raw whole-genome (WGS) high throughput
1359 sequencing data was adapted for human, murine and bowhead whale data ⁴⁹.

1360 Sequencing FASTA files were applied to FastQC¹²⁹ for quality control, adapters were
1361 trimmed by Trimmomatic¹³⁰, and the genomic fragments were aligned to the human,
1362 mouse, and whale genome reference (hg19, mm10 and the published bowhead whale
1363 genome assembly¹⁷) using Burrows-Wheeler Aligner (BWA)¹³¹, then sorted and indexed
1364 by Samtools¹³². Somatic mutations were detected from tumor samples using MuTect
1365 v2¹³³ to call somatic single-nucleotide variants (SNVs) and small indels (<10bp). Tumor
1366 samples from WGS were compared to their respective matched healthy tissue. All
1367 mutations were also filtered for depth (tumor sample coverage > 30x, normal sample
1368 coverage > 30x) and variant allele frequency (VAF \geq 0.1). Structural variations were
1369 called by Manta applying default settings and structural variant length > 6000bp were
1370 used for downstream analysis¹³⁴.

1371 **Alkaline Comet Assay**

1372 For the alkaline comet assay, we adapted the Alkaline CometAssay protocol provided
1373 by TREVIGEN based on a published in-gel comet assay method¹³⁵ to increase the
1374 number of cell lines and time points assessed and minimize assay variation introduced
1375 during sample harvesting and processing. Slides were pre-coated with a base layer 50 μ l
1376 of 1% SeaKem LE Agarose (Lonza) to enhance adhesion. We cultured cells to near
1377 100% confluency and then resuspended them in CometAssay LMAgarose (R&D
1378 Systems). We applied 500 cells suspended in 100 μ L LMAgarose onto each slide. The
1379 slides were then placed in the dark at 4°C for 10 minutes to allow the agarose to solidify.
1380 After that, slides with live cells were incubated in tissue culture incubators in fibroblast
1381 culture medium containing 700 μ M freshly diluted H₂O₂ for 30 minutes, followed by
1382 washing with PBS and incubation for various recovery periods (ranging from 0 minutes

1383 to 12 hours) in culture medium. Slides were collected at each time point, washed with
1384 PBS, and immersed in CometAssay Lysis Solution (R&D Systems). Before
1385 electrophoresis, slides were placed in alkaline unwinding solution prepared according to
1386 TREVIGEN's protocol for 10 minutes. After electrophoresis at 22V for 30 minutes, the
1387 slides were placed in a DNA precipitation buffer following the TREVIGEN protocol for 10
1388 minutes and subsequently washed three times with distilled water. The slides were then
1389 immersed in 70% ethanol for 10 minutes and allowed to air dry in the dark. Before
1390 imaging, each sample was stained with 50 μ l of 1x SYBR Gold (Thermo Fisher
1391 Scientific) for 5 minutes before being washed three times with distilled water. Comet
1392 images were acquired through fluorescent microscopy. For scoring, we used profile
1393 analysis in OpenComet¹³⁶ within ImageJ. Outliers automatically flagged by OpenComet
1394 were excluded from analysis and remaining incorrectly demarcated comets were further
1395 systematically filtered out according to two criteria: a comet area greater than 5000 or
1396 head area greater than 500.

1397 **Tissue processing**

1398 Tissues obtained from wild-caught animals were assumed to be of younger/middle age
1399 since predation normally precedes aging in the wild. Postmortem interval was
1400 minimized, and, in all cases, samples were kept on ice and frozen in less than 24h. At
1401 the earliest opportunity after dissection, tissues from representative animals from each
1402 species were flash frozen in liquid nitrogen and stored at -80°C. Tissues were
1403 pulverized to a fine powder within a Biosafety cabinet under liquid nitrogen using a
1404 stainless-steel pulverizer Cell Crusher (Fisher Scientific) chilled in liquid nitrogen and
1405 delivered to storage tubes with a scoop that had also been pre-chilled in liquid nitrogen

1406 and kept on dry ice. Similarly, when sampled for various “omics” processing, pulverized
1407 tissues were removed with a stainless-steel spatula that was pre-chilled in liquid
1408 nitrogen. Samples were never thawed after initial freezing until extractions were
1409 performed.

1410 **Cross-species tissue proteomics**

1411 We employed a “shotgun” style untargeted data-dependent acquisition (DDA) label-free
1412 quantitative (LFQ) approach. Approximately 5 mg of tissue was mixed with 250µl of
1413 50mM TEAB pH7.6; 5% SDS, mixed by pipetting, and briefly vortexed. Samples were
1414 sonicated in a chilled cup-horn Q800R3 Sonicator System (Qsonica; Newtown, CT) for
1415 a total of 15min at 30% output and duration of 30 x 30 sec pulses (with 30 sec in
1416 between pulses) at 6°C using a chilled circulating water bath. When nuclear proteomes
1417 were analyzed, nuclei were first isolated using a hypotonic lysis approach as in the
1418 preparation of histones¹³⁷. Isolated nuclei were lysed and processed as indicated above
1419 with SDS and sonication and then handled similarly for the rest of the prep. Samples
1420 were heated to 90°C for 2min and allowed to cool to room temperature (RT). Next,
1421 samples were centrifuged at 14,000xg for 10min to pellet insoluble debris and the
1422 supernatants were transferred to clean tubes. Total protein was quantified by the BCA
1423 assay and 100µg was reduced with 5 mM dithiothreitol (DTT) for 30min at 60°C.
1424 Samples were cooled to RT and then alkylated with 10mM iodoacetamide (from a
1425 freshly prepared stock) for 30 min at RT in the dark. Samples were processed using the
1426 standard S-trap mini column method (Protifi; Farmingdale, NY). Samples were digested
1427 with 4µg trypsin overnight at 37°C. Elution fractions were pooled and dried using a
1428 Speedvac (Labconco). Peptides were resuspended in 100µl MS-grade water

1429 (resistance $\geq 18\text{M}\Omega$) and quantified using the Pierce Quantitative Fluorometric Peptide
1430 Assay (Thermo). Common internal Retention Time standards (CiRT) peptide mix was
1431 added (50 fmol mix/2 μg tryptic peptides) and 2 μg (in 4 μL) of tryptic peptides were
1432 injected/analyzed by mass spectrometry (MS) on a Orbitrap Tribrid Fusion Lumos
1433 instrument (Thermo) equipped with an EASY-Spray HPLC Column (500mm x 75 μm
1434 2 μm 100A P/N ES803A, Nano-Trap Pep Map C18 100A; Thermo). Buffer A was 0.1%
1435 formic acid and buffer B was 100% acetonitrile (ACN) with 0.1% FA. Flow rate was
1436 300nl/min and runs were 150 min: 0-120 min, 5% B to 35% B; then from 120-120.5 min,
1437 35-80% B; followed by a 9-minute 80% B wash until 130min. From 130-130.5min B was
1438 decreased to 5% and the column was re-equilibrated for the remaining 20-min at 5% B.
1439 the instrument was run in data dependent analysis (DDA) mode. MS2 fragmentation
1440 was with HCD (30% energy fixed) and dynamic exclusion was operative after a single
1441 time and lasted for 30sec. Additional instrument parameters may be found in the
1442 Thermo RAW files.

1443 **Computational proteomics analysis**

1444 Raw files were analyzed directly with the MSFragger/Philosopher pipeline^{138,139} and
1445 included Peptide and Protein Prophet modules¹⁴⁰ for additional quality control.
1446 Quantitation at the level of MS1 was performed with the “LFQ-MBR; label-free quant
1447 match-between-runs” workflow using default parameters. This allows for alignment of
1448 chromatographic peaks between separate runs. Methionine oxidation and N-terminal
1449 acetylation were set as variable modifications. MaxLFQ with a minimum of two ions was
1450 implemented and normalization of intensity across runs was selected¹⁴¹.

1451 **LC-MS proteomic analysis of fibroblasts**

1452 2 15-cm dishes of growing primary fibroblasts from 2 cell lines for each species were
1453 harvested for protein. Cells were washed with PBS and pellets were snap frozen and
1454 stored in liquid nitrogen until processing. Cells were solubilized with 5% SDS; 50 mM
1455 TEAB pH 7 and sonicated at 8°C with 10x 45s pulses using 30% power with 15 s rest
1456 between each pulse with a cup horn Q800R3 Sonicator System (Qsonica; Newtown
1457 CT). Soluble proteins were reduced with 10 mM DTT for 30 min at 55°C, followed by
1458 alkylation with 15 mM iodoacetamide at 25°C in the dark for 30 min. S-trap micro
1459 columns (Protifi; Farmingdale, NY) were employed after this step for overnight tryptic
1460 digestion and peptide isolation according to manufacturer instructions. All solvents were
1461 MS-grade. Resulting tryptic peptides were resuspended in MS-grade water and were
1462 quantified using a Pierce™ Quantitative Fluorometric Peptide Assay (Thermo Fisher cat
1463 #23290). Prior to MS, peptides were mixed with a common internal retention time
1464 standards115 (CiRT) peptide mix (50 fmol CiRT/2µg total tryptic peptides) and
1465 acetonitrile (ACN) and formic acid were added to concentrations of 5% and 0.2%
1466 respectively. The final concentration of the peptide mix was 0.5µg/µl. 2 µg (4µl) of each
1467 were resolved by nano-electrospray ionization on an Orbitrap Fusion Lumos MS
1468 instrument (Thermo) in positive ion mode. A 30 cm home-made column packed with 1.8
1469 µm C-18 beads was employed to resolve the peptides. Solvent A was 0.1% formic acid
1470 and solvent B was 80% acetonitrile with 0.1% formic acid and flow rate was 300 nl/min.
1471 The length of the run was 3 h with a 155 min gradient from 10-38% B. HCD (30%
1472 collision energy) was used for MS2 fragmentation and dynamic exclusion was operative
1473 after a single time and lasted for 30s. Other details of the run parameters may be found

1474 in the embedded run report of the RAW data file uploaded to the ProteomeXchange
1475 database. Peptide assignments and quantitation were done using the label-free quant
1476 match between runs (LFQ-MBR) workflow of MSFragger^{138–140}. MaxLFQ with a
1477 minimum of two ions was implemented and normalization was selected. Additional
1478 details are available in MSFragger log files. Searches were performed within the
1479 Philosopher/Fragpipe pipeline that incorporates PeptideProphet and ProteinProphet
1480 filtering steps to increase the likelihood of correct assignments¹⁴⁰. The databases used
1481 for searches were predicted proteins from the published bowhead genome¹⁷ as well as
1482 our custom proteome derived from our de novo sequenced and Trinity^{89,142}-assembled
1483 pool of transcriptomes from whale tissues. Human (UP000005640), mouse
1484 (UP000000589), and bovine (UP000009136) databases were from the latest build
1485 available from Uniprot¹⁴³. For the searches, databases also included a reverse
1486 complement form of all peptides as well as common contaminants to serve as decoys
1487 for false discovery rate (FDR) calculation by the target/decoy approach (decoy present
1488 at 50%). Final FDR was below 1%. To distinguish between non-quantifiable and non-
1489 detected proteins in figure displays, proteins detected but below the limit of
1490 quantification were imputed to an abundance of 10^4 , and proteins not detected were
1491 imputed to an abundance of 0.

1492 **LC-MS identification of proteins upregulated after DNA damage**

1493 3 primary fibroblast lines each for human and bowhead whale were prepared under 3
1494 conditions: untreated control, H₂O₂-treated, and UV treated. For H₂O₂ treatment, culture
1495 medium was replaced with medium containing 400 μ M H₂O₂ that had been diluted into
1496 the medium immediately prior to use. For UV treatment, culture medium was aspirated

1497 and replaced with a thin layer of PBS. Cells were exposed to 6 J/m² UVC in a UV
1498 Crosslinker (Fisher Scientific) with the culture dish lid removed. 4h after treatments,
1499 cells were harvested by washing with PBS and lysed directly in-dish by addition of 2x
1500 SDS lysis buffer for S-trap. Cells were subsequently processed for LC-MS as described
1501 in "LC-MS proteomic analysis of fibroblasts." Data were acquired on an Orbitrap Astral
1502 Mass Spectrometer (Thermo) equipped with an EASY-Spray HPLC Column (500mm x
1503 75µm 2µm 100A P/N ES803A, Nano-Trap Pep Map C18 100A; Thermo). Samples were
1504 run in DIA mode. Computational- Raw data files were converted to mzML files using
1505 ProteoWizard with peak picking set to 1-n, and demultiplexing selected^{144,145}. The mzML
1506 files were searched using DIANN¹⁴⁶ with along with FASTA file databases described
1507 above for tissue extracts using library-free search/library generation with deep learning-
1508 based spectra retention time (RT) and IMs prediction criteria selected. Mass accuracy
1509 was set to 20 and MS1 accuracy set to 5.0, and oxidized methionine (Ox(M)) was also
1510 selected. Nearest human homologs for each species' protein (determined by BLAST as
1511 previously described⁸⁹) were added to the protein group matrix (DIANN output). As
1512 before, the human annotation was used to facilitate cross-species comparisons. Missing
1513 values for protein groups were imputed using deterministic minimum imputation^{147,148}.

1514 **Stimulated emission depletion (STED) microscopy**

1515 Immortalized primary fibroblast cultures were plated on 10mm diameter glass coverslips
1516 embedded in 35mm plates (Mattek, P35G-1.5-10-C) at a concentration of 10,000 cells
1517 per plate. 48 hours after plating, plates were washed once with 1x PBS and fixed in
1518 3.7% formaldehyde for 15min on a shaking platform. Plates were washed 3x 10min in
1519 PBS and permeabilized in 0.5% Triton X-100 for 15 minutes on a shaking platform.

1520 Plates were washed again 3x 10min in PBS before blocking for 1h at RT with 5% BSA
1521 in PBS. After blocking, primary antibody was added at a concentration of 1:50 diluted in
1522 100 μ L blocking buffer and incubated overnight at 4°C. Plates were washed in wash
1523 buffer (0.1% Triton X-100 in PBS) 4x 10min before adding Alexa Fluor 594-labelled
1524 secondary antibody (Abcam, ab150080) at a concentration of 1:50 diluted in 100 μ L
1525 blocking buffer and incubating for 1h at RT. Plates were washed 4x 10min with wash
1526 buffer and incubated with 100 μ L of 1 μ g/mL DAPI in PBS for 5min. Plates were washed
1527 once with PBS for 5min before adding mountant (Invitrogen, P10144) and placing a
1528 cover slip. Gated Stimulated Emission Depletion microscopy was performed in the
1529 URM Center for Advanced Light Microscopy and Nanoscopy (RRID:SCR_023177) on
1530 an Abberior) Göttingen, Germany) 3D STED instrument (S10 OD023440) equipped with
1531 an Olympus UPlanSApo 100x/1.4NA objective. Images were acquired with a pixel size
1532 of 20nm and 775nm depletion laser at 30% power with 15% directed toward 3D
1533 resolution. Single-channel images were pseudocolored red (Alexa-Fluor 594) and blue
1534 (DAPI), merged, and scale bars added using ImageJ software.

1535 **Doxycycline-inducible I-SceI NHEJ reporter**

1536 The plasmid was assembled from several parts. The backbone was amplified from a
1537 pN1 plasmid without f1 bacteriophage origin of replication and modified by the addition
1538 of short insulator sequences¹⁴⁹ (E2, A2 and A4) purchased from Integrated DNA
1539 Technologies (IDT). The GFP reporter gene with I-SceI endonuclease sites was
1540 amplified from the reporter described above and fused via the P2A self-cleaving peptide
1541 with TetOn transactivator, amplified from Lenti-X™ Tet-One™ Inducible Expression
1542 System Puro (Takara, 631847). A bi-directional promoter sequence featuring hPGK and

1543 TRE3GS was amplified from the same plasmid and cloned upstream of the GFP
1544 reporter, in the orientation for TetOn-P2A-reporter to be driven by the constitutive hPGK
1545 promoter. Downstream of the Tre3GS promoter was closed codon-optimized sequence
1546 for intron-encoded endonuclease I (I-SceI) with SV40 nuclear localization sequence
1547 (NLS) at the N-terminus and nucleoplasmin NLS at the C-terminus fused to the
1548 enhanced blue fluorescent protein (eBFP2) via P2A. The fusion was purchased from
1549 IDT. EBFP2 sequence was derived from eBFP2-N2 plasmid (Addgene #54595).
1550 Cloning was done with In-fusion Snap assembly kit (Takara 638947), NEBuilder HiFi
1551 DNA Assembly (NEB, E5520) and T4 DNA ligase (NEB, M0202). The efficiency of non-
1552 homologous end-joining (NHEJ) double-strand break (DSB) repair was analyzed in
1553 immortalized normal human dermal fibroblasts (NHDF2T). The expression cassette
1554 containing a GFP reporter gene under hPGK promoter and an I-SceI endonuclease
1555 under doxycycline-inducible Tre3GS promoter was inserted into the genome by random
1556 integration method. The positive clones were selected by G418 for 10 days and the
1557 clones were pooled together. The GFP reporter had a short adeno-exon flanked by two
1558 I-SceI recognition sites (in inverted orientation) surrounded by the rat Pem1 intron.
1559 Upon stimulation with doxycycline (100 ng/ml), I-SceI produced two non-ligatable
1560 double strand breaks, resulting in excision of the adeno-exon and reconstitution of the
1561 functional GFP.

1562 **EMSA**

1563 Recombinant human CIRP protein (Abcam AB106903) was incubated in the indicated
1564 amounts with the indicated nucleic acid substrates in 20 μ L EMEM (ATCC) at 37°C for 1
1565 hour. Subsequently, reactions were mixed with 4 μ L sucrose loading dye (2M sucrose +

1566 0.2% Orange G) and loaded into agarose gels immersed in 0.5x TAE buffer followed by
1567 electrophoresis at 30V. Following electrophoresis, gels were stained in 1x SYBR Gold
1568 (Thermo Fisher Scientific) and imaged. Extraction of genomic DNA from human primary
1569 fibroblasts was with the Monarch HMW DNA Extraction Kit for Cells & Blood (NEB
1570 #T3050L). To produce the damaged DNA samples and induce PAR formation, cells
1571 were treated with H₂O₂ and UV prior to genomic DNA extraction. For H₂O₂ treatment,
1572 culture medium was replaced with medium containing 400 μM H₂O₂ that had been
1573 diluted into the medium immediately prior to use. For UV treatment, culture medium was
1574 aspirated and replaced with a thin layer of PBS. Cells were exposed to 6 J/m² UVC in a
1575 UV Crosslinker (Fisher Scientific) with the culture dish lid removed. During genomic
1576 DNA extraction from damaged chromatin, Proteinase K was added per manufacturer
1577 instructions, but RNase A was omitted and Protector Rnase inhibitor (Sigma-Aldrich)
1578 was added to the extraction buffers and eluate. Nucleic acids used in reactions were
1579 sonicated to uniform size in a QSONICA Sonicator.

1580 **Statistical analyses**

1581 Statistical comparisons were performed as indicated in the figure legends. Unless
1582 otherwise specified in the text or legend, *n* refers to separate biological replicate cell
1583 lines, isolated from different individuals for a given species. Exceptions include specific
1584 genetically modified cell lines or clones, e.g. tumor suppressor knockout lines and Ku-
1585 deficient MEFs. In such cases, *n* refers to technical replicates and indicates the number
1586 of times the experiment was repeated with the specified cell line. Details for
1587 comparisons done by ANOVA are included in Supplementary Information.

1588 **Data Availability**

1589 Proteomics data are accessible through ProteomeXchange [URL to be added]. DNA
1590 and RNA sequencing data are accessible through NCBI Sequence Read Archive (SRA)
1591 [URL to be added].

1592 References

- 1593 1. Tacutu, R. *et al.* Human Ageing Genomic Resources: new and updated databases. *Nucleic Acids*
1594 *Res* **46**, D1083–D1090 (2018).
- 1595 2. Peto, R. Epidemiology, multistage models, and short-term mutagenicity tests. in *The origins of*
1596 *human cancer* (eds. Hiatt, H., Watson, J. & Winsten, J.) vol. 4 1403–1428 (Cold Spring Harbor
1597 Conferences on Cell Proliferation, NY, 1977).
- 1598 3. Abegglen, L. M. *et al.* Potential Mechanisms for Cancer Resistance in Elephants and Comparative
1599 Cellular Response to DNA Damage in Humans. *JAMA* **314**, 1850 (2015).
- 1600 4. Vazquez, J. M., Sulak, M., Chigurupati, S. & Lynch, V. J. A Zombie LIF Gene in Elephants Is
1601 Upregulated by TP53 to Induce Apoptosis in Response to DNA Damage. *Cell Rep* **24**, 1765–1776
1602 (2018).
- 1603 5. Sulak, M. *et al.* TP53 copy number expansion is associated with the evolution of increased body
1604 size and an enhanced DNA damage response in elephants. *Elife* **5**, (2016).
- 1605 6. TEK & Bowhead Life History and Longevity - The North Slope Borough. [https://www.north-](https://www.north-slope.org/departments/wildlife-management/studies-research-projects/bowhead-whales/traditional-ecological-knowledge-of-bowhead-whales/tek-bowhead-life-history-and-longevity/)
1606 [slope.org/departments/wildlife-management/studies-research-projects/bowhead-](https://www.north-slope.org/departments/wildlife-management/studies-research-projects/bowhead-whales/traditional-ecological-knowledge-of-bowhead-whales/tek-bowhead-life-history-and-longevity/)
1607 [whales/traditional-ecological-knowledge-of-bowhead-whales/tek-bowhead-life-history-and-](https://www.north-slope.org/departments/wildlife-management/studies-research-projects/bowhead-whales/traditional-ecological-knowledge-of-bowhead-whales/tek-bowhead-life-history-and-longevity/)
1608 [longevity/](https://www.north-slope.org/departments/wildlife-management/studies-research-projects/bowhead-whales/traditional-ecological-knowledge-of-bowhead-whales/tek-bowhead-life-history-and-longevity/).
- 1609 7. George, J. C. & Bockstoce, J. R. Two historical weapon fragments as an aid to estimating the
1610 longevity and movements of bowhead whales. *Polar Biol* **31**, 751–754 (2008).
- 1611 8. Rosa, C. *et al.* Age estimates based on aspartic acid racemization for bowhead whales (*Balaena*
1612 *mysticetus*) harvested in 1998–2000 and the relationship between racemization rate and body
1613 temperature. *Mar Mamm Sci* **29**, 424–445 (2013).
- 1614 9. Philo, L. M., Shotts, E. B. & George, J. C. Morbidity and mortality- The bowhead whale. *Soc. Mar.*
1615 *Mammal., Spec. Publ* 275–312 (1993).
- 1616 10. George, J. C. *et al.* Age and growth estimates of bowhead whales (*Balaena mysticetus*) via
1617 aspartic acid racemization. *Can J Zool* **77**, 571–580 (1999).
- 1618 11. Wetzel, D. *et al.* Age estimation for bowhead whales, *Balaena mysticetus*, using aspartic acid
1619 racemization with enhanced hydrolysis and derivatization procedures. *Paper SC/65b/BRG05*
1620 *presented to the Scientific Committee of the International Whaling Commission* (2014).
- 1621 12. George, J. C. *et al.* A new way to estimate the age of bowhead whales (*Balaena mysticetus*) using
1622 ovarian corpora counts. <https://doi.org/10.1139/z11-057> **89**, 840–852 (2011).
- 1623 13. Vincze, O. *et al.* Cancer risk across mammals. *Nature* **601**, 263–267 (2022).
- 1624 14. Boddy, A. M. *et al.* Lifetime cancer prevalence and life history traits in mammals. *Evol Med Public*
1625 *Health* **2020**, 187–195 (2020).
- 1626 15. Vincze, O. *et al.* Cancer risk across mammals. *Nature* **601**, 263–267 (2022).

- 1627 16. Tollis, M., Boddy, A. M. & Maley, C. C. Peto's Paradox: how has evolution solved the problem of
1628 cancer prevention? *BMC Biol* **15**, (2017).
- 1629 17. Keane, M. *et al.* Insights into the evolution of longevity from the bowhead whale genome. *Cell*
1630 *Rep* **10**, 112–122 (2015).
- 1631 18. Tollis, M. *et al.* Return to the Sea, Get Huge, Beat Cancer: An Analysis of Cetacean Genomes
1632 Including an Assembly for the Humpback Whale (*Megaptera novaeangliae*). *Mol Biol Evol* **36**,
1633 1746–1763 (2019).
- 1634 19. Seim, I. *et al.* The transcriptome of the bowhead whale *Balaena mysticetus* reveals adaptations of
1635 the longest-lived mammal. *Aging* **6**, 879–899 (2014).
- 1636 20. Armitage, P. & Doll, R. The age distribution of cancer and a multi-stage theory of carcinogenesis.
1637 *Br J Cancer* **8**, 1–12 (1954).
- 1638 21. Rangarajan, A., Hong, S. J., Gifford, A. & Weinberg, R. A. Species- and cell type-specific
1639 requirements for cellular transformation. *Cancer Cell* **6**, 171–183 (2004).
- 1640 22. Vazquez, J. M., Sulak, M., Chigurupati, S. & Lynch, V. J. A Zombie LIF Gene in Elephants Is
1641 Upregulated by TP53 to Induce Apoptosis in Response to DNA Damage. *Cell Rep* **24**, 1765–1776
1642 (2018).
- 1643 23. Vazquez, J. M. & Lynch, V. J. Pervasive duplication of tumor suppressors in Afrotherians during
1644 the evolution of large bodies and reduced cancer risk. *Elife* **10**, 1–45 (2021).
- 1645 24. Vazquez, J. M. *et al.* Parallel evolution of reduced cancer risk and tumor suppressor duplications
1646 in Xenarthra. *Elife* **11**, (2022).
- 1647 25. Preston, A. J. *et al.* Elephant TP53-RETROGENE 9 induces transcription-independent apoptosis at
1648 the mitochondria. *Cell Death Discov* **9**, 66 (2023).
- 1649 26. García-Cao, I. *et al.* 'Super p53' mice exhibit enhanced DNA damage response, are tumor
1650 resistant and age normally. *EMBO J* **21**, 6225–6235 (2002).
- 1651 27. Tyner, S. D. *et al.* p53 mutant mice that display early ageing-associated phenotypes. *Nature* **415**,
1652 45–53 (2002).
- 1653 28. Boveri, T. Concerning the origin of malignant tumours by Theodor Boveri. Translated and
1654 annotated by Henry Harris. *J Cell Sci* **121**, 1–84 (2008).
- 1655 29. Hastly, P., Campisi, J., Hoeijmakers, J., Van Steeg, H. & Vijg, J. *Aging and Genome Maintenance:*
1656 *Lessons from the Mouse?* <http://science.sciencemag.org/>.
- 1657 30. Kashiyama, K. *et al.* Malfunction of nuclease ERCC1-XPF results in diverse clinical manifestations
1658 and causes Cockayne syndrome, xeroderma pigmentosum, and Fanconi anemia. *Am J Hum Genet*
1659 **92**, 807–819 (2013).
- 1660 31. Navarro, C. L., Cau, P. & Lévy, N. Molecular bases of progeroid syndromes. *Human Molecular*
1661 *Genetics* vol. 15 R151–R161 Preprint at <https://doi.org/10.1093/hmg/ddl214> (2006).

- 1662 32. Varon, R. *et al.* Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen
1663 breakage syndrome. *Cell* **93**, 467–476 (1998).
- 1664 33. Liu, B. *et al.* Genomic instability in laminopathy-based premature aging. *Nat Med* **11**, 780–785
1665 (2005).
- 1666 34. Lorenzini, A. *et al.* Significant Correlation of Species Longevity with DNA Double Strand Break-
1667 Recognition but not with Telomere Length. *Mech Ageing Dev* **130**, 784 (2009).
- 1668 35. Zhang, L. *et al.* Maintenance of genome sequence integrity in long- And short-lived rodent
1669 species. *Sci Adv* **7**, (2021).
- 1670 36. Cagan, A. *et al.* Somatic mutation rates scale with lifespan across mammals. *Nature* 2022 1–8
1671 (2022) doi:10.1038/s41586-022-04618-z.
- 1672 37. Tian, X. *et al.* SIRT6 Is Responsible for More Efficient DNA Double-Strand Break Repair in Long-
1673 Lived Species. *Cell* **177**, 622-638.e22 (2019).
- 1674 38. Fortunato, A., Fleming, A., Aktipis, A. & Maley, C. C. Upregulation of DNA repair genes and cell
1675 extrusion underpin the remarkable radiation resistance of *Trichoplax adhaerens*. *PLoS Biol* **19**,
1676 (2021).
- 1677 39. Tian, X. *et al.* Evolution of telomere maintenance and tumour suppressor mechanisms across
1678 mammals. *Philosophical Transactions of the Royal Society B: Biological Sciences* **373**, (2018).
- 1679 40. Borowicz, S. *et al.* The soft agar colony formation assay. *J Vis Exp* e51998 (2014)
1680 doi:10.3791/51998.
- 1681 41. Zhou, B. *et al.* Preparation of heteroduplex enhanced green fluorescent protein plasmid for in
1682 vivo mismatch repair activity assay. *Anal Biochem* **388**, 167–169 (2009).
- 1683 42. Kucab, J. E. *et al.* A Compendium of Mutational Signatures of Environmental Agents. *Cell* **177**, 821
1684 (2019).
- 1685 43. Cagan, A. *et al.* Somatic mutation rates scale with lifespan across mammals. *Nature* 2022 1–8
1686 (2022) doi:10.1038/s41586-022-04618-z.
- 1687 44. Zhang, L. *et al.* Maintenance of genome sequence integrity in long- And short-lived rodent
1688 species. *Sci Adv* **7**, (2021).
- 1689 45. Johnson, G. E. Mammalian Cell HPRT Gene Mutation Assay: Test Methods. in 55–67 (2012).
1690 doi:10.1007/978-1-61779-421-6_4.
- 1691 46. Seluanov, A., Mao, Z. & Gorbunova, V. Analysis of DNA Double-strand Break (DSB) Repair in
1692 Mammalian Cells. *J Vis Exp* 43 (2010) doi:10.3791/2002.
- 1693 47. Guo, T. *et al.* Harnessing accurate non-homologous end joining for efficient precise deletion in
1694 CRISPR/Cas9-mediated genome editing. *Genome Biol* **19**, (2018).

- 1695 48. Richardson, C. D., Ray, G. J., Bray, N. L. & Corn, J. E. Non-homologous DNA increases gene
1696 disruption efficiency by altering DNA repair outcomes. *Nature Communications* 2016 7:1 7, 1–7
1697 (2016).
- 1698 49. Perelli, L. *et al.* Interferon signaling promotes tolerance to chromosomal instability during
1699 metastatic evolution in renal cancer. *Nat Cancer* 4, 984–1000 (2023).
- 1700 50. Chen, J. K., Lin, W. L., Chen, Z. & Liu, H. wen. PARP-1–dependent recruitment of cold-inducible
1701 RNA-binding protein promotes double-strand break repair and genome stability. *Proc Natl Acad*
1702 *Sci U S A* 115, E1759–E1768 (2018).
- 1703 51. Sartori, A. A. *et al.* Human CtIP promotes DNA end resection. *Nature* 450, 509–514 (2007).
- 1704 52. Nishiyama, H. *et al.* A glycine-rich RNA-binding protein mediating cold-inducible suppression of
1705 mammalian cell growth. *J Cell Biol* 137, 899–908 (1997).
- 1706 53. Sheikh, M. S. *et al.* Identification of several human homologs of hamster DNA damage-inducible
1707 transcripts. Cloning and characterization of a novel UV-inducible cDNA that codes for a putative
1708 RNA-binding protein. *J Biol Chem* 272, 26720–26726 (1997).
- 1709 54. Wellmann, S. *et al.* Oxygen-regulated expression of the RNA-binding proteins RBM3 and CIRP by
1710 a HIF-1-independent mechanism. *J Cell Sci* 117, 1785–1794 (2004).
- 1711 55. Yang, C. & Carrier, F. The UV-inducible RNA-binding protein A18 (A18 hnRNP) plays a protective
1712 role in the genotoxic stress response. *J Biol Chem* 276, 47277–47284 (2001).
- 1713 56. Yang, R., Weber, D. J. & Carrier, F. Post-transcriptional regulation of thioredoxin by the stress
1714 inducible heterogenous ribonucleoprotein A18. *Nucleic Acids Res* 34, 1224–1236 (2006).
- 1715 57. Yang, R. *et al.* Functional significance for a heterogenous ribonucleoprotein A18 signature RNA
1716 motif in the 3′-untranslated region of ataxia telangiectasia mutated and Rad3-related (ATR)
1717 transcript. *J Biol Chem* 285, 8887–8893 (2010).
- 1718 58. Roilo, M., Kullmann, M. K. & Hengst, L. Cold-inducible RNA-binding protein (CIRP) induces
1719 translation of the cell-cycle inhibitor p27Kip1. *Nucleic Acids Res* 46, 3198–3210 (2018).
- 1720 59. Puigbò, P., Bravo, I. G. & Garcia-Vallvé, S. E-CAI: a novel server to estimate an expected value of
1721 Codon Adaptation Index (eCAI). *BMC Bioinformatics* 9, (2008).
- 1722 60. Spruijt, C. G. *et al.* Dynamic readers for 5-(hydroxy)methylcytosine and its oxidized derivatives.
1723 *Cell* 152, 1146–1159 (2013).
- 1724 61. Huang, Z. L. *et al.* Identification of G-Quadruplex-Binding Protein from the Exploration of RGG
1725 Motif/G-Quadruplex Interactions. *J Am Chem Soc* 140, 17945–17955 (2018).
- 1726 62. Seif-El-Dahan, M. *et al.* PAXX binding to the NHEJ machinery explains functional redundancy with
1727 XLF. *Sci Adv* 9, (2023).
- 1728 63. Ahnesorg, P., Smith, P. & Jackson, S. P. XLF Interacts with the XRCC4-DNA Ligase IV Complex to
1729 Promote DNA Nonhomologous End-Joining. *Cell* 124, 301–313 (2006).

- 1730 64. Zou, Y., Liu, Y., Wu, X. & Shell, S. M. Functions of Human Replication Protein A (RPA): From DNA
1731 Replication to DNA Damage and Stress Responses. *J Cell Physiol* **208**, 267 (2006).
- 1732 65. Wold, M. S. Replication protein A: a heterotrimeric, single-stranded DNA-binding protein
1733 required for eukaryotic DNA metabolism. *Annu Rev Biochem* **66**, 61–92 (1997).
- 1734 66. Paulsen, R. D. *et al.* A genome-wide siRNA screen reveals diverse cellular processes and pathways
1735 that mediate genome stability. *Mol Cell* **35**, 228–239 (2009).
- 1736 67. Toledo, L. I. *et al.* ATR prohibits replication catastrophe by preventing global exhaustion of RPA.
1737 *Cell* **155**, 1088 (2013).
- 1738 68. Velegzhaninov, I. O. *et al.* Radioresistance, DNA Damage and DNA Repair in Cells With Moderate
1739 Overexpression of RPA1. *Front Genet* **11**, 855 (2020).
- 1740 69. Guven, M., Brem, R., Macpherson, P., Peacock, M. & Karran, P. Oxidative damage to RPA limits
1741 the nucleotide excision repair capacity of human cells. *J Invest Dermatol* **135**, 2834 (2015).
- 1742 70. Graziano, S. *et al.* Lamin A/C recruits ssDNA protective proteins RPA and RAD51 to stalled
1743 replication forks to maintain fork stability. *Journal of Biological Chemistry* **297**, 101301 (2021).
- 1744 71. Perrault, R., Cheong, N., Wang, H., Wang, H. & Iliakis, G. RPA facilitates rejoining of DNA double-
1745 strand breaks in an in vitro assay utilizing genomic DNA as substrate. *int. j. radiat. biol* **77**, 593–
1746 607 (2001).
- 1747 72. Krasner, D. S., Daley, J. M., Sung, P. & Niu, H. Interplay between Ku and Replication Protein A in
1748 the Restriction of Exo1-mediated DNA Break End Resection. *J Biol Chem* **290**, 18806–18816
1749 (2015).
- 1750 73. Chen, H., Lisby, M. & Symington, L. S. RPA coordinates DNA end resection and prevents
1751 formation of DNA hairpins. *Mol Cell* **50**, 589–600 (2013).
- 1752 74. Shuck, S. C. & Turchi, J. J. Targeted inhibition of RPA reveals cytotoxic activity, synergy with
1753 chemotherapeutic DNA damaging agents and insight into cellular function. *Cancer Res* **70**, 3189
1754 (2010).
- 1755 75. Reber, S. *et al.* The phase separation-dependent FUS interactome reveals nuclear and
1756 cytoplasmic function of liquid-liquid phase separation. *Nucleic Acids Res* **49**, 7713–7731 (2021).
- 1757 76. Pessina, F. *et al.* Functional transcription promoters at DNA double-strand breaks mediate RNA-
1758 driven phase separation of damage-response factors. *Nat Cell Biol* **21**, 1286–1299 (2019).
- 1759 77. Lenard, A. J. *et al.* Phosphorylation Regulates CIRBP Arginine Methylation, Transportin-1 Binding
1760 and Liquid-Liquid Phase Separation. *Front Mol Biosci* **8**, (2021).
- 1761 78. Huelsmann, M. *et al.* Genes lost during the transition from land to water in cetaceans highlight
1762 genomic changes associated with aquatic adaptations. *Sci Adv* **5**, 6671 (2019).
- 1763 79. Pryor, J. M. *et al.* Essential role for polymerase specialization in cellular nonhomologous end
1764 joining. *Proc Natl Acad Sci U S A* **112**, E4537–E4545 (2015).

- 1765 80. Moon, A. F., Gosavi, R. A., Kunkel, T. A., Pedersen, L. C. & Bebenek, K. Creative template-
1766 dependent synthesis by human polymerase mu. *Proc Natl Acad Sci U S A* **112**, E4530–E4536
1767 (2015).
- 1768 81. Soniat, M. M., Myler, L. R., Kuo, H. C., Paull, T. T. & Finkelstein, I. J. RPA Phosphorylation Inhibits
1769 DNA Resection. *Mol Cell* **75**, 145-153.e5 (2019).
- 1770 82. Vassin, V. M., Wold, M. S. & Borowiec, J. A. Replication Protein A (RPA) Phosphorylation Prevents
1771 RPA Association with Replication Centers. *Mol Cell Biol* **24**, 1930 (2004).
- 1772 83. Shi, W. *et al.* The role of RPA2 phosphorylation in homologous recombination in response to
1773 replication arrest. *Carcinogenesis* **31**, 994–1002 (2010).
- 1774 84. Nam, K. *et al.* Analysis of the FGF gene family provides insights into aquatic adaptation in
1775 cetaceans. *Scientific Reports* **2017 7:1 7**, 1–13 (2017).
- 1776 85. Tejada-Martinez, D., De Magalhães, J. P. & Opazo, J. C. Positive selection and gene duplications in
1777 tumour suppressor genes reveal clues about how cetaceans resist cancer. *Proceedings of the*
1778 *Royal Society B* **288**, (2021).
- 1779 86. Doherty, A. & de Magalhães, J. P. Has gene duplication impacted the evolution of Eutherian
1780 longevity? *Aging Cell* **15**, 978 (2016).
- 1781 87. Vazquez, J. M., Kraft, M. & Lynch, V. J. A CDKN2C retroduplication in Bowhead whales is
1782 associated with the evolution of extremely long lifespans and alerted cell cycle dynamics. *bioRxiv*
1783 2022.09.07.506958 (2022) doi:10.1101/2022.09.07.506958.
- 1784 88. Keil, G., Cummings, E. & de Magalhães, J. P. Being cool: how body temperature influences ageing
1785 and longevity. *Biogerontology* **16**, 383 (2015).
- 1786 89. Lu, J. Y. *et al.* Comparative transcriptomics reveals circadian and pluripotency networks as two
1787 pillars of longevity regulation. *Cell Metab* **34**, 836-856.e5 (2022).
- 1788 90. Evdokimov, A. *et al.* Naked mole rat cells display more efficient excision repair than mouse cells.
1789 *Aging* **10**, 1454–1473 (2018).
- 1790 91. Tian, X. *et al.* SIRT6 Is Responsible for More Efficient DNA Double-Strand Break Repair in Long-
1791 Lived Species. *Cell* **177**, 622-638.e22 (2019).
- 1792 92. Kolora, S. R. R. *et al.* Origins and evolution of extreme life span in Pacific Ocean rockfishes.
1793 *Science* **374**, 842–847 (2021).
- 1794 93. Suárez-Menéndez, M. *et al.* Wild pedigrees inform mutation rates and historic abundance in
1795 baleen whales. *Science* **381**, 990–995 (2023).
- 1796 94. Yoshioka, K. I., Kusumoto-Matsuo, R., Matsuno, Y. & Ishiai, M. Genomic Instability and Cancer
1797 Risk Associated with Erroneous DNA Repair. *International Journal of Molecular Sciences* **2021**,
1798 *Vol. 22, Page 12254 22*, 12254 (2021).
- 1799 95. Yokoyama, A. *et al.* Age-related remodelling of oesophageal epithelia by mutated cancer drivers.
1800 *Nature* **565**, 312–317 (2019).

- 1801 96. Martincorena, I. *et al.* Somatic mutant clones colonize the human esophagus with age. *Science*
1802 **362**, 911–917 (2018).
- 1803 97. Jaiswal, S. *et al.* Age-related clonal hematopoiesis associated with adverse outcomes. *N Engl J*
1804 *Med* **371**, 2488–2498 (2014).
- 1805 98. Martincorena, I. *et al.* High burden and pervasive positive selection of somatic mutations in
1806 normal human skin. *Science (1979)* **348**, 880–886 (2015).
- 1807 99. Mitchell, E. *et al.* Clonal dynamics of haematopoiesis across the human lifespan. *Nature* **2022**
1808 *606:7913* **606**, 343–350 (2022).
- 1809 100. Chen, Y. *et al.* Fight to the bitter end: DNA repair and aging. *Ageing Res Rev* **64**, 101154 (2020).
- 1810 101. Seluanov, A., Vaidya, A. & Gorbunova, V. Establishing Primary Adult Fibroblast Cultures From
1811 Rodents. *J Vis Exp* **44**, (2010).
- 1812 102. Elsner, R., Meiselman, H. J. & Baskurt, O. K. TEMPERATURE-VISCOSITY RELATIONS OF BOWHEAD
1813 WHALE BLOOD: A POSSIBLE MECHANISM FOR MAINTAINING COLD BLOOD FLOW. *Mar Mamm Sci*
1814 **20**, 339–344 (2004).
- 1815 103. George, J. C. Growth, morphology and energetics of bowhead whales (*Balaena mysticetus*).
1816 (University of Alaska Fairbanks, 2009).
- 1817 104. Maslov, A. Y. *et al.* Single-molecule, quantitative detection of low-abundance somatic mutations
1818 by high-throughput sequencing. *Sci Adv* **8**, (2022).
- 1819 105. Quail, M. A. *et al.* Optimal enzymes for amplifying sequencing libraries. *Nat Methods* **9**, 10–11
1820 (2012).
- 1821 106. Blackburn, M. C. Development of new tools and applications for high-throughput sequencing of
1822 microbiomes in environmental or clinical samples. (2010).
- 1823 107. Clement, K. *et al.* CRISPResso2 provides accurate and rapid genome editing sequence analysis.
1824 *Nature Biotechnology* **2019 37:3** **37**, 224–226 (2019).
- 1825 108. Lee, H. J., Chang, H. Y., Cho, S. W. & Ji, H. P. CRISPRpic: fast and precise analysis for CRISPR-
1826 induced mutations via prefixed index counting. *NAR Genom Bioinform* **2**, (2020).
- 1827 109. GitHub - jstjohn/SeqPrep: Tool for stripping adaptors and/or merging paired reads with overlap
1828 into single reads. <https://github.com/jstjohn/SeqPrep>.
- 1829 110. Franken, N. A. P., Rodermond, H. M., Stap, J., Haveman, J. & van Bree, C. Clonogenic assay of cells
1830 in vitro. *Nat Protoc* **1**, 2315–2319 (2006).
- 1831 111. Rose, J. C. *et al.* Rapidly inducible Cas9 and DSB-ddPCR to probe editing kinetics. *Nat Methods* **14**,
1832 891 (2017).
- 1833 112. Hudon, S. F. *et al.* Primers to highly conserved elements optimized for qPCR-based telomere
1834 length measurement in vertebrates. *Mol Ecol Resour* **21**, 59–67 (2021).

- 1835 113. Dimri, G. P. *et al.* A biomarker that identifies senescent human cells in culture and in aging skin in
1836 *vivo*. *Proc Natl Acad Sci U S A* **92**, 9363 (1995).
- 1837 114. Debacq-Chainiaux, F., Erusalimsky, J. D., Campisi, J. & Toussaint, O. Protocols to detect
1838 senescence-associated beta-galactosidase (SA- β gal) activity, a biomarker of senescent cells in
1839 culture and in vivo. *Nature Protocols* **2009 4:12 4**, 1798–1806 (2009).
- 1840 115. Mao, Z. *et al.* SIRT6 promotes DNA repair under stress by activating PARP1. *Science (1979)* **332**,
1841 1443–1446 (2011).
- 1842 116. Vu, D.-D. *et al.* Multivalent interactions of the disordered regions of XLF and XRCC4 foster robust
1843 cellular NHEJ and drive the formation of ligation-boosting condensates in vitro. *bioRxiv* (2023)
1844 doi:10.1101/2023.07.12.548668.
- 1845 117. Roy, S. *et al.* XRCC4/XLF Interaction Is Variably Required for DNA Repair and Is Not Required for
1846 Ligase IV Stimulation. *Mol Cell Biol* **35**, 3017–3028 (2015).
- 1847 118. Dasovich, M. *et al.* Identifying Poly(ADP-ribose)-Binding Proteins with Photoaffinity-Based
1848 Proteomics. *J Am Chem Soc* **143**, 3037–3042 (2021).
- 1849 119. Tan, E. S., Krukenberg, K. A. & Mitchison, T. J. Large-scale preparation and characterization of
1850 poly(ADP-ribose) and defined length polymers. *Anal Biochem* **428**, 126–136 (2012).
- 1851 120. Tian, X. *et al.* SIRT6 Is Responsible for More Efficient DNA Double-Strand Break Repair in Long-
1852 Lived Species. *Cell* **177**, 622-638.e22 (2019).
- 1853 121. Benchling. <https://www.benchling.com/>.
- 1854 122. Chen, S., Zhou, Y., Chen, Y. & Gu, J. fastp: an ultra-fast all-in-one FASTQ preprocessor.
1855 *Bioinformatics* **34**, i884–i890 (2018).
- 1856 123. Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-
1857 aware quantification of transcript expression. *Nat Methods* **14**, 417–419 (2017).
- 1858 124. Anders, S. & Huber, W. Differential expression analysis for sequence count data. *Genome Biol* **11**,
1859 (2010).
- 1860 125. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-
1861 seq data with DESeq2. *Genome Biol* **15**, (2014).
- 1862 126. Lange, S. S., Takata, K. I. & Wood, R. D. DNA polymerases and cancer. *Nat Rev Cancer* **11**, 96–110
1863 (2011).
- 1864 127. Wood, R. D., Mitchell, M. & Lindahl, T. Human DNA repair genes, 2005. *Mutat Res* **577**, 275–283
1865 (2005).
- 1866 128. Perelli, L. *et al.* Evolutionary fingerprints of EMT in pancreatic cancers. *bioRxiv* (2023)
1867 doi:10.1101/2023.09.18.558231.
- 1868 129. Babraham Bioinformatics - FastQC A Quality Control tool for High Throughput Sequence Data.
1869 <https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>.

- 1870 130. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data.
1871 *Bioinformatics* **30**, 2114–2120 (2014).
- 1872 131. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform.
1873 *Bioinformatics* **25**, 1754–1760 (2009).
- 1874 132. Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**, 2078 (2009).
- 1875 133. Van der Auwera, G. A. *et al.* From FastQ data to high confidence variant calls: the Genome
1876 Analysis Toolkit best practices pipeline. *Curr Protoc Bioinformatics* **43**, (2013).
- 1877 134. Chen, X. *et al.* Manta: rapid detection of structural variants and indels for germline and cancer
1878 sequencing applications. *Bioinformatics* **32**, 1220–1222 (2016).
- 1879 135. Nickson, C. M. & Parsons, J. L. Monitoring regulation of DNA repair activities of cultured cells in-
1880 gel using the comet assay. *Front Genet* **5**, (2014).
- 1881 136. Gyori, B. M., Venkatachalam, G., Thiagarajan, P. S., Hsu, D. & Clement, M. V. OpenComet: An
1882 automated tool for comet assay image analysis. *Redox Biol* **2**, 457–465 (2014).
- 1883 137. Shechter, D., Dormann, H. L., Allis, C. D. & Hake, S. B. Extraction, purification and analysis of
1884 histones. *Nature Protocols* **2007 2:6 2**, 1445–1457 (2007).
- 1885 138. da Veiga Leprevost, F. *et al.* Philosopher: a versatile toolkit for shotgun proteomics data analysis.
1886 *Nature Methods* **2020 17:9 17**, 869–870 (2020).
- 1887 139. Kong, A. T., Leprevost, F. V., Avtonomov, D. M., Mellacheruvu, D. & Nesvizhskii, A. I. MSFragger:
1888 ultrafast and comprehensive peptide identification in mass spectrometry-based proteomics.
1889 *Nature Methods* **2017 14:5 14**, 513–520 (2017).
- 1890 140. Ma, K., Vitek, O. & Nesvizhskii, A. I. A statistical model-building perspective to identification of
1891 MS/MS spectra with PeptideProphet. *BMC Bioinformatics* **13 Suppl 16**, 1–17 (2012).
- 1892 141. Yu, F., Haynes, S. E. & Nesvizhskii, A. I. IonQuant Enables Accurate and Sensitive Label-Free
1893 Quantification With FDR-Controlled Match-Between-Runs. *Mol Cell Proteomics* **20**, (2021).
- 1894 142. Haas, B. J. *et al.* De novo transcript sequence reconstruction from RNA-seq using the Trinity
1895 platform for reference generation and analysis. *Nature Protocols* **2013 8:8 8**, 1494–1512 (2013).
- 1896 143. Bateman, A. *et al.* UniProt: the universal protein knowledgebase in 2021. *Nucleic Acids Res* **49**,
1897 D480–D489 (2021).
- 1898 144. Adusumilli, R. & Mallick, P. Data Conversion with ProteoWizard msConvert. *Methods Mol Biol*
1899 **1550**, 339–368 (2017).
- 1900 145. Chambers, M. C. *et al.* A cross-platform toolkit for mass spectrometry and proteomics. *Nature*
1901 *Biotechnology* **2012 30:10 30**, 918–920 (2012).
- 1902 146. Demichev, V., Messner, C. B., Vernardis, S. I., Lilley, K. S. & Ralser, M. DIA-NN: neural networks
1903 and interference correction enable deep proteome coverage in high throughput. *Nature Methods*
1904 **2019 17:1 17**, 41–44 (2019).

- 1905 147. Lazar, C., Gatto, L., Ferro, M., Bruley, C. & Burger, T. Accounting for the Multiple Natures of
1906 Missing Values in Label-Free Quantitative Proteomics Data Sets to Compare Imputation
1907 Strategies. *J Proteome Res* **15**, 1116–1125 (2016).
- 1908 148. Gardner, M. L. & Freitas, M. A. Multiple imputation approaches applied to the missing value
1909 problem in bottom-up proteomics. *Int J Mol Sci* **22**, (2021).
- 1910 149. Liu, M. *et al.* Genomic discovery of potent chromatin insulators for human gene therapy. *Nature*
1911 *Biotechnology* **2014 33:2 33**, 198–203 (2015).

1912

1913

1914

1915

1916

1917

1918

1919

1920

1921

1922

1923

1924

1925

1926

1927

1928

1929

1930

1931

1932

1933

1934

Figure Legends

1935

1936

1937 **Figure 1. Bowhead whale fibroblasts exhibit senescence with reduced SASP and**
1938 **low basal p53 activity. a**, Growth curves of primary and hTERT-immortalized skin
1939 fibroblasts (n=2 for each cell line). **b**, Telomerase activity and telomere length in skin
1940 fibroblasts. **c**, Quantification of β -gal-positive human and bowhead skin fibroblasts in
1941 response to γ -irradiation (12 days) and replicative senescence (n=3 for each
1942 species). **d**, Representative images of SA- β -gal staining of human and bowhead skin
1943 fibroblasts in response to γ -irradiation and replicative senescence. The bar is 100 μ m. **e**,
1944 Apoptosis of human and bowhead whale fibroblasts in response to γ -irradiation. Three
1945 days after γ -irradiation, cells were harvested and subjected to an Annexin V apoptosis
1946 assay using flow cytometry (n=3 for each species). **f**, Log fold change of SASP mRNA
1947 expression in human and bowhead whale skin fibroblasts 12 days after γ -irradiation. **g**,
1948 Relative luciferase expression in mouse, cow, human and bowhead whale fibroblasts
1949 transfected with the p53 reporter vector. Data are shown as ratios of firefly/renilla
1950 luciferase (to normalize for transfection efficiency) expression 24 h after transfections
1951 (n=3 for mouse, human, BW; n=2 for cow). **h**, Apoptosis of mouse, cow, human and
1952 bowhead whale fibroblasts in response to UVC. Two days after UVC, cells were
1953 harvested and subjected to an Annexin V apoptosis assay using flow cytometry. Error
1954 bars represent mean \pm SD. * p<0.05, *** p<0.001. Welch's t-test was used to quantify
1955 the significance. Whale, bowhead whale; NMR, naked mole-rat. RS, replicative
1956 senescence.

1957 **Figure 2. Fewer tumor suppressor hits are required for oncogenic transformation**
1958 **of bowhead fibroblasts than for human fibroblasts. a**, Images of representative
1959 fibroblast colonies for tested cell lines after 4 weeks of growth in soft agar. The top
1960 panel indicates whether the cell lines in the column below have the indicated protein
1961 overexpressed (+), inactivated (-), or expressed in the active endogenous form (WT).
1962 Text above individual images indicate for that cell line whether tumor suppressors are
1963 inactivated through genetic knockout or SV40 Large T (or LT mutants) or Small T (ST)
1964 antigen. Icons in corners of images indicate species. Scale bar represents 250 μ m. **b**,
1965 Volumetric growth curves for the indicated bowhead whale fibroblast cell lines in mouse
1966 xenograft assays. All cell lines shown stably express H-Ras^{G12V} and hTERT in addition
1967 to the genotype indicated in the figure legend. Data points represent averages from 3
1968 immunodeficient nude mice injected bilaterally (6 injections) for each cell line, except for
1969 *TP53*^{-/-}*RB1*^{-/-} double knockouts, for which 2 independent cell lines were tested, for a
1970 total of 6 mice/12 injections. Experiments were terminated based on predetermined
1971 thresholds for maximum tumor length or duration of experiment as described in
1972 Methods. Images in the legend show a representative mouse for the indicated cell line
1973 at the final measured time point. Error bars show SEM. **c**, Western blot for p53 protein
1974 in clonally isolated fibroblast colonies following CRISPR targeting of *TP53*. Underlined
1975 lanes indicate colonies selected for further validation and experiments. **d**, Western blot

1976 for Rb protein in clonally isolated fibroblast colonies following CRISPR targeting of *RB1*
1977 on an existing p53 knockout background.

1978 **Figure 3. The bowhead whale repairs DSBs with higher accuracy and efficiency**
1979 **than other mammals. a,b**, NHEJ and HR efficiency were measured using fluorescent
1980 reporter constructs. Successful NHEJ and HR event leads to reactivation of the GFP
1981 gene. NHEJ and HR reporter constructs were integrated into primary, low passage skin
1982 fibroblasts. NHEJ and HR repair efficiency were assayed by transfecting cells with I-
1983 Scl expression vector and a DsRed plasmid as a transfection control. The repair
1984 efficiency was calculated as the ratio of GFP+/DsRed+ cells. Experiments were
1985 repeated at least 3 times for each cell line. Error bars represent SD. * $p < 0.05$ (Welch's t-
1986 test). Whale, bowhead whale. **c**, Percent of binucleated cells containing micronuclei in
1987 human and bowhead whale fibroblasts after 2Gy γ -irradiation (n=4). Error bars
1988 represent SD. ** $p < 0.005$ (Welch's t-test). **d**, Endogenous γ -H2AX/53BP1 foci in human
1989 and whale cells. Results are combined from two independent experiments. 200 nuclei
1990 were analyzed. Error bars represent SEM. *** $p < 0.001$ (two-tailed t-test). **e**,
1991 Representative confocal images of human and bowhead whale cells stained for γ -
1992 H2AX and 53BP1 at no treatment (control) and 1h-24h after bleomycin treatment at
1993 concentration 5 μ g/mL. Scale bar indicates 10 μ m. **f**, Quantification of γ H2AX/53BP1 foci
1994 with and without DSB induction. Exponentially growing cells were treated for 1h with
1995 bleomycin (BLM) at concentration 5 μ g/mL, washed twice with PBS and fresh media was
1996 added. At indicated time-points cells were fixed and processed for
1997 immunocytochemistry. Foci were counted by eye in green and red channels. 150-170
1998 nuclei were analyzed. Error bars represent SEM. * $p < 0.05$, ** $p < 0.01$ (two-tailed t-test).
1999 **g**, Histograms of CRISPR indel size distribution by species. Data for biological
2000 replicates are superimposed and partially transparent with lines connecting data points
2001 for each sample. Unmodified alleles and alleles with substitutions only are excluded
2002 from this analysis. **h**, Distribution of sequenced PTEN allele variants by species after
2003 CRISPR DSB induction at a conserved region of the endogenous PTEN gene. Data are
2004 averages from multiple primary dermal fibroblast lines isolated from different individual
2005 animals for bowhead whale (n=3), human (n=3), cow (n=2), and mouse (n=3). Error
2006 bars represent SEM. **i**, Allele plots showing 15 most frequent allele types after CRISPR
2007 for one representative cell line per species. Sequences are displayed within a window
2008 centered on the cleavage site and extending 20 bp in each direction. Data bars and
2009 values indicate proportion of total alleles represented by each row. For the purposes of
2010 this display and quantification, all individual alleles with identical sequences in the 40-bp
2011 window have been pooled, so rows represent composites of alleles that may differ
2012 outside the display window.

2013 **Figure 4. CIRBP is highly expressed in bowhead whale fibroblasts and promotes**
2014 **DNA DSB repair and genome stability. a**, Western blots of DNA repair proteins in
2015 primary fibroblasts from different species. **b-c**, bwCIRBP promotes NHEJ and HR in
2016 human cells as measured by flow cytometric GFP-reporter assays (see Methods). In
2017 these assays DSBs are induced within inactive NHEJ or HR reporter cassettes by

2018 expressing I-SceI endonuclease. Successful NHEJ or HR events lead to reactivation of
2019 the fluorescent GFP reporters that are scored by flow cytometry. All experiments in
2020 these figures were repeated at least 3 times. **d,e**, Knockdown of CIRBP in bowhead
2021 whale fibroblasts decreases NHEJ and HR efficiency. siNT = non-targeting siRNA. **f**,
2022 Western blot of human fibroblasts overexpressing human CIRBP, whale CIRBP or 9R/A
2023 mutated whale CIRBP; **g**, Western blot of bowhead whale fibroblasts with knockdown of
2024 CIRBP. **h**, Overexpression of CIRBP decreases the percentage of binucleated cells
2025 containing micronuclei in human cells 3d after 2Gy γ -irradiation (n=3) (left panel);
2026 Western blot of human fibroblasts overexpressing human CIRBP, human CIRBP with
2027 optimized codons and whale CIRBP (right panel). Error bars represent mean \pm SD. *
2028 $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ (Welch's t-test). siNT - negative control siRNAs that do
2029 not target any gene product. **i**, Number of endogenous γ H2AX/53BP1 foci in human
2030 cells with bwCIRBP overexpression. Error bars represent SEM. *** $p < 0.001$ (two-tailed
2031 t-test). **j**, CIRBP stimulates NHEJ-mediated ligation *in vitro in*. Linearized pUC19
2032 plasmid with cohesive ends was mixed with human recombinant proteins XRCC4/
2033 Ligase IV complex, and 0 to 1 μ M CIRBP. Where indicated, reaction mixtures contained
2034 Ku70/80 heterodimer, PAXX dimer or XLF dimer. The reaction mixtures were incubated
2035 for 1 hr at 30°C, proteins were denatured with SDS at 65°C and loaded onto agarose
2036 gel. Each sample were loaded onto 0.7% agarose gel, followed by gel electrophoresis.
2037 The gel was stained with ethidium bromide.

2038 **Figure 5. RPA and CIRBP contribute to increased DNA repair fidelity. a**,
2039 Distribution of sequenced PTEN allele variants in human primary fibroblasts treated with
2040 TDRL-505 or rhRPA after CRISPR DSB induction at a conserved region of the
2041 endogenous PTEN gene. Data are averages from experiments performed in triplicate.
2042 Error bars represent SEM. **b**, Distribution of sequenced PTEN allele variants by species
2043 in bowhead whale primary fibroblasts treated with TDRL-505 after CRISPR DSB
2044 induction at a conserved region of the endogenous PTEN gene. Data are averages from
2045 experiments performed in triplicate. Error bars represent SEM. **c**, Distribution of
2046 sequenced PTEN allele variants by species in human fibroblasts with lentiviral
2047 overexpression of luciferase or bwCIRBP after CRISPR DSB induction at a conserved
2048 region of the endogenous PTEN gene. Data are averages from experiments performed
2049 in triplicate. Error bars represent SEM. * $p < 0.05$, **** $p < 0.0001$. All charts analyzed by
2050 two-way ANOVA with Fisher's LSD. p-values should be considered nominal indices of
2051 significance. **d**, Graphical summary. The bowhead whale has evolved efficient and
2052 accurate DSB repair mediated by high levels of CIRBP and RPA2. This enhanced DNA
2053 repair may help the bowhead whale resist cancer despite its cells requiring fewer
2054 mutational hits for malignant transformation than human cells. Improved DNA repair
2055 rather than enhanced elimination of damaged cells through apoptosis or senescence
2056 may promote longevity in the bowhead whale.

2057 **Extended Data Figure 1. Mutation rates in bowhead whale cells during tumor**
2058 **progression. a**, Western blot for p53 protein in clonally isolated fibroblast colonies
2059 following CRISPR targeting of *TP53*. Underlined lanes indicate colonies selected for

2060 further validation and experiments. **b**, Western blot for Rb protein in clonally isolated
2061 fibroblast colonies following CRISPR targeting of *RB1* on an existing p53 knockout
2062 background. **c**, Ratio of firefly:renilla luciferase luminescence in fibroblasts transfected
2063 with firefly luciferase reporter of p53 transcriptional activity and renilla luciferase control.
2064 Cells were treated with etoposide to induce p53 activity. **d**, Ratio of firefly:renilla
2065 luciferase luminescence in fibroblasts transfected with firefly luciferase reporter of E2F
2066 transcriptional activity and renilla luciferase control. Transfected cells were serum
2067 starved for 24h and returned to complete medium for 24h before luminescence
2068 measurement. Higher E2F activity results from reduced Rb activity. Error bars represent
2069 SD. $p < 0.001$ (two-tailed t test), $n=3$. **e**, Schematic showing experimental design and
2070 samples processed for WGS (whale $N = 9$ tumors; human $N = 2$ tumors; mouse $N = 1$
2071 tumor). **f**, Bar plot displaying percentages of SNV types across species with similarities
2072 of mutational processes across species. **g-l**, Bar plot showing quantifications of
2073 numbers of SNVs and small indels (size 1-10bp) across species. **j-l**, Bar plot showing
2074 quantification of number of large SVs (size > 6000 bp) across species. **m**, Histograms
2075 and trend curves showing distribution of SVs size across species. **n**, Bar plot showing
2076 distribution of small, medium and large (6-50Kb, 50-500Kb, >500 Kb respectively) SVs
2077 and deletions across species. Error bars represent SD. P values are a result of ordinary
2078 One-Way Anova with Tukey's multiple comparison test (**g-l**) and chi-square test (**n**). * p
2079 < 0.05 ; ** $p < 0.01$; *** $p < 0.0001$; ns = not significant.

2080 **Extended Data Figure 2. Mismatch repair, excision repair, and mutagenesis in**
2081 **bowhead whale cells.** **a**, MMR reactivation of a heteroduplex eGFP plasmid containing
2082 a G/T mismatch. Growing fibroblasts were transfected with the heteroduplex plasmid
2083 and a DsRed plasmid as a transfection control. The repair efficiency was calculated as
2084 the ratio of GFP+/DsRed+ cells. Each dot represents cell line isolated from different
2085 individual ($n=3$). **b**, NER efficiency was measured by host cell reactivation assay where
2086 a plasmid containing luciferase reporter is UV-irradiated *in vitro* to induce DNA damage,
2087 transfected into cells, and reactivation of the reporter is measured ($n=3$ for each cell
2088 line). **c**, Kinetics of cyclobutane pyrimidine dimer repair after 30 J/m^2 UVC. Confluent
2089 human and whale skin fibroblasts were subjected to UVC, harvested at different time-
2090 points, genomic DNA was isolated and analyzed for cyclobutene dimers as described in
2091 Methods ($n=2$ for each cell line). **d**, BER efficiency was measured by host cell
2092 reactivation where luciferase reporter plasmid is treated with methylene blue and light to
2093 induce oxidative DNA damage, transfected into cells, and luciferase activity measured
2094 as described in Methods. **e**, ENU-induced mutational load by SMM-seq in fibroblasts of
2095 the indicated species. Delta SNV frequency was calculated for each cell line ($n=6-8$
2096 fibroblasts/species; Kruskal-Wallis test). **f**, Analysis of mutational spectra showing a
2097 pattern typical for ENU. An increase in A>T transversions (orange bars) can be found in
2098 ENU-treated mammalian cells. **g**, HPRT mutagenesis assay in ENU-treated cells,
2099 adjusted by plating efficiency measured for each cell line ($n=3$ cell lines/species) **h**,
2100 Colony forming efficiency for HPRT mutagenesis assay. Error bars represent mean \pm
2101 SD. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$ ns=not significant (heteroscedastic
2102 two-tailed t test). **i**, Apoptosis/necrosis of human and bowhead whale fibroblasts in

2103 response to ENU. Cells at growing stage were treated for 3h with ENU at indicated
2104 dosages. After treatment cells were washed in PBS and incubated for 3 days. For
2105 measuring Apoptosis/Necrosis cells were stained with AnnexinV/PI and analyzed by
2106 flow cytometry. **j**, HPRT mutagenesis assay in cells treated with 2 Gy γ -irradiation,
2107 adjusted by plating efficiency measured for each cell line (n=2 cell lines/species) **k**,
2108 Colony forming efficiency for HPRT mutagenesis assay.

2109 **Extended Data Figure 3. Poly-ADP-ribosylation and DNA repair of oxidative**
2110 **damage in bowhead whale cells. a**, Bowhead whale cells show greater poly-ADP-
2111 ribosylation in response to hydrogen peroxide treatment. **b**, Bowhead whale cells show
2112 greater poly-ADP-ribosylation after γ -irradiation. Cells were harvested immediately or at
2113 indicated time-points after radiation for Western blot analysis (top panel).
2114 Representative images of comet tails under neutral conditions (bottom panel). Cells
2115 were processed immediately after radiation. **c**, Nuclear extracts of bowhead whale
2116 fibroblasts exhibit higher endogenous PARP activity (n=3). Error bars represent mean \pm
2117 SD. * p<0.05 (Welch's t-test). Whale=bowhead whale. **d**, Apoptosis/Necrosis of human
2118 and bowhead whale fibroblasts in response to hydrogen peroxide at concentration
2119 700 μ M. Two days after hydrogen peroxide, cells were harvested and subjected to an
2120 Annexin V apoptosis assay using flow cytometry. Error bars represent mean \pm SD. ***
2121 p<0.001. Welch's t-test was used to quantify the significance (n=12). **e**, Percent tail
2122 DNA by alkaline comet assay at various time points after 700 μ M H₂O₂ treatment in 2
2123 cell lines each of human and bowhead whale fibroblasts. Points represent individual
2124 cells. Representative comet images shown below. Bars indicate mean \pm SEM.

2125 **Extended Data Figure 4. DSB repair efficiency in bowhead whale cells. a**, NHEJ
2126 efficiency in extrachromosomal assay. NHEJ reporter construct was pre-digested with I-
2127 Scl, purified and co-transfected with DsRed into human and bowhead skin fibroblasts.
2128 Three days after transfection cells were harvested and subjected to flow cytometry to
2129 calculate NHEJ efficiency (n=3). Error bars represent mean \pm SD. *** p<0.001 (two-
2130 tailed t-test) **b**, Representative images of human and bowhead whale binucleated cells
2131 containing micronuclei after 2 Gy of γ -irradiation. Scale bar indicates 20 μ m. **c**,
2132 Frequency of micronuclei after DSB induction with I-Scl in primary fibroblasts carrying
2133 a chromosomally integrated NHEJ reporter cassette. Each cell line was transiently
2134 transfected with a BFP-expressing control plasmid or an I-Scl expression plasmid and
2135 micronuclei were quantified after 5d in media containing cytochalasin B to prevent
2136 cytokinesis. Micronucleus frequencies for each cell line are shown normalized to BFP
2137 control (paired t-test, n=3 cell lines/species). **d**, Pulse-field gel stained with ethidium
2138 bromide, showing chromosomal DNA fragmentation in human and bowhead confluent
2139 skin fibroblasts immediately after different doses of γ -irradiation 0.7, 1.5, 3 and 6h after
2140 40 Gy of γ -irradiation. **e**, Kinetics of DSB repair measured by PFGE in confluent human
2141 and bowhead fibroblasts after 40 Gy of γ -irradiation. n=2 for each species.

2142 **Extended Data Figure 5. Sequencing of DNA DSB repair products in bowhead**
2143 **whale cells. a**, Possible repair outcomes after induction of DSBs with incompatible

2144 ends by I-SceI in NHEJ reporter construct. **b**, Allele plot of Sanger sequencing products
2145 resulting from repair of integrated NHEJ reporter cassette after I-SceI cleavage. **c**,
2146 NHEJ fidelity in extrachromosomal assay. NHEJ reporter construct was pre-digested
2147 with I-SceI, purified and co-transfected with DsRed into human and bowhead skin
2148 fibroblasts. Three days after transfection genomic DNA was isolated, subjected to PCR,
2149 cloned and analyzed by Sanger sequencing. At least 100 clones were analyzed for
2150 each species. Correct – annealing on 2 of the 4 protruding nucleotides **d**, Time course
2151 of CRISPR cleavage measured by digital droplet PCR (ddPCR). PTEN copy number at
2152 varying time points after CRISPR RNP transfection was measured with ddPCR using
2153 primers flanking the predicted cleavage site and normalized within each sample to a
2154 single-copy genomic ultraconserved element as described in Methods. Error bars show
2155 confidence intervals of Poisson distribution calculated in QuantaSoft. **e**, Pearson
2156 correlation between 5th percentile indel size and species lifespan ($r=0.8508$, 95% CI =
2157 0.5125 to 0.9605, $p=0.0009$, $n=11$). **f**, Absolute frequencies of alleles by base pairs of
2158 microhomology across species in CRISPR-targeted PTEN repair products. **g**, Relative
2159 proportions of deletion alleles by base pairs of microhomology across species in
2160 CRISPR-targeted PTEN repair products.

2161 **Extended Data Figure 6. Proteomic quantification of DNA repair proteins. a**,
2162 Western blot for CIRBP on bowhead whale and mouse organs **b**, Abundance of CIRBP
2163 protein by LC-MS in liver tissue of mammal species ($n=12$ per species; 3 biological x 4
2164 technical replicates; N.D.=not detected) **c**, Abundance of RPA2 protein by LC-MS in
2165 liver tissue of mammal species ($n=12$ per species; 3 biological x 4 technical replicates;
2166 N.D.=not detected) **d**, Abundance of CIRBP protein by LC-MS in nuclear extracts of
2167 liver tissue of mammal species ($n=3$ biological replicates per species) **e**, Abundance of
2168 RPA2 protein by LC-MS in nuclear extracts of liver tissue of mammal species ($n=3$
2169 biological replicates per species; N.D.=not detected) **f**, Heatmap of LC-MS protein
2170 abundance for primary fibroblasts of the indicated species and proteins. Color intensity
2171 scale corresponds to \log_{10} ion intensity. **g**, Per-protein normalized abundance by LC-MS
2172 of proteins identified in pulldowns of His-tagged Cas9/dCas9 bound to a plasmid
2173 containing the genomic *PTEN* target sequence after incubation in extracts of soluble
2174 nuclear proteins from human and bowhead whale.

2175 **Extended Data Figure 7. Transcriptome, Western blot, and STED quantification of**
2176 **DNA repair proteins. a**, Relative expression level of genes in 6 DNA repair pathways
2177 among species. Z-scores are scaled by row. Genes in each pathway are ordered
2178 decreasingly based on the expression level in bowhead whale. Genes with higher
2179 expression in bowhead whale compared to all 3 other species are highlighted in red text
2180 to the right of the heatmap. Genes of each gene set were compiled from 3 resources:
2181 MsigDB database, GO ontology, and a curated gene list
2182 (www.mdanderson.org/documents/Labs/Wood-Laboratory/human-dna-repair-genes.html) **b**, Western blot abundance of RPA2 in cultured skin fibroblasts, using 2
2183 different monoclonal primary antibodies targeting conserved epitopes and normalized to
2184 histone H3. A third polyclonal antibody produced the same results but had higher
2185

2186 background reactivity and is not shown. Each lane is a primary fibroblast line from a
2187 different adult individual. Fluorescent secondary antibodies were used to increase linear
2188 dynamic range for higher quantitative accuracy. **c**, Western blot for CIRBP with 3
2189 different antibodies in 3 fibroblast lines per species. mAb=monoclonal antibody,
2190 pAb=polyclonal antibody. **d**, Stimulated emission depletion (STED) images of RPA2 and
2191 CIRBP localization in human and bowhead whale fibroblasts. Target protein in red,
2192 nuclear DAPI stain in blue. **e**, Western blot for CIRBP in fibroblasts isolated from various
2193 mammalian species.

2194 **Extended Data Figure 8. Analysis of CIRBP's role in DNA DSB repair.** **a**, CIRBP
2195 localization in whale cells. Before formaldehyde fixation, cells were pre-extracted with
2196 CSK buffer +/- RNaseA for 3min. After standard immunocytochemistry procedure
2197 images were collected using confocal microscope. **b**, Western blot of bowhead whale
2198 fibroblasts with knockdown of CIRBP (left panel) and band intensity quantification from
2199 3 independent experiments (right panel) suggesting partial dependence of RPA2 protein
2200 abundance on CIRBP expression. **c**, Ion intensity by LC-MS of RPA2 in human
2201 fibroblasts with and without lentiviral overexpression of bwCIRBP (n=3 human cell
2202 lines). Error bars show mean +-SEM. **d**, DSBs induce CIRBP enrichment in chromatin.
2203 Exponentially growing cells were treated with neocarzinostatin (NCS) for the indicated
2204 period of time and lysed in CSK buffer to enrich chromatin-bound fraction. α -Tubulin
2205 staining was used to verify the absence of cytoplasmic contamination in chromatin-
2206 bound fraction. **e**, DSBs induced by γ -irradiation lead to CIRBP enrichment in
2207 chromatin. This enrichment is promoted by RNA. Exponentially growing cells were
2208 treated with γ -irradiation and at the indicated period of time were lysed in CSK buffer
2209 with/without RNase A to enrich proteins in chromatin-bound fraction. **f**, Overexpression
2210 of CIRBP decreases the percentage of binucleated cells containing micronuclei in
2211 human cells after I-Sce1-induced DSBs. Each bar indicates an experimental replicate.
2212 At least 150 binucleated cells were scored per condition. **g**, Frequency of chromosomal
2213 aberrations in human fibroblasts with and without CIRBP overexpression after 2Gy γ -
2214 irradiation. 100 metaphases were analyzed per sample. C=control untreated cells. **h**,
2215 Frequency of insertions and deletions >20 bp in NHEJ reporter constructs PCR-
2216 amplified from human fibroblasts with and without bwCIRBP overexpression after I-Sce1
2217 expression. Insertion/deletion frequencies were determined from Nanopore sequencing
2218 data of PCR products and normalized within each sample to total frequency of all
2219 insertions or deletions. **i**, Frequency of insertions and deletions as shown in (**h**) but for
2220 bowhead whale fibroblasts with negative control or CIRBP-targeting siRNAs. **j**,
2221 Calculated dissociation constants (K_D) and fluorescence polarization (FP)
2222 measurements for CIRBP proteins titrated into solutions containing a fixed
2223 concentration (3 nM) of fluorescently labeled PAR of various polymer lengths. **k**, EMSA
2224 of increasing amounts of recombinant human CIRBP incubated in vitro with 300 ng
2225 sheared chromatin from fibroblasts exposed to UVC and oxidative DNA damage as
2226 described in Methods. Chromatin was treated with Proteinase K but not RNase. Nucleic
2227 acids are stained with SYBR Gold. Red overlay indicates saturated pixels. **l**, EMSA of

2228 300 ng sheared purified genomic DNA, purified cellular RNA, or chromatin as described
2229 in (k) incubated in vitro with 5 µg rhCIRBP. m, Hypothermia promotes NHEJ efficiency
2230 in primary human fibroblasts (left panel). Cells were pre-incubated at 33°C for 2 days,
2231 co-transfected with I-SceI-digested NHEJ reporter and DsRed, and returned to the 33°C
2232 incubator. NHEJ efficiency was measured by flow cytometry 3 days following
2233 transfection (n=3). Western blot showing CIRBP upregulation in human cells exposed to
2234 33°C for 2 days (right panel). Western blot images were analyzed in ImageLab software
2235 (Bio-Rad). Error bars represent mean ± SD. ** p<0.01 (Welch's t-test).

2236 **Extended Data Figure 9. Analysis of bwCIRBP coding sequence mutations and**
2237 **protein expression levels. a,** Comparison of amino acid sequences between human
2238 and bowhead whale CIRBP through BLAST analysis. **b,** Phylogenetic tree illustrating
2239 the relationships among CIRBP coding sequences from representative species with
2240 genome sequence information available. The asterisk indicates the presence of BHW-
2241 specific variants in the species. The colors indicate the position of variants shown in (a).
2242 **c,** SwissModel/AlphaFold models of human (left, pink) and bowhead whale (right, blue).
2243 Side chains of whale residues that diverge from human are shown, and their ribbon is
2244 colored yellow in the model. The key takeaway is that all the residues that differ
2245 between whale and human are in the C-terminal disordered region, whereas the N-
2246 terminal RNA recognition motif (RRM) is structured and conserved. **d,** Western blot
2247 abundance of bwCIRBP, hCIRBP, and reciprocal amino acid mutants overexpressed in
2248 human cells. **e,** Calculated codon adaptation index (CAI) for CIRBP coding sequence
2249 variants.

2250 **Extended Data Figure 10. Analysis of bowhead whale RPA2 sequence. a,**
2251 Comparison of amino acid sequences between human and bowhead whale RPA2
2252 through BLAST analysis. **b,** Phylogenetic tree illustrating the relationships among RPA2
2253 coding sequence from different representative species. The asterisk indicates the
2254 presence of BHW-specific variants in the species. The colors indicate the position of
2255 variants shown in (a). **c,** AlphaFold protein structures of human and bowhead whale
2256 RPA2 showing the position of the variants.

2257 **Extended Data Figure 11. Bowhead whale CIRBP reduces anchorage-independent**
2258 **cell growth. a,** Images of representative human transformed fibroblast colonies with
2259 and without bwCIRBP overexpression after 23 days of growth in soft agar. 20x
2260 magnification. Bar 100µm. **b,** Quantification of colonies after staining with nitro blue
2261 tetrazolium chloride. Colonies were counted using ImageJ software as described in
2262 Methods. Error bars represent SD. *p<0.05 (Welch's t-test). **c,** Cell proliferation MTT
2263 assay. **d,** Trypan Blue exclusion test of cell viability. **e,** Western blot showing expression
2264 of LT, Ras, p16 and p21 after overexpression of bwCIRBP. **f,** Frequency of
2265 chromosomal aberrations in human transformed cells after bwCIRBP overexpression.
2266 100 metaphases were analyzed per sample.

2267




Figure 1

Figure 1. Bowhead whale fibroblasts exhibit senescence with reduced SASP and low basal p53 activity.

a, Growth curves of primary and hTERT-immortalized skin fibroblasts (n=2 for each cell line). **b**, Telomerase activity and telomere length in skin fibroblasts. **c**, Quantification of β -gal-positive human and bowhead skin fibroblasts in response to γ -irradiation (12 days) and replicative senescence (n=3 for each species). **d**, Representative images of SA- β -gal staining of human and bowhead skin fibroblasts in response to γ -irradiation and replicative senescence. The bar is 100 μ m. **e**, Apoptosis of human and bowhead whale fibroblasts in response to γ -irradiation. Three days after γ -irradiation, cells were harvested and subjected to an Annexin V apoptosis assay using flow cytometry (n=3 for each species). **f**, Log fold change of SASP mRNA expression in human and bowhead whale skin fibroblasts 12 days after γ -irradiation. **g**, Relative luciferase expression in mouse, cow, human and bowhead whale fibroblasts transfected with the p53 reporter vector. Data are shown as ratios of firefly/renilla luciferase (to normalize for transfection efficiency) expression 24 h after transfections (n=3 for mouse, human, BW; n=2 for cow). **h**, Apoptosis of mouse, cow, human and bowhead whale fibroblasts in response to UVC. Two days after UVC, cells were harvested and subjected to an Annexin V apoptosis assay using flow cytometry. Error bars represent mean \pm SD. * p<0.05, *** p<0.001. Welch's t-test was used to quantify the significance. Whale, bowhead whale; NMR, naked mole-rat. RS, replicative senescence.




Figure 2

Figure 2. Fewer tumor suppressor hits are required for oncogenic transformation of bowhead fibroblasts than for human fibroblasts. **a**, Images of representative fibroblast colonies for tested cell lines after 4 weeks of growth in soft agar. The top panel indicates whether the cell lines in the column below have the indicated protein overexpressed (+), inactivated (-), or expressed in the active endogenous form (WT). Text above individual images indicate for that cell line whether tumor suppressors are inactivated through genetic knockout or SV40 Large T (or LT mutants) or Small T (ST) antigen. Icons in corners of images indicate species. Scale bar represents 250 μm . **b**, Volumetric growth curves for the indicated bowhead whale fibroblast cell lines in mouse xenograft assays. All cell lines shown stably express H-Ras^{G12V} and *hTERT* in addition to the genotype indicated in the figure legend. Data points represent averages from 3 immunodeficient nude mice injected bilaterally (6 injections) for each cell line, except for *TP53*^{-/-}*RB1*^{-/-} double knockouts, for which 2 independent cell lines were tested, for a total of 6 mice/12 injections. Experiments were terminated based on predetermined thresholds for maximum tumor length or duration of experiment as described in Methods. Images in the legend show a representative mouse for the indicated cell line at the final measured time point. Error bars show SEM. **c**, Western blot for p53 protein in clonally isolated fibroblast colonies following CRISPR targeting of *TP53*. Underlined lanes indicate colonies selected for further validation and experiments. **d**, Western blot for Rb protein in clonally isolated fibroblast colonies following CRISPR targeting of *RB1* on an existing p53 knockout background.




Figure 3

Figure 3. The bowhead whale repairs DSBs with higher accuracy and efficiency than other mammals. **a,b**, NHEJ and HR efficiency were measured using fluorescent reporter constructs. Successful NHEJ and HR event leads to reactivation of the GFP gene. NHEJ and HR reporter constructs were integrated into primary, low passage skin fibroblasts. NHEJ and HR repair efficiency were assayed by transfecting cells with I-SceI expression vector and a DsRed plasmid as a transfection control. The repair efficiency was calculated as the ratio of GFP+/DsRed+ cells. Experiments were repeated at least 3 times for each cell line. Error bars represent SD. * $p < 0.05$ (Welch's t-test). Whale, bowhead whale. **c**, Percent of binucleated cells containing micronuclei in human and bowhead whale fibroblasts after 2Gy γ -irradiation ($n=4$). Error bars represent SD. ** $p < 0.005$ (Welch's t-test). **d**, Endogenous γ -H2AX/53BP1 foci in human and whale cells. Results are combined from two independent experiments. 200 nuclei were analyzed. Error bars represent SEM. *** $p < 0.001$ (two-tailed t-test). **e**, Representative confocal images of human and bowhead whale cells stained for γ -H2AX and 53BP1 at no treatment (control) and 1h-24h after bleomycin treatment at concentration $5\mu\text{g/mL}$. Scale bar indicates $10\mu\text{m}$. **f**, Quantification of γ H2AX/53BP1 foci with and without DSB induction. Exponentially growing cells were treated for 1h with bleomycin (BLM) at concentration $5\mu\text{g/mL}$, washed twice with PBS and fresh media was added. At indicated time-points cells were fixed and processed for immunocytochemistry. Foci were counted by eye in green and red channels. 150-170 nuclei were analyzed. Error bars represent SEM. * $p < 0.05$, ** $p < 0.01$ (two-tailed t-test). **g**, Histograms of CRISPR indel size distribution by species. Data for biological replicates are superimposed and partially transparent with lines connecting data points for each sample. Unmodified alleles and alleles with substitutions only are excluded from this analysis. **h**, Distribution of sequenced PTEN allele variants by species after CRISPR DSB induction at a conserved region of the endogenous PTEN gene. Data are averages from multiple primary dermal fibroblast lines isolated from different individual animals for bowhead whale ($n=3$), human ($n=3$), cow ($n=2$), and mouse ($n=3$). Error bars represent SEM. **i**, Allele plots showing 15 most frequent allele types after CRISPR for one representative cell line per species. Sequences are displayed within a window centered on the cleavage site and extending 20 bp in each direction. Data bars and values indicate proportion of total alleles represented by each row. For the purposes of this display and quantification, all individual alleles with identical sequences in the 40-bp window have been pooled, so rows represent composites of alleles that may differ outside the display window.





Figure 4


Figure 4. CIRBP is highly expressed in bowhead whale fibroblasts and promotes DNA DSB repair and genome stability.

a, Western blots of DNA repair proteins in primary fibroblasts from different species. **b-c**, bwCIRBP promotes NHEJ and HR in human cells as measured by flow cytometric GFP-reporter assays (see Methods). In these assays DSBs are induced within inactive NHEJ or HR reporter cassettes by expressing I-SceI endonuclease. Successful NHEJ or HR events lead to reactivation of the fluorescent GFP reporters that are scored by flow cytometry. All experiments in these figures were repeated at least 3 times. **d,e**, Knockdown of CIRBP in bowhead whale fibroblasts decreases NHEJ and HR efficiency. siNT = non-targeting siRNA. **f**, Western blot of human fibroblasts overexpressing human CIRBP, whale CIRBP or 9R/A mutated whale CIRBP; **g**, Western blot of bowhead whale fibroblasts with knockdown of CIRBP. **h**, Overexpression of CIRBP decreases the percentage of binucleated cells containing micronuclei in human cells 3d after 2Gy γ -irradiation (n=3) (left panel); Western blot of human fibroblasts overexpressing human CIRBP, human CIRBP with optimized codons and whale CIRBP (right panel). Error bars represent mean \pm SD. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ (Welch's t-test). siNT - negative control siRNAs that do not target any gene product. **i**, Number of endogenous γ H2AX/53BP1 foci in human cells with bwCIRBP overexpression. Error bars represent SEM. *** $p < 0.001$ (two-tailed t-test). **j**, CIRBP stimulates NHEJ-mediated ligation *in vitro*. Linearized pUC19 plasmid with cohesive ends was mixed with human recombinant proteins XRCC4/Ligase IV complex, and 0 to 1 μ M CIRBP. Where indicated, reaction mixtures contained Ku70/80 heterodimer, PAXX dimer or XLF dimer. The reaction mixtures were incubated for 1 hr at 30°C, proteins were denatured with SDS at 65°C and loaded onto agarose gel. Each sample were loaded onto 0.7% agarose gel, followed by gel electrophoresis. The gel was stained with ethidium bromide.


a



b



c



■ Deletions >20 bp ■ Deletions ≤20bp
■ Insertions >1 bp ■ Insertions 1 bp
■ Substitutions ■ Unmodified
■ Complex Deletions

■ Deletions >3 bp ■ Deletions ≤3 bp
■ Insertions >1 bp ■ Insertions 1 bp
■ Substitutions ■ Unmodified
■ Complex Deletions

■ Deletions >20 bp ■ Deletions ≤20bp
■ Insertions >1 bp ■ Insertions 1 bp
■ Substitutions ■ Unmodified
■ Complex Deletions

d






Figure 5


Figure 5. RPA and CIRBP contribute to increased DNA repair fidelity. **a**, Distribution of sequenced PTEN allele variants in human primary fibroblasts treated with TDRL-505 or rhRPA after CRISPR DSB induction at a conserved region of the endogenous PTEN gene. Data are averages from experiments performed in triplicate. Error bars represent SEM. **b**, Distribution of sequenced PTEN allele variants by species in bowhead whale primary fibroblasts treated with TDRL-505 after CRISPR DSB induction at a conserved region of the endogenous PTEN gene. Data are averages from experiments performed in triplicate. Error bars represent SEM. **c**, Distribution of sequenced PTEN allele variants by species in human fibroblasts with lentiviral overexpression of luciferase or bwCIRBP after CRISPR DSB induction at a conserved region of the endogenous PTEN gene. Data are averages from experiments performed in triplicate. Error bars represent SEM. * $p < 0.05$, **** $p < 0.0001$. All charts analyzed by two-way ANOVA with Fisher's LSD. p-values should be considered nominal indices of significance. **d**, Graphical summary. The bowhead whale has evolved efficient and accurate DSB repair mediated by high levels of CIRBP and RPA2. This enhanced DNA repair may help the bowhead whale resist cancer despite its cells requiring fewer mutational hits for malignant transformation than human cells. Improved DNA repair rather than enhanced elimination of damaged cells through apoptosis or senescence may promote longevity in the bowhead whale.



Extended Data Figure 1. Mutation rates in bowhead whale cells during tumor progression. **a**, Western blot for p53 protein in clonally isolated fibroblast colonies following CRISPR targeting of *TP53*. Underlined lanes indicate colonies selected for further validation and experiments. **b**, Western blot for Rb protein in clonally isolated fibroblast colonies following CRISPR targeting of *RB1* on an existing p53 knockout background. **c**, Ratio of firefly:renilla luciferase luminescence in fibroblasts transfected with firefly luciferase reporter of p53 transcriptional activity and renilla luciferase control. Cells were treated with etoposide to induce p53 activity. **d**, Ratio of firefly:renilla luciferase luminescence in fibroblasts transfected with firefly luciferase reporter of E2F transcriptional activity and renilla luciferase control. Transfected cells were serum starved for 24h and returned to complete medium for 24h before luminescence measurement. Higher E2F activity results from reduced Rb activity. Error bars represent SD. $p < 0.001$ (two-tailed t test), $n = 3$. **e**, Schematic showing experimental design and samples processed for WGS (whale $N = 9$ tumors; human $N = 2$ tumors; mouse $N = 1$ tumor). **f**, Bar plot displaying percentages of SNV types across species with similarities of mutational processes across species. **g-l**, Bar plot showing quantifications of numbers of SNVs and small indels (size 1-10bp) across species. **j-l**, Bar plot showing quantification of number of large SVs (size > 6000 bp) across species. **m**, Histograms and trend curves showing distribution of SVs size across species. **n**, Bar plot showing distribution of small, medium and large (6-50Kb, 50-500Kb, > 500 Kb respectively) SVs and deletions across species. Error bars represent SD. P values are a result of ordinary One-Way Anova with Tukey's multiple comparison test (**g-l**) and chi-square test (**n**). * $p < 0.05$; ** $p < 0.01$; *** $p < 0.0001$; ns = not significant.






Extended Data Figure 2. Mismatch repair, excision repair, and mutagenesis in bowhead whale cells. **a**, MMR reactivation of a heteroduplex eGFP plasmid containing a G/T mismatch. Growing fibroblasts were transfected with the heteroduplex plasmid and a DsRed plasmid as a transfection control. The repair efficiency was calculated as the ratio of GFP+/DsRed+ cells. Each dot represents cell line isolated from different individual (n=3). **b**, NER efficiency was measured by host cell reactivation assay where a plasmid containing luciferase reporter is UV-irradiated *in vitro* to induce DNA damage, transfected into cells, and reactivation of the reporter is measured (n=3 for each cell line). **c**, Kinetics of cyclobutane pyrimidine dimer repair after 30 J/m² UVC. Confluent human and whale skin fibroblasts were subjected to UVC, harvested at different time-points, genomic DNA was isolated and analyzed for cyclobutene dimers as described in Methods (n=2 for each cell line). **d**, BER efficiency was measured by host cell reactivation where luciferase reporter plasmid is treated with methylene blue and light to induce oxidative DNA damage, transfected into cells, and luciferase activity measured as described in Methods. **e**, ENU-induced mutational load by SMM-seq in fibroblasts of the indicated species. Delta SNV frequency was calculated for each cell line (n=6-8 fibroblasts/species; Kruskal-Wallis test). **f**, Analysis of mutational spectra showing a pattern typical for ENU. An increase in A>T transversions (orange bars) can be found in ENU-treated mammalian cells. **g**, HPRT mutagenesis assay in ENU-treated cells, adjusted by plating efficiency measured for each cell line (n=3 cell lines/species) **h**, Colony forming efficiency for HPRT mutagenesis assay. Error bars represent mean ± SD. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 ns=not significant (heteroscedastic two-tailed t test). **i**, Apoptosis/necrosis of human and bowhead whale fibroblasts in response to ENU. Cells at growing stage were treated for 3h with ENU at indicated dosages. After treatment cells were washed in PBS and incubated for 3 days. For measuring Apoptosis/Necrosis cells were stained with AnnexinV/PI and analyzed by flow cytometry. **j**, HPRT mutagenesis assay in cells treated with 2 Gy γ -irradiation, adjusted by plating efficiency measured for each cell line (n=2 cell lines/species) **k**, Colony forming efficiency for HPRT mutagenesis assay.




Extended Data Figure 3. Poly-ADP-ribosylation and DNA repair of oxidative

damage in bowhead whale cells. a, Bowhead whale cells show greater poly-ADP-ribosylation in response to hydrogen peroxide treatment. **b**, Bowhead whale cells show greater poly-ADP-ribosylation after γ -irradiation. Cells were harvested immediately or at indicated time-points after radiation for Western blot analysis (top panel).

Representative images of comet tails under neutral conditions (bottom panel). Cells were processed immediately after radiation. **c**, Nuclear extracts of bowhead whale fibroblasts exhibit higher endogenous PARP activity (n=3). Error bars represent mean \pm SD. * $p < 0.05$ (Welch's t-test). Whale=bowhead whale. **d**, Apoptosis/Necrosis of human and bowhead whale fibroblasts in response to hydrogen peroxide at concentration 700 μ M. Two days after hydrogen peroxide, cells were harvested and subjected to an Annexin V apoptosis assay using flow cytometry. Error bars represent mean \pm SD. *** $p < 0.001$. Welch's t-test was used to quantify the significance (n=12). **e**, Percent tail DNA by alkaline comet assay at various time points after 700 μ M H₂O₂ treatment in 2 cell lines each of human and bowhead whale fibroblasts. Points represent individual cells. Representative comet images shown below. Bars indicate mean \pm SEM.




Extended Data Figure 4. DSB repair efficiency in bowhead whale cells. **a**, NHEJ efficiency in extrachromosomal assay. NHEJ reporter construct was pre-digested with I-SceI, purified and co-transfected with DsRed into human and bowhead skin fibroblasts. Three days after transfection cells were harvested and subjected to flow cytometry to calculate NHEJ efficiency (n=3). Error bars represent mean \pm SD. *** $p < 0.001$ (two-tailed t-test) **b**, Representative images of human and bowhead whale binucleated cells containing micronuclei after 2 Gy of γ -irradiation. Scale bar indicates 20 μ m. **c**, Frequency of micronuclei after DSB induction with I-SceI in primary fibroblasts carrying a chromosomally integrated NHEJ reporter cassette. Each cell line was transiently transfected with a BFP-expressing control plasmid or an I-SceI expression plasmid and micronuclei were quantified after 5d in media containing cytochalasin B to prevent cytokinesis. Micronucleus frequencies for each cell line are shown normalized to BFP control (paired t-test, n=3 cell lines/species). **d**, Pulse-field gel stained with ethidium bromide, showing chromosomal DNA fragmentation in human and bowhead confluent skin fibroblasts immediately after different doses of γ -irradiation 0.7, 1.5, 3 and 6h after 40 Gy of γ -irradiation. **e**, Kinetics of DSB repair measured by PFGE in confluent human and bowhead fibroblasts after 40 Gy of γ -irradiation. n=2 for each species.



Extended Data Figure 5. Sequencing of DNA DSB repair products in bowhead

whale cells. a, Possible repair outcomes after induction of DSBs with incompatible ends by I-SceI in NHEJ reporter construct. **b**, Allele plot of Sanger sequencing products resulting from repair of integrated NHEJ reporter cassette after I-SceI cleavage. **c**, NHEJ fidelity in extrachromosomal assay. NHEJ reporter construct was pre-digested with I-SceI, purified and co-transfected with DsRed into human and bowhead skin fibroblasts. Three days after transfection genomic DNA was isolated, subjected to PCR, cloned and analyzed by Sanger sequencing. At least 100 clones were analyzed for each species. Correct – annealing on 2 of the 4 protruding nucleotides **d**, Time course of CRISPR cleavage measured by digital droplet PCR (ddPCR). PTEN copy number at varying time points after CRISPR RNP transfection was measured with ddPCR using primers flanking the predicted cleavage site and normalized within each sample to a single-copy genomic ultraconserved element as described in Methods. Error bars show confidence intervals of Poisson distribution calculated in QuantaSoft. **e**, Pearson correlation between 5th percentile indel size and species lifespan ($r=0.8508$, 95% CI = 0.5125 to 0.9605, $p=0.0009$, $n=11$). **f**, Absolute frequencies of alleles by base pairs of microhomology across species in CRISPR-targeted PTEN repair products. **g**, Relative proportions of deletion alleles by base pairs of microhomology across species in CRISPR-targeted PTEN repair products.



Extended Data Figure 6. Proteomic quantification of DNA repair proteins. a,

Western blot for CIRBP on bowhead whale and mouse organs **b,** Abundance of CIRBP

protein by LC-MS in liver tissue of mammal species (n=12 per species; 3 biological x 4

technical replicates; N.D.=not detected) **c,** Abundance of RPA2 protein by LC-MS in

liver tissue of mammal species (n=12 per species; 3 biological x 4 technical replicates;

N.D.=not detected) **d,** Abundance of CIRBP protein by LC-MS in nuclear extracts of liver

tissue of mammal species (n=3 biological replicates per species) **e,** Abundance of RPA2

protein by LC-MS in nuclear extracts of liver tissue of mammal species (n=3 biological

replicates per species; N.D.=not detected) **f,** Heatmap of LC-MS protein abundance for

primary fibroblasts of the indicated species and proteins. Color intensity scale


corresponds to \log_{10} ion intensity. **g,** Per-protein normalized abundance by LC-MS of

proteins identified in pull-downs of His-tagged Cas9/dCas9 bound to a plasmid


containing the genomic *PTEN* target sequence after incubation in extracts of soluble

nuclear proteins from human and bowhead whale.


a




b




c



d




e



**Extended
Data
Figure 7**

Extended Data Figure 7. Transcriptome, Western blot, and STED quantification of DNA repair proteins. **a**, Relative expression level of genes in 6 DNA repair pathways among species. Z-scores are scaled by row. Genes in each pathway are ordered decreasingly based on the expression level in bowhead whale. Genes with higher expression in bowhead whale compared to all 3 other species are highlighted in red text to the right of the heatmap. Genes of each gene set were compiled from 3 resources: MsigDB database, GO ontology, and a curated gene list (www.mdanderson.org/documents/Labs/Wood-Laboratory/human-dna-repair-genes.html) **b**, Western blot abundance of RPA2 in cultured skin fibroblasts, using 2 different monoclonal primary antibodies targeting conserved epitopes and normalized to histone H3. A third polyclonal antibody produced the same results but had higher background reactivity and is not shown. Each lane is a primary fibroblast line from a different adult individual. Fluorescent secondary antibodies were used to increase linear dynamic range for higher quantitative accuracy. **c**, Western blot for CIRBP with 3 different antibodies in 3 fibroblast lines per species. mAb=monoclonal antibody, pAb=polyclonal antibody. **d**, Stimulated emission depletion (STED) images of RPA2 and CIRBP localization in human and bowhead whale fibroblasts. Target protein in red, nuclear DAPI stain in blue. **e**, Western blot for CIRBP in fibroblasts isolated from various mammalian species.






Extended Data Figure 8

Extended Data Figure 8. Analysis of CIRBP's role in DNA DSB repair. **a**, CIRBP localization in whale cells. Before formaldehyde fixation, cells were pre-extracted with CSK buffer +/- RNaseA for 3min. After standard immunocytochemistry procedure images were collected using confocal microscope. **b**, Western blot of bowhead whale fibroblasts with knockdown of CIRBP (left panel) and band intensity quantification from 3 independent experiments (right panel) suggesting partial dependence of RPA2 protein abundance on CIRBP expression. **c**, Ion intensity by LC-MS of RPA2 in human fibroblasts with and without lentiviral overexpression of bwCIRBP (n=3 human cell lines). Error bars show mean +/- SEM. **d**, DSBs induce CIRBP enrichment in chromatin. Exponentially growing cells were treated with neocarzinostatin (NCS) for the indicated period of time and lysed in CSK buffer to enrich chromatin-bound fraction. α -Tubulin staining was used to verify the absence of cytoplasmic contamination in chromatin-bound fraction. **e**, DSBs induced by γ -irradiation lead to CIRBP enrichment in chromatin. This enrichment is promoted by RNA. Exponentially growing cells were treated with γ -irradiation and at the indicated period of time were lysed in CSK buffer with/without RNase A to enrich proteins in chromatin-bound fraction. **f**, Overexpression of CIRBP decreases the percentage of binucleated cells containing micronuclei in human cells after I-Sce1-induced DSBs. Each bar indicates an experimental replicate. At least 150 binucleated cells were scored per condition. **g**, Frequency of chromosomal aberrations in human fibroblasts with and without CIRBP overexpression after 2Gy γ -irradiation. 100 metaphases were analyzed per sample. C=control untreated cells. **h**, Frequency of insertions and deletions >20 bp in NHEJ reporter constructs PCR-amplified from human fibroblasts with and without bwCIRBP overexpression after I-SceI expression. Insertion/deletion frequencies were determined from Nanopore sequencing data of PCR products and normalized within each sample to total frequency of all insertions or deletions. **i**, Frequency of insertions and deletions as shown in (**h**) but for bowhead whale fibroblasts with negative control or CIRBP-targeting siRNAs. **j**, Calculated dissociation constants (K_D) and fluorescence polarization (FP) measurements for CIRBP proteins titrated into solutions containing a fixed concentration (3 nM) of fluorescently labeled PAR of various polymer lengths. **k**, EMSA of increasing amounts of recombinant human CIRBP incubated in vitro with 300 ng sheared chromatin from fibroblasts exposed to UVC and oxidative DNA damage as described in Methods. Chromatin was treated with Proteinase K but not RNase. Nucleic acids are stained with SYBR Gold. Red overlay indicates saturated pixels. **l**, EMSA of 300 ng sheared purified genomic DNA, purified cellular RNA, or chromatin as described in (**k**) incubated in vitro with 5 μ g rhCIRBP. **m**, Hypothermia promotes NHEJ efficiency in primary human fibroblasts (left panel). Cells were pre-incubated at 33°C for 2 days, co-transfected with I-SceI-digested NHEJ reporter and DsRed, and returned to the 33°C incubator. NHEJ efficiency was measured by flow cytometry 3 days following transfection (n=3). Western blot showing CIRBP upregulation in human cells exposed to 33°C for 2 days (right panel). Western blot images were analyzed in ImageLab software (Bio-Rad). Error bars represent mean \pm SD. ** p<0.01 (Welch's t-test).

Score Expect Method available under aCC-BY-NC-ND 4.0 International license.
 315 bits(806) 1e-116 Compositional matrix adjust. 167/172(97%) 168/172(97%) 0/172(0%)

BHW 1 MASDEGKLFVGGLSFDTNEQSLEQVFSKYGQISEV V V V K D R E T Q R S R G F G F V T F E N I D D A 60
 Human 1 MASDEGKLFVGGLSFDTNEQSLEQVFSKYGQISEV V V V K D R E T Q R S R G F G F V T F E N I D D A 60
 61 K D A M M A N G K S V D G R Q I R V D Q A G K S S D N R S R G Y R G G S A G G R G F F R G G R G R G R G F S R G G G D 120
 61 K D A M M A N G K S V D G R Q I R V D Q A G K S S D N R S R G Y R G G S A G G R G F F R G G R G R G R G F S R G G G D 120
 121 R G Y G G S R F E S R S G G Y G G S R D Y Y S S R S Q G G S C G D R S S G G S Y R D S Y D S Y A T H N E 172
 121 R G Y G G + R F E S R S G G Y G G S R D Y Y S S R S Q G D R S S G G S Y R D S Y D S Y A T H N E
 121 R G Y G G N R F E S R S G G Y G G S R D Y Y S S R S Q G G Y S D R S S G G S Y R D S Y D S Y A T H N E 172

↑ BHW variant ↑ BHW variant



e

CDS variant	CAI
hCIRBP	0.811
bwCIRBP	0.845
H5BW	0.809
BW5H	0.848


Extended Data Figure 9. Analysis of bwCIRBP coding sequence mutations and protein expression levels. **a**, Comparison of amino acid sequences between human and bowhead whale CIRBP through BLAST analysis. **b**, Phylogenetic tree illustrating the relationships among CIRBP coding sequences from representative species with genome sequence information available. The asterisk indicates the presence of BHW-specific variants in the species. The colors indicate the position of variants shown in **(a)**. **c**, SwissModel/AlphaFold models of human (left, pink) and bowhead whale (right, blue). Side chains of whale residues that diverge from human are shown, and their ribbon is colored yellow in the model. The key takeaway is that all the residues that differ between whale and human are in the C-terminal disordered region, whereas the N-terminal RNA recognition motif (RRM) is structured and conserved. **d**, Western blot abundance of bwCIRBP, hCIRBP, and reciprocal amino acid mutants overexpressed in human cells. **e**, Calculated codon adaptation index (CAI) for CIRBP coding sequence variants.

a


Score	Expect	Method	Positives	Gaps
511 bits(1316)	0	Cons	263/270(97%)	0/270(0%)
			Identities 253/270(94%)	

Species	Accession	Residue	Sequence	Residue
BHW	1	MWTSGFESYSSSSFGGAGSYTQSPGGFGSPTPSQAEKSRARAQHI	V	60
Human	1	MW SGFESY SSS+GGAG YTQSPGGFGSP PSQAEKSRARAQHI	V	60
	61	DEVFKIGNVEISQVTIVGIIRNAEKAATNIVYKIDDMTAAPMDVRQ	W	120
	61	DEVF+IGNVEISQVTIVGIIR+AEGA TNIVYKIDDMTAAPMDVRQ	W	120
	121	PPETYVKVAGHLRSFQNKKSLVAFKIMPLEDMNEFTTHILEVNAHM	L	180
	121	PPETYVKVAGHLRSFQNKKSLVAFKIMPLEDMNEFTTHILEV+NAHM	L	180
	181	APISNPGMGEAGNFGGNSFMPANGLTVAQNQVLNLIKACPRPEGLN	F	240
	181	APISNPGM EAGNFGGNSFMPANGLTVAQNQVLNLIKACPRPEGLN	F	240
	241	SVKQAVDFLSNEGHIYSTVDDDDHFKSTDAE		270
	241	S+KQAVDFLSNEGHIYSTVDDDDHFKSTDAE		270
	241	SIKQAVDFLSNEGHIYSTVDDDDHFKSTDAE		270


b



c



Extended Data Figure 10. Analysis of bowhead whale RPA2 sequence. a, Comparison of amino acid sequences between human and bowhead whale RPA2 through BLAST analysis. **b,** Phylogenetic tree illustrating the relationships among RPA2 coding sequence from different representative species. The asterisk indicates the presence of BHW-specific variants in the species. The colors indicate the position of variants shown in **(a)**. **c,** AlphaFold protein structures of human and bowhead whale RPA2 showing the position of the variants.



Extended Data Figure 11. Bowhead whale CIRBP reduces anchorage-independent cell growth. **a**, Images of representative human transformed fibroblast colonies with and without bwCIRBP overexpression after 23 days of growth in soft agar. 20x magnification. Bar 100 μ m. **b**, Quantification of colonies after staining with nitro blue tetrazolium chloride. Colonies were counted using ImageJ software as described in Methods. Error bars represent SD. * $p < 0.05$ (Welch's t-test). **c**, Cell proliferation MTT assay. **d**, Trypan Blue exclusion test of cell viability. **e**, Western blot showing expression of LT, Ras, p16 and p21 after overexpression of bwCIRBP. **f**, Frequency of chromosomal aberrations in human transformed cells after bwCIRBP overexpression. 100 metaphases were analyzed per sample.